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Transcriptional responses of tumor 
cell lines to interferon-alpha
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III. L'Avion, p. 60 [Paris] (Gallimard 1946)
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1Summary
Interferon is an antiviral and antiproliferative cytokine therapeutically applied to treat 
hepatitis infection and cancer expansion. The beneficial effects of interferon-alpha are 
dependent on efficient signaling by activation of defined JAK-STAT pathway and the 
induction of interferon stimulation genes. These genes are translated to proteins with 
antiviral, antiproliferative, anti-tumor and apoptotic properties. Induction of gene 
expression is consolidated by binding of interferon activated transcription factors to 
interferon-specific elements in the promoter of such genes. This interaction is dependent 
on the accessibility of the chromosomal region given by an open chromatin structure. 
Some interferon-induced proteins are negatively regulating the signal transduction to avoid 
overreactions such as triggering senescence and to restore responsiveness to a next 
round of cytokine stimulation. The response to interferon was characterized using whole-
genome gene-expression microarrays. Interferon induced proteins were characterized for 
their antiproliferative effects by measuring growth in cell culture. These proteins were 
tagged fluorescently to localize them to cell compartments. Suppressor of cytokine 
signaling proteins were overexpressed in cancer cell lines and their effect on gene 
expression was described by genome-wide micro-array analyzes. The epigenetic state in 
tumor samples was determined, the effect of interferon-alpha on DNA mehtylation was 
described for one gene and the epigenetic changes documented in embryonic cells 
defective in a gene involved in DNA damage repair. Our results document antiproliferative 
action for the interferon-stimulated genes IFI44 and IFITM3. Induction of gene expression 
can be blocked by overexpression of SOCS1 proteins in cancer cell lines. The epigenetic 
DNA methylation status is altered in tumor cells and methylation of unique CpG sites can 
dynamically change during cytokine treatment and may involve a DNA demethylation 
factor. The interferon-alpha response of cancer cell lines depends on the expression, the 
inducibility and the epigenetic state of interferon-stimulated genes. The genes studied here 
are effective in blocking proliferation or signal transduction in interferon-alpha sensitive cell 
lines. Screening of clinical samples for the expression of these genes or their proteins or 
determination of the DNA methylation status therein is promising in customization of drug 
therapy for personalized healthcare.
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Abbreviation Description
ADC antibody-drug conjugates
aza 5-aza-2'-deoxycytidine
BED browser extensible data
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4General introduction
Interferon-alpha
'INTERFERON is the name that was given to a substance produced by the interaction of 
inactivated influenza virus with cells1.'
(Isaacs et al. 1958) on 1 (Isaacs et al. 1957).
Interferons are originally defined as proteins secreted by virus-infected cells that inhibit 
viral replication in infected and uninfected cells (Isaacs and Lindenmann 1957). The name 
of the protein originates from its activity to “interfere” with viral infections. Later on, 
interferon (IFN) showed more than antiviral activity, it can inhibit cellular growth; it has 
effects on the immune system and on apoptosis (Stark et al. 1998). Thus, IFN can be used 
for antiviral and antitumor applications. Almost every cell in the body has the capacity to 
induce IFNs, but the type of IFN produced by different cells varies. Therefore, IFNs were 
classified in two subgroups, type I (leucocyte [α] and fibroblast [β] interferon)(Havell et al. 
1975) and type II IFN (immune interferon [γ])(Stewart 1980). A third subgroup, type III IFN 
(antiviral interferons [λ]) has been defined some years later (Kotenko et al. 2003). 
Interferon alpha (IFNα) family consists of proteins coded by 17 non-allelic genes in a 
single region of the human genome on chromosome 9 together with a single gene for 
interferon beta (IFNβ) (Owerbach et al. 1981; Shows et al. 1982; Weissmann et al. 1982; 
Díaz et al. 1994).
IFNs are able to induce the expression of a variety of interferon-stimulated genes (ISG). 
Several types of IFN and transcription factors can induce many of them. Some messenger 
RNAs (mRNA) are known since more than a quarter century to be regulated by IFNα 
signaling (Stark et al. 1984). These mRNA include the genes coded by the clones 1-8 
(IFITM2), 9-27 (IFITM1), 6-16 (IFI6), 6-26 (TMSB4X), 10Q (unknown), 2A (HLA-C) and 
MTII (MT2A, coding for the metallothionein 2 protein); being 1-8 the most abundant IFN-
induced mRNA (Friedman et al. 1984). Signaling is propagated by activation of cytokine 
receptors, kinases and transcriptional activators mainly through transient phosphorylation 
of these molecules. There are plenty of genes induced and they act through different 
mechanisms to protect the body from viruses and to control cellular growth. The 
mechanism of action of ISGs is manifold, they are involved in RNA editing and 
degradation, block of protein synthesis, protein modifications such as polyubiquitation 
resulting in protein degradation, induction of cytokines and cross talk with signaling 
pathways, antiviral, antitumor, antiangiogenic and apoptotic actions (Borden et al. 2007). 
The antiproliferative action of IFNα involves control of cell cycle checkpoints (Roos et al. 
1984). The mechanism how IFNα is able to induce cell-cycle arrest or apoptosis is 
mediated by induction of tumor protein 53 (p53) signaling for example (Thyrell et al. 2002). 
However, p53 is not required for IFN mediated induction of apoptosis (Herzer et al. 2009).
JAK-STAT signaling
Many cytokines, more than 38 if we count type I IFN as a single one, signal through a 
discrete number of Janus kinases (Jaks) to phosphorylate seven signal transducer and 
activator of transcription (STAT) phospho-tyrosine recognition site (SH2 domain) 
containing proteins (Schindler et al. 2007). IFNα and IFNβ signal transduction is initiated 
by binding of the cytokine to and consequently dimerizing of interferon type I receptors 
5(IFNAR1 and IFNAR2). The cell-surface interaction induces conformational changes down 
to the cytosolic part of the receptors, attracts receptor associated tyrosine kinases (Tyk): 
Jak1 and Tyk2, which get rapidly auto-phosphorylated (Platanias et al. 1994). This 
activation of Jaks leads to tyrosine-phosphorylation of the receptors and subsequent 
recruitment of various signaling proteins, including STATs (Schindler et al. 1992). After 
IFNα driven JAK1 / Tyk2 activation, primarily STAT1 and STAT2 are recruited from the 
cytosol to the membrane where they get phosphorylated, too (Fu et al. 1992). Once 
activated, the STATs dimerize and relocate to the cytosol. IFNα signaling cascade primarily 
promotes STAT2 binding to the co-factor IRF9 (ISGF3γ or p48) and they form together with 
STAT1 the interferon stimulated gene factor 3 (ISGF3) (Fu et al. 1990). This complex 
translocates to the nucleus where it can bind interferon stimulated response elements 
(ISRE) and consequently initiate the transcription of IFN type I specific genes (Darnell et 
al. 1994; Darnell 1997; Stark et al. 1998; Caraglia et al. 2005). Beside this prototypical 
transcription factor, STAT1 homodimers are formed as well and consequently initiate 
transcription of IFN (gamma) stimulated genes through the binding to gamma-activated 
sequences (GAS). Additionally, STAT1-IRF9 complexes, STAT3-STAT1 and rarely 
occurring dimers such as STAT2 homodimers may be formed (Bluyssen et al. 1996; 
Wesoly et al. 2007). Subsequently, phosphorylated as well as unphosphoryated STAT 
proteins shuttle rapidly in and out the nucleus (Xu et al. 2004; Meyer et al. 2004; Meyer et 
al. 2007). STAT molecules are non-tyrosine phosphorylated in absence of cytokine 
stimulus. Nevertheless, they can assemble into dimers and higher order complexes and 
may have some activity in the nucleus (Ndubuisi et al. 1999; Haan et al. 2000). 
Interestingly, these IFN-unstimulated and unphosphorylated STAT1 molecules are also 
bound to DNA and may alter gene expression in a different manner (Robertson et al. 
2007). This allows IFN signaling to control gene expression in addition to the short-lived 
JAK-STAT phosphorylation. Unphosphorylated STAT1 accumulates after IFN stimulus and 
maintains or increases the expression of certain ISG (Yang et al. 2008; Cheon et al. 2009). 
However, this accumulation is a very dynamic process and not static. Shuttling of 
transcription factors typically occurs without tyrosine phosphorylation of STAT1 (Meyer and 
Vinkemeier 2007). Interestingly, nuclear transition of unphosphorylated STAT2 is 
dependent on its constitutive association with IRF9 (Banninger et al. 2004). The ability of 
IFNs and other cytokines to induce STAT molecules in any number of ratios explains why 
the IFN response varies dependent on IFN subtype and cellular conditions. STAT1 
primarily promotes growth arrest, apoptosis and antitumor immunity downstream of type I 
and II IFNs. By contrast, STAT3 mediates activity of cytokines generally associated with 
systemic acute phase and cancer-promoting inflammation (Jarnicki et al. 2010). In addition 
to IFN signaling through STATs, there is signaling through IFN receptor dimerization 
without activation of STATs. Therefore, cells with mutations in crucial tyrosines for IFN type 
1 signaling are able to induce IRF9 independently of STAT phosphorylation and for 
example linked to IRF1 and C/EBP-β signaling (Rani et al. 2010).
ISRE and GAS
The sequence composition of IFN response elements is defined by a set of promoter 
sequences of ISG that show similarities to other IFN response factor binding sites that 
have been analyzed biochemically (Brierley et al. 2007). A list of such sequences is shown 
in table 1. The data of high confident ISRE and GAS sequences was merged from 
published lists (Tsukahara et al. 2006; Robertson et al. 2007; Montgomery et al. 2006). In 
addition, IFITM ISRE sequences were added, which we have identified as potential ISRE 
sequences due to evolutionary conservation (Siegrist et al. 2011). In table 1 the STAT1 
regulatory elements are split into GAS and ISRE sequences but the ISRE subgroups are 
6refined by counting the distance of the first 'TTT' (3T) nucleotide stretch to the 'C' after the 
second 3Ts instead of looking at 3Ts only (Robertson et al. 2007). To get a better overview 
of the sequence characteristics of ISRE and GAS elements, nucleic acid occurrence is 
plotted for all the GAS elements and all ISRE elements including these subgroups. This 
grouping then points out the importance of a 'TTTC' element repetition with a spacer of two 
or three nucleotides in size between them (Illustration 1 and 2).
The use of large scale and genome wide microarray expression data for a more 
comprehensive definition of ISRE sequences has been recently described (Hertzog et al. 
2011). New definitions will replace these biased and rigid consensus sequences that are 
still part of transcription factor binding site databases. However, we should keep in mind 
that the consensus sequence defined for a database, TransFac for example, is based on a 
small number of highly induced genes after stimulation of type I IFN signaling. Promoter 
sequences of lower affinity binding sites to the ISRE transcription complex seem to be as 
well sensitive to IFN signaling if other transcription factors are abundant.
Illustration 2: Nucleotide frequency in ISRE_3 sequences (left) and Nucleotide frequency 
in ISRE_2 sequences (right).
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Illustration 1: Nucleotide frequency in all GAS (left) and ISRE sequences (right).
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7Gene Symbol Group Organism Sequence Reference
GBP1 GAS Human ATTACTCTAAA (Lew et al. 1991)
CSF1 GAS Human TTTCCCATAAA (Tsuchimoto et al. 2004)
FCGR1A GAS Human TTTCCCAGAAA (Pearse et al. 1993)
FOS GAS Human GTTCCCGTCAA (Eilers et al. 1994)
SERPINA3 GAS Human ATTACCAGAAA (Kordula et al. 1998)
SERPINA3 GAS Human AGTCCGAGAAC (Kordula et al. 1998)
WARS GAS Human ATTCTCAGAAA (Seegert et al. 1994)
CIITA GAS Human CTTCTGATAAA (Muhlethaler-Mottet et al. 1998)
MVP GAS Human CTGCCGGGAAG (Steiner et al. 2006)
NOS2A GAS Human TTTACTGGAAA (Gao et al. 1997)
NOS2A GAS Human GTTCTGGGAAA (Gao et al. 1997)
CCL2 GAS Human GTTCCTGGAAA (Guyer et al. 1995)
ICAM1 GAS Human TTTCCTTGAAA (Tessitore et al. 1998)
ICAM1 GAS Human TTTCCGGGAAA (Tessitore et al. 1998)
CD40 GAS Human CTTCCTTGAAA (Nguyen et al. 2000)
CD86 GAS Human TTTGGTCTAAA (Li et al. 2000)
CD86 GAS Human CTTGCTTTAAA (Li et al. 2000)
IL6ST GAS Human ATTCCCGTAAC (O'Brien et al. 1997)
IRF1 GAS Human TTTCCCCGAAA (Sims et al. 1993)
HLA-E GAS Human TTGCTGGGAAA (Gustafson et al. 1996)
TAP1 GAS Human TTTAGGGGAAA (Chatterjee-Kishore et al. 1998)
IDO1 GAS Human TTTCCTGTAAA (Chon et al. 1996)
IRF1 GAS Mouse TTTCCCCGAAA (Coccia et al. 1999)
LY6E GAS Mouse ATTCCTGTAAG (Khan et al. 1993)
IRF8 GAS Mouse TTTCTCGGAAA (Kanno et al. 1993)
FOS67 GAS Human TTTCCCGTAAA (Eilers et al. 1994)
ADAR ISRE_2 Human CGCTTTCGTTTCCTC (George et al. 1999)
OAS1 ISRE_2 Human TGGTTTCGTTTCCTC (Rutherford et al. 1988)
MX1 ISRE_2 Human AGGTTTCGTTTCTGC (Ronni et al. 1998)
MX1 ISRE_2 Human GAGTTTCATTTCTTC (Ronni et al. 1998)
ISG15 ISRE_3 Human CAGTTTCGGTTTCCC (Levy et al. 1988)
IFI6 ISRE_3 Human CAGTTTCATTTTCCC (Porter et al. 1988)
IFI6 ISRE_3 Human GAGTTTCATTTTCCC (Porter et al. 1988)
IFIT2 ISRE_3 Human TAGTTTCACTTTCCC (Levy et al. 1988)
IFIT1 ISRE_3 Human TAGTTTCACTTTCCC (Grandvaux et al. 2002)
IFITM1 ISRE_3 Human AAGTTTCTATTTCCT (Reid et al. 1989)
IFITM3 ISRE_3 Human TAGTTTCGGTTTCTC (Lewin et al. 1991)
IFITM3 ISRE_3 Human CAGTTTCCTTTTCCT (Lewin et al. 1991)
ISG20 ISRE_3 Human CTGTTTCAGTTTCTA (Gongora et al. 2000)
EIF2AK2 ISRE_3 Human CAGTTTCGTTTTCCC (Ward et al. 2002)
CXCL10 ISRE_3 Human AGGTTTCACTTTCCA (Cheng et al. 1998)
HLA-E ISRE_3 Human CAGTTTCCCGTTCCT (Gustafson and Ginder 1996)
CFB ISRE_3 Human CAGTTTCTGTTTCCT (Huang et al. 2001)
IDO1 ISRE_3 Human TGGTTTCAGTTTTCC (Konan et al. 1996)
IDO1 ISRE_3 Human TGGTTTCATTTTCTA (Konan and Taylor 1996)
IFITM1 ISRE_3 Human TCGTTTCAGTTTCAG (Siegrist et al. 2011)
IFITM2 ISRE_p Human CAGTTTCCTCTTCGA (Siegrist et al. 2011)
IFITM2 ISRE_p Human TAGTTCCGTTTTCTC (Siegrist et al. 2011)
Table 1: High confident ISRE and GAS motifs
8Therapeutic use of interferon-alpha
Interestingly, it was not the initially described antiviral action that led to the licensing of 
IFNα, the first recombinant cytokine, for the treatment of a malignancy but its antitumor 
activity. In 1986, IFNα2a (Hoffman-La Roche) and IFNα2b (Schering-Plough) got the 
approval in the USA for the treatment of Hairy Cell Leukemia. Other approved antitumor 
applications exist for AIDS-related Kaposi's Sarcoma, Chronic Myelogenous Leukemia, 
Malignant Melanoma and Follicular Lymphoma (Bekisz et al. 2010). The idea that HCV 
infected patients might benefit from IFNα was based on the observation that hepatitis often 
cause a chronic infection leading to cirrhosis and hepatocellular carcinoma (HCC) 
(Blumberg 1977). The following idea was to administer IFNα in CHC patients as cancer 
prevention and only secondary as antiviral therapy. In the beginning, low dose of IFNα 
showed a partial effect on cancer occurrence and had limited antiviral effect. Then, high 
dose IFNα therapy confirmed beneficial effects in the treatment of hepatitis after 
affordable, recombinant IFNα became available for therapeutic application (Hoofnagle et 
al. 1988).
HCV treatment
Combination therapy with antivirals and a new formulation of IFNα have proven to be more 
effective than IFNα alone. The recommended therapy for chronic hepatitis C (CHC) and 
standard-of-care (SOC) medication for hepatitis C virus (HCV) infections in general was for 
more than a decade pegylated interferon-alpha-2a (Pegasys) in combination with ribavirin 
(RBV), a weak antiviral medication (Glue et al. 2000; Borden et al. 2007). Moreover, 
Pegasys is used to treat other type of chronic hepatitis (B and D) infection and HIV-HCV 
co-infections (Poynard et al. 2003; Flamm 2003). There is no cure for hepatitis B but 
medication can suppress the virus for a long time period. Patients may achieve HCV 
eradication but in some cases there is recurrence of viral infection. Another problem is that 
some patients with hepatitis C benefit from the treatment and others do not. This may be 
due to cellular factors such as STAT3, CD81, DICER, TP53, ISGF3G all of them important 
for viral replication in vitro (Randall et al. 2007). Diagnostic factors such as virus genotype 
or insulin resistance have an independent effect on the treatment response (Persico et al. 
2007; Moucari et al. 2008; Petta et al. 2008).
Another factor that correlates with insulin resistance and differs between HCV genotypes 
are genes of the family of suppressor of cytokine signaling (SOCS) (Persico et al. 2009; 
Vanni et al. 2009). Recent results indicate a correlation of SOCS3 expression and 
outcome of IFN therapy in HCV patients (Miyaaki et al. 2009; Kim et al. 2009b). Properties 
of the virus itself may also differ in patients and several viral mechanisms may interfere 
with IFNα signaling in infected cells. HCV protein mediates upregulation of protein 
phosphatase 2A resulting in STAT hypomethylation (Duong et al. 2004). HCV core protein 
also regulates SOCS3 and causes a blockage of IFNα-induced ISGF3G formation and 
proteasome-dependent degradation of STAT1 (Bode et al. 2003; Lin et al. 2005).
Melanoma treatment
IFNα therapy has been first approved for other cancer treatment and shows also a 
beneficial effect as adjuvant therapy of stage II to III melanomas after physical removal of 
the tumor (Kirkwood et al. 1996; Pehamberger et al. 1998; Kirkwood et al. 2000). IFNs are 
stimulants of the immune system and can induce antitumor effects. They have some 
antiangiogenic properties and antiproliferative effect on fast growing cancer cells. Meta-
analysis of several clinical trials with IFNα treatment in melanoma patients with limited 
statistical significance demonstrates an increase in relapse-free survival (Garbe et al. 
92010). However, only a small percentage of patients benefit from IFNα treatment. The 
molecular basis for this is not clear. SOCS proteins are also involved in the resistance of 
IFN in melanoma cells after several passages in vitro (Fojtova et al. 2007). This indicates 
that tumor cells change their responsiveness to IFNα during the treatment period and 
counteract the antiproliferative effect of IFNα by upregulation of suppressors of IFN 
signaling.
Limits of therapeutic use of interferon-alpha
There are some disadvantages of IFNα therapy, despite the ability to erase HCV or 
reduction below the detection level in some patients. A major disadvantage is the 
resistance that often already exist in patients, in contrast to specific antiviral agents for 
example peptidase and polymerase inhibitors. This may be due to preexisting viral evasion 
of ISGs (Short 2009; Bonjardim et al. 2009). In other cases, host factors limit the action of 
IFNα in infected cells or immune cells (Del Campo et al. 2009).
HCV can be cleared in almost all IFNα rapid responder patients, but there is no effective 
treatment for HCV in resistant patients. Therefore, it is important to understand the 
molecular mechanism underlying the resistance to IFNα therapy to establish personalized 
healthcare and a more effective therapy. The limited efficacy in eliminating the infection 
with SOC therapy and its relative toxicity inspired many researcher and pharmaceutical 
companies to invest in new and improved therapeutics (Shimakami et al. 2009).
In contrast to HCV therapy, the question whether patients benefit from IFNα in melanoma 
treatment remains controversial. The application is very limited and only few patients may 
really benefit and toxicity is a concerning issue, especially after surgery to eliminate the 
cancer.
Improvements: pegylated interferon and new formulations
The future of HCV therapy will focus on new strategies including new IFN formulations 
(Albuferon, oral IFNs), the use of IFN type III (peg-IFNλ) or a RBV prodrug (taribavirin). 
Other strategies aim for agents that target cellular (host) factors such as cyclophilin 
inhibitors with the potential to avoid the development of HCV mutational resistance and 
“specifically targeted antiviral therapy for HCV” (STAT-C). The list of STAT-C drugs 
includes NS3/4 protease inhibitors (R7227), NS5B polymerase inhibitors for example a 
nucleoside analogue of cytidine (R7128), internal ribosomal entry site inhibitors and 
interfering RNAs. Moreover, inhibitors of HCV assembly, HCV release and inhibitors of 
HCV entry are under development. (Mallet et al. 2010; Flisiak et al. 2010). In the next 
years, research focus lies on the use of triple therapy with a combination of Pegasys, RBV 
and one of these new STAT-C drugs (Flisiak and Parfieniuk 2010). They are very effective 
and also trials with combination of R7227 and R7128 without IFN and RBV are ongoing 
and preliminary results confirm greater than additive activity (Bartels et al. 2008). Another 
approach is to enhance endogenous viral defense by boosting SOC with ritonavir. 
Ritonavir is an inhibitor of cytochrome P450-3A4, a liver enzyme that normally metabolizes 
protease inhibitors and was originally developed as inhibitor of HIV protease (Merry et al. 
1997).
Gene-expression analysis
There are at least 8 different microarray formats and they use different technology and 
have specific advantages and weakness (Ahmed 2006). The Illumina beadarray 
technology, a cost effective, flexible has become available in our lab to examine whole 
genome expression. Illumina Sentrix beadarray technology is a direct hybridization based 
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approach to detect fluorescent-labeled copy RNA on DNA probes linked to glass beads 
randomly distributed on glass slides. Similarly, small non-coding RNA such as micro-RNAs 
(miRNA) can be processed, labeled with a generic nucleic acid code and hybridized to 
beadarrays used for general purpose. A similar technology is applied for the detection of 
single nucleotide polymorphisms, copy number variations and DNA CpG methylation ratio 
in genetic material of samples.
Bioinformatic and statistic challenges
The flexibility of Illumina gene expression arrays is not only an optional property, but the 
use of only one gene specific DNA sequence for most of the genes makes a greater 
flexibility necessary. Therefore, probes that do not behave optimally can be exchanged 
with annually updates of the bead pool. As a result, DNA probe sequences are 
continuously changing and this can be very challenging when signals form different bead 
versions are compared. The use of probe IDs that correspond to the DNA sequence of the 
given probe makes it easier for a better annotation to the newest genome assembly (Du et 
al. 2007). The use of open source software such as R/Bioconductor and customizable 
methods can be used to find the optimal procedure for analyzing microarray data (Du et al. 
2008). These methods include normalization methods to reduce or adjust signal intensities 
among or within strips. A simple method to stabilize the variance bias for some probes is to 
apply the logarithmic function to the signals. The results often get optimized when the log 
transformation is replaced by variance stabilizing transformation (VST) that converts high 
signals on a logarithmic scale and low values in a more linear way (Lin et al. 2008). To 
reduce different signal intensities among the samples a simple and fast method is to apply 
quantile normalization. This has usually little influence on single probe intensities because 
the high number of probes used for Illumina beadarrays limits strong manipulation of 
intensity data. However, there is no appropriate method for an absolute estimate of mRNA 
abundance. In addition, the sigmoid intensity shape, demonstrated when RNA is spiked in, 
indicates that fold changes are dependent on the signal intensity and that methods as 
quantitative PCR (qPCR) or transcriptomic deep sequencing are more adequate to 
estimate ratios across genes. In comparison with Affymetrix gene expression arrays, the 
background for Illumina beadarrays is not estimated on several probes for one gene but on 
the intensity of all probes on the chip. This results in high intensity values for not detected 
probes. Thus, a background subtraction or a filter for low intensity probes is necessary to 
avoid positive results for not expressed genes. An optimal method is VST or adjustments 
in the test statistics to keep high probability candidate probes with low expression signal in 
the test set without applying a exclusion filter on probes with low intensity values. It is also 
useful to adjust the resulting p-values for the multiple testing for these thousands of 
probes. To avoid problems for the bioinformatic processing of the gene expression data, a 
proper study design is absolutely essential. Replicates should be evenly distributed among 
the strips and the chips used. The processing of the biological material for example the in 
vitro transcription is also biased and therefore amplification of mRNA should be minimized.
Transformations and normalizations
There are many different ways to pre-process microarray data and combination of different 
transformations, normalizations and adjustments may be ideal for a study to be analyzed 
(Schmid et al. 2010). Many methods for the analysis of Illumina beadarrays have been 
developed on advanced methods used for Affymetrix gene chips. The main use of Illumina 
gene expression arrays here is the identification of genes with different expression under 
conditions with or without IFNα treatment. For a better illustration how Illumina gene 
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expression values behave with different processing, we used the data from knock-out 
animals. This data from mouse cells with deletions in the given gene illustrates differences 
in the data transformation and normalization of intensities (Illustration 3).
As expected, most of the transformations result in a normalization of the knocked-out gene 
to a background value. The heterozygous cells have expression values between knock-out 
and wt cells and the normalization for the outlying data from one wt cell (indicated in light 
blue) bring the value for the Tdg gene in the range of the other wt cells. A look at the 
literature indicates that several possibilities to improve normalization for every new Illumina 
beadarray type are reported from the labs. Illumina whole genome 6 sample arrays contain 
two strips, for example. One strip with probes for well expressed RefSeq genes and a 
second one for expressed sequence tags, hypothetical genes and genes from other 
sources. It has been recommended to normalize each of the strips separately to reduced 
influences of non-RefSeq genes and for better comparison to RefSeq arrays (Shi et al. 
2009).
Illustration 3: Comparison of normalization from knock-out, heterozygote and wild-type 
(wt) mouse embryonic cells. The expression data of the probe for TDG (matching to the 
deleted sequence of the knock-out mice) was transformed by a simple log2 transformation  
(RawData) or the variance stabilizing transformation (VST). After VST, Robust Spline 
Normalization (rsn), Simple Scaling Normalization (ssn), Quantile or Loess normalization 
was applied. The last method used for variance stabilization and normalization (vsn) is 
based on another approach (Huber et al. 2002). Values in light color were detected as 
outliers.
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Moderate t-test and false discovery rate correction of p-values
Advanced normalization methods may be useful in special cases to look deeper in to the 
samples than just to detect differential expression of some genes. Some of the methods 
can be useful for most of the microarrays available on the market. A list of differentially 
expressed genes with less than 5% false positives for example can be generated using a 
moderate t-test and application of false discovery rate (fdr) correction of the resulting 
p-value (Smyth et al. 2003). Moderate t-statistics take the absolute (fold) change in to 
account and p-value adjustment reduces the chances for reporting false positives to a 
meaningful cut-off (Illustration 4). The comparison between limma moderated t-test and 
equal variance t-test for samples generated from Tdg heterozygous or knockout fibroblasts 
shows as an example the effect of these adjustments (Cortázar et al. 2011).
Benefits of in-house and public databases & visualization in genome browser
The processing of micro-array data with open source programs enables fast and simple 
transformation of the results to genome browsers such as the USCS genome browser 
(Fujita et al. 2011) for better visualization and easy browsing of genes or chromosome 
locations. Once transformed to the BED14 format, custom tracks such as a panel of ten 
cancer cell lines treated with IFNα can be used to merge information on IFN response to 
annotations of the genome (Illustration 5).
Illustration 4: Comparison of t-test used for microarray analysis. Data taken from 
Affymetrix gene expression data set (Gene Omnibus Series GSE20693). Left: Ordinary p-
values from t-test statistic are compared to p-values of moderated t-test limma statistics 
and colored by absolute fold changes (yellow indicates small change and red indicates big  
differences in expression levels). Right: Effect of false discovery rate adjustment to the 
moderated t-test shown on the left, the values on x-axis show t-test statistics.
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Illustration 5: Data integration to the USCS genome browser taken from the data-set 
GSE21158 (Siegrist et al. 2011). Identification label of 10 cancer cell lines is indicated in 
the first column with treatment label: C (control, no IFNα, medium changed 24 hours 
before cell harvest), H (4 hours IFNα), D (24 hours IFNα). The color of the bars on the 
chromosomal location of the gene indicates the intensities of IFIT genes with undetectable  
levels in black and high expression levels in red (on a log scale).
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Introduction to the Chapters
Chapter 1 - Characterization of IFNα transcriptional responses in cancer 
cell lines
A hallmark of cellular resistance to type I IFNs is the lack of antiproliferative responses. 
Earlier results in our lab have shown that co-stimulation with IFNα and transforming growth 
factor beta-1 (TGFβ) potentates antiproliferative activity in a sensitive (ME-15) and 
resistant (D10) human melanoma cell line (Foser et al. 2006). IFNα therapy can be 
beneficial in the treatment of a diversity of cancer types partially due to stimulation of the 
immune system. Many cell types and some of the cancer cells have IFNARs and respond 
to IFNα. However, IFNα signals are different from tissue to tissue and do not always 
translate to a reduction in cellular growth or inhibit replication in cancer cells (table 2). 
Differences of growth inhibition in ME-15 and D10 cells are reported to be 21 % and 9 %, 
respectively (Pansky et al. 2000). These growth response rates are not stable over 
multiple passages of the cell lines. D10 cells acquired a more pronounced resistance to 
the growth-inhibitory action of IFNα during cultivation in our labs for example. This is 
partially due to massive rearrangements in the genome such as chromosomal crossover, 
duplications and deletion of entire parts of their genome. Cell-lines have been genotyped 
to generate a genomic fingerprint of the clones used in different laboratories and some of 
them acquired substantial rearrangements in the genome (unpublished data).
Cell line Origin / morphology Response 
on Chip
Response
apoptotic 
IFNα
Response
IFNα and 
TGFβ
Response
TGFβ
Response
IFNα
ME-15 Endothelian +++ + +++ ++ ++
D10 Endothelian +++ + +++ ++ +
AsPC-1 Pancreas +++ ++ +++ ++ ++
MIA PACA 2 Pancreas / epithelial ++ +++ + - +
HCT 116 Colon / epithelial ++ + - - -
LS 174T Colon / epithelial + +++ - - -
JUSO Endothelian + N/D + + -
Calu-6 Prob. Lung - N/D + + -
PANC-1 Pancreas / epithelial - N/D + + -
A549 Lung / epithelial - N/D + + -
Table 2: Panel of ten cancer cells lines cultivated for different purposes. Overview of gene 
expression responses and growth related responses to cytokines involved in cancer 
growth. Apoptotic response was estimated based on microscopic inspection of cell 
cultures treated with 10000 U / ml of IFNα. Stefan Foser, F. Hoffman-La Roche Ltd., Basel,  
kindly provided experimental data of growth-inhibition by IFNα and TGFβ. Experimental 
setup has been described (Foser et al. 2006).
DNA index in cultivated cancer cell lines
The acquired resistance to IFNα in D10 cells could be a result of higher rearrangement in 
the chromosome of D10 cells compared with ME-15 cells. The amplification rate is usually 
higher in cultivated cancer cells than the deletion rate. Thus the ratio of total DNA content 
of a cancer cell lines compared with healthy donor peripheral blood mononuclear cells 
(PBMC) was measured to estimate the 'chromosomal age' of these immortal cells. ME-15 
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and D10 melanoma cell lines were tested for their DNA content in the presence of IFNα 
and in control cells. Assignment of the cell cycle phase to IFNα-treated sensitive 
melanoma cells was less clear than for control cells (Illustration 6). However, no significant 
accumulation of cells in a specific cell cycle was observed. The DNA index (DI) of both 
ME-15 and D10 cell lines was 1.3. Therefore we can conclude that both cell lines have 
accumulated during carcinogenesis, immortalization and passaging an increase in DNA 
content of about 30%. The DNA accumulation is composed of an increase in chromosome 
number of about 47-49 chromosomes for D10 and 45-59 chromosomes for ME-15 (Pansky 
et al. 2000). On the other hand, duplications in the chromosomes and recombination of 
them attribute for the rest of the excess DNA.
Characterization of IFNα signaling in cancer cell lines 
Gene induction by small concentration of IFNα (100 U/ml) was analyzed in human cancer 
cell lines with differences in sensitivity to IFNα and TGFβ. The cell lines are separated 
according to their tissue of origin by expressing specific mRNAs (Illustration 7). The 
response to IFNα can be validated by filtering for primary and secondary response genes 
(Certa et al. 2003). Interferon induced 3 and 6 (IFI3 / IFI6) can be used for example as 
representatives of these two subgroups of stimulated genes (Hallen et al. 2007).
For some genes the mode of action has not been well characterized. Among them, genes 
like IFI44 and IFITM3 have highly changed expression levels in presence of IFNα (Siegrist 
et al. 2010). Some of the cells lines (Calu-6, PANC-1, A549) had no significant induction of 
classical ISGs what explains their resistance to growth control. Another panel of cancer 
cell lines (HCT 116, LS 174T, JUSO) are proficient in inducing ISGs to some extend but 
this does not translate in a block of proliferation. Therefore, the most promising cell lines to 
study antiproliferative function of ISG are ME-15, D10, AsPC-1 and MIA PACA 2 because 
they have most of the ISGs induced and IFNα affects their cell proliferation rate.
Illustration 6: Cell cycle inhibition of melonama cell lines (ME-15) treated with Pegasys. 
Control cells day 2 (right) and pegylated- IFNα (1000 U / ml) treated cells day 2 (left). No 
significant block of cell cycle observable.
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IFNα inducible microRNA profiles
There is a newly discovered group of non-protein coding genes that is also regulated by 
IFNα stimulation of cancer cell lines (Pedersen et al. 2007). These microRNAs (miRNA) 
are positive and negative regulators of eukaryotic gene expression that modulate transcript 
abundance by specific binding to sequence motifs located prevalently in the 3’ 
untranslated regions (3’-UTR) of target mRNA. IFNα induces a large set of protein-coding 
genes mediating antiproliferative and antiviral responses. The small number of identified 
miRNA and their small size of 19-22 nucleotides request fundamental changes in the 
detection technology and analysis. Here we used global microarray-based miRNA 
detection platform to identify miRNA genes that are induced by IFNα in HCC- or 
melanoma-derived human tumor cell lines. Despite the enormous differences in 
expression levels between these models, we were able to identify miRNAs that are 
upregulated by IFNα in both lines, suggesting the possibility that interferon-regulated 
microRNAs (IRmiRs) are involved in the transcriptional repression of mRNA relevant to 
cytokine responses (GSE16421).
IFITM3 expression and signal translation
For many years it has been known that the antiproliferative activity of IFNα can be 
effectively transferred to untreated recipient cells (Lloyd et al. 1983). We have shown that 
Illustration 7: Principal components analysis of 10 cancer cell lines. RNA of 10 untreated 
cell lines (C) was collected or from cells treated with IFNα (100 U / ml) and 4 (H) and 24 
hours (D) and analyzed on Illumina RefSeq8 gene-expression arrays.
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one of the differences between an IFNα antiproliferative sensitive (ME-15) and an 
insensitive (D10) cell line is the expression of IFITM3 at the unstimulated status in 
insensitive cell line (Brem et al. 2003). Thus, if a cancer cell becomes insensitive to the 
antiproliferative effect of IFITM3 its cellular levels are no longer a handicap and these cells 
are likely have deregulated protein levels. A recent report shows the antiproliferative 
function of IFITM1, a closely related family member of IFITM3 lacking the N-terminal 
sequence (Yang et al. 2007). IFITM proteins are also localized in cellular structures that 
appear as dots in the microscope and can be found associated to exosomes (Brem et al. 
2003). Therefore, they have the potential to transfer the antiproliferative signals to immune 
cells for example, what could explain the different evolution of these genes in man and 
mouse. We have detected this protein in the supernatant of expressing cells and that the 
addition of IFITM3 antibodies to the medium has a proproliferative effect on the generators 
(unpublished data that reproduced the initial observation from Stefan Foser, F. Hoffman-La 
Roche Ltd., Basel). IFITM family member are supposed to act as proliferation control 
proteins crossing the boundaries of a single cell. The cultivation of cells that do express 
IFITM with fluorescent-labeled recipient cells is therefore a potential method to analyze the 
effect in cell culture (Illustration 8).
Illustration 9: Overexpression of IFITM3 can induce senescence-like morphology: 
Melanoma cells (ME-15) were transfected with a SNAP-tag IFITM3 vector construct. The 
picture shows an extreme case of slow growing cell lines (clone SUE) before 
singularization.
Illustration 8: Snapshots of cocultures of IFN sensitive ME-15 cell line and the melanoma 
cell line D10 not showing a growth response to IFN.
MEV & D10 - 3d
MEV & D10 - 6d
MEV & ME-15 - 3d
MEV & ME-15 - 6d
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In addition the generation of IFITM expressing cells could result in a well-defined cancer 
cell line that has acquired resistance to IFNα. The cells infected with the plasmid are 
resistant against the selection antibiotic and are halted in proliferation and take flat shape 
of senescent cells (Illustration 9). This morphology has been described already for IFN 
treated cells (Pammer et al. 2006). However, some cells recover from the antiproliferative 
pressure of the IFITM3 by blocking expression of IFITM3 proteins. Some rare cell clones 
do proliferate and maintain the expression of small amounts of IFITM3 proteins. In contrast 
to our expectations, the cell lines analyzed (SUEG, SUEL and USDG) are normally 
responding to the antiproliferative effect of IFNα (Illustration 10). This result indicates that 
expression of IFITM3 is no indication for resistance to IFNα, but does not rule out the 
possibility that inhibition of IFITM3 transcription in cancer cells indicate sensitivity to IFNα.
Illustration 10: Growth response to IFNα of 
IFITM3-expressing cell lines
Growth response to IFNα of 
IFITM3-expressing cell lines
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Chapter 2 -Characterization of IFNα transcriptional responses in cancer 
cell lines overexpressing suppressor genes
Negative regulation of JAK-STAT signaling
A rapid onset of the IFNα signaling cascade and subsequent decay of JAK-STAT signaling 
is characteristic for this pathway and important for optimal regulation of transcriptional 
responses. Kinases, phosphatases and other enzymes can be recruited to the membrane 
rapidly after cytokine stimulation to inhibit signaling through the same pathway or in 
crosstalk with other pathways. The most direct way to interfere in kinase dependent 
signaling is deactivation by dephosphorylation of the crucial proteins. The phosphatase 
involved in IFN signaling is SHP2 and acts by inhibiting IFN-induced JAK-STAT signaling 
(You et al. 1999). PIAS proteins are another class of IFNα inhibitory proteins (Shuai 2000). 
They promote the sumoylation of STAT1 (Ungureanu et al. 2003; Rogers et al. 2003; 
Ungureanu et al. 2005). The last class of JAK-STAT inhibitory proteins has been described 
recently (Yoshimura et al. 1995; Endo et al. 1997; Masuhara et al. 1997; Minamoto et al. 
1997). Eight proteins with high similarity in amino acid structure form the family of 
suppressors of cytokine singaling (SOCS) proteins (See Illustration 11).
Suppressor of cytokine signaling
A plethora of cytokines induces SOCS1 and SOCS3 and the induction is dependent on 
different STAT molecules for example STAT6 (Albanesi et al. 2007). SOCS1 is induced by 
IFNα and several other cytokines, growth factors and pathogen associated patterns 
(Dickensheets et al. 1999; Wang et al. 2000). The IFNα mediated induction is dependent 
on the functionality of STAT2 and an active ISRE is present in the SOCS1 promoter region 
(Zhao et al. 2007). IFNα increases all small SOCS proteins tested (CISH, SOCS1-3) in T 
Illustration 11: SOCS protein inducing factors and signaling pathways controlled by 
negative feedback. Modified from (Yoshimura et al. 2005) and other reviews.
Name Structure Factors that induce expression Critical role in cytokine signaling
CIS1/CISH EPO, IL2, IL3, IL6, IL9, INFα, TNFα,GH, prolactin, EPO, TSLP GH, prolactin, IL2, IL3, EPO
JAB/SSI1/SOCS1
IL2, IL3, IL4, IL6, IL7, IL9, IL13, LIF, IFNγ, 
IFNα/β, TNFα, GH, prolactin, EPO, TPO, 
TSLP, G-/GM/M-CSF,  TPO, LPS, CpG
IL2, IL4, IL6, IL7, IL12, IL15, IFNα/β, 
IFNγ, LIF, TNFα, EPO, TPO, TSLP, GH, 
prolactin, insulin, leptin, LPS, CpG
CIS2/SOCS2 GH, IL6, LIF, IGF1, IFNγ, IFNα, prolactin, insulin, CTNF, cadiotropin, TSH GH, IGF1, IL6
CIS3/SSI3/SOCS3
IL1, IL2, IL3, IL4, IL6, IL9, IL10, IL11, IL13,
 GH, prolactin, EPO, GM-CSF, LIF, IFNα, IFNγ, 
leptin, IL10, LPS, insulin, CTNF, LPS, CpG
GCSF, IL2, IL4, IL6, IL9, IL11, IL23, IFNγ, 
IFNα/β, LIF, leptin, prolactin, insulin, EPO
CIS7/SOCS4
CIS6/SOCS5 IL6, IL4 IL4, IL6
CIS4/SOCS6 insulin
CIS5/NAP4/SOCS7 insulin
KIR
SOCS-boxSH2
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cells, this indicates a more general effect of IFNα on SOCS expression in haemopoietic 
cells compared to epithelial cells (Brender et al. 2001). Among the eight SOCS proteins 
that may be able to interfere in IFN signaling, genetic evidence from knockout mice show a 
direct target receptor regulatory role only for SOCS1 and SOCS3 (Illustration 12 A) 
(Alexander et al. 2004; Yoshimura et al. 2007). The inhibitory interaction of SOCS is 
partially kinase-independent by a steric block of the activated IFNAR and requires 
functional SH2 and SOCS box domain in the case of SOCS1 (Fenner et al. 2006; Gingras 
et al. 2004; Walsh et al. 2006). The primary mode of action is SOCS1 interaction with a 
critical phospho-tyrosine residue within the JAK2 catalytic loop (Endo et al. 1997) 
(Illustration 12 B). The interaction may be through a specific domain in SOCS1 and 
SOCS3, the kinase inhibitory region (KIR) or by the phospho-tyrosine binding domain SH2 
in dependence of the N-terminal domain. The kinase inhibitory regions of SOCS1 and 
SOCS3 are able to block kinase activity of JAKs by acting as pseudo-substrate (Yasukawa 
et al. 1999; Sasaki et al. 1999). This domain may also bind to the autophosphorylation 
loop of Jaks (Waiboci et al. 2007; Flowers et al. 2004). Furthermore, structural modeling 
indicates that a block of kinase activity can operate simultaneously with restriction of target 
protein access to the catalytic cleft (Giordanetto et al. 2003). A direct and persistent way to 
inhibit IFNα activated JAK-STAT signaling by SOCS proteins is the recognition of tyrosine-
phosphorylated sites of the signaling proteins involved by the SH2 domain and poly-
ubiquitination through the SOCS-box (Illustration 12 C). This results in the degradation of 
JAK-STAT proteins and consequently reduces the amplitude of ISG expression. There is 
evidence for an association of SOCS3 with JAK1 and SOCS1 mediated ubiquitination and 
degradation of Tyk2 (Qing et al. 2005; Nguyen et al. 2006). In addition to SOCS1-IFNAR, 
receptor-kinase interactions are blocked dependent on SH2-phospho-tyrosine recognition 
during inhibition of IFNα by SOCS3 (Illustration 12 D) (Vlotides et al. 2004; Pauli et al. 
2008).
SOCS dependent ubiquitination and proteasomal activity is involved in the regulation of 
JAK-STAT pathways for several other cytokines (Kim et al. 1996; Yu et al. 1997; Boyle et 
al. 2009; Lang et al. 2003). These mechanistic studies are crucial to understand SOCS3-
dependent IFNα signaling suppression and cross-talks of negative feedback-loops in 
Illustration 12: Mechanism of JAK-STAT pathway regulation by SOCS1, SOCS3 and PIAS.
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different signaling pathways (Illustration 12 E). There is no reported function for nuclear 
SOCS proteins in IFN signaling although SOCS1 molecules can locate to the nucleus and 
have a nuclear-import signal (Ben-Yair et al. 2002; Baetz et al. 2008; Koelsche et al. 
2009). In contrast, PIAS proteins act primary on activated STAT proteins in the nucleus 
(Illustration 12 F) (Liu et al. 1998; Liao et al. 2000; Ungureanu et al. 2003; Rogers et al. 
2003).
As summarized in Illustration 11, there is support for an important role of other SOCS 
molecules in the regulation of IFNα signals. However, imbalances in SOCS2 levels have a 
strong effect on growth hormone signaling and both knockout as well as overexpression 
correlates with abnormal growth (Favre et al. 1999). Interestingly, SOCS2 overexpression 
blocks the inhibitory action of SOCS1, SOCS3 and CISH. Thus, SOCS2 may also regulate 
IFNα-dependent signaling pathways (Shen et al. 2000). This requires an intact SOCS-box 
and suggests that SOCS2 is involved in the ubiquitination of SOCS1 and SOCS3 (Rico-
Bautista et al. 2006). We have analyzed the induction of SOCS4 over a period of 72 hours 
by qPCR. SOCS4 mRNA signals were elevated after incubation of ME-15 cells with IFNα 
compared to untreated cells before treatment but no protein could be detected in the cells 
to confirm this result (unpublished data). To our knowledge, there is no study on 
overexpressed SOCS1, SOCS3 and SOCS4 proteins in suppression of IFNα signaling and 
a report of nuclear functions of SOCS proteins in JAK-STAT signaling.
SOCS proteins may be targeted to control JAK-STAT signaling in cancer cells or to 
enhance responses to IFNα therapy. The therapeutic effect of IFNα is due to ISG induction 
in infected / cancer cells or immune cells. Therefore, the analysis of gene expression in 
response to IFNα treatment of cancer cell lines has the potential to conclude from the 
expression pattern of cells with elevated SOCS levels what the potential of a new class of 
IFNα combination therapy with SOCS inhibitors may be. Recent reports on miRNA 
induction by IFNα and miRNAs that target SOCS mRNA are indicating a feedback-loop for 
the negative regulators in cytokine signaling (Pedersen et al. 2007; Pichiorri et al. 2008; 
Sun et al. 2008; Hu et al. 2009; Lu et al. 2009; Androulidaki et al. 2009; Hu et al. 2010; 
Pogribny et al. 2010; Jiang et al. 2010b; Wang et al. 2010). Deregulation of miRNA 
Drawing 1: Model: Therapeutic regulation of SOCS proteins. 
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involved in this pathway could play a role in IFNα resistance and may be measured 
systematically in the blood of patients. We have therefore analyzed the potential role of 
IFNα-induced miRNA in the regulation of SOCS mRNA translation.
Interferon-dependent gene expression profiling in SOCS expressing cell lines
To clarify the impact of SOCS proteins on IFNα induced gene expression in the melanoma 
(ME-15) and HCC (HuH-7) cell lines, we have generated SOCS overexpressing cell lines 
and characterized their IFNα-induced gene expression profile. This data refines the reports 
on cytokine suppression mechanisms in our cell culture model system. The analysis of 
cytokine signal-suppression in a similar cellular context as in vivo with HCV infection and 
cancer is important for the understanding of resistance to the therapy. SOCS proteins act 
in a classical negative feedback-loop against the action of IFNs and many other cytokines 
(Fujimoto et al. 2003). SOCS1 and SOCS3 inhibit the expression of IFNα inducible 
antiviral proteins (Vlotides et al. 2004). In contrast to SOCS1 and SOCS3, the importance 
of SOCS4 is not known. Limited by the assay set-up, sample triplicates, two time-points, 
two cell lines and controls for every sample, we decided to analyze cell lines expressing 
three different SOCS proteins and the parental cancer cell lines. The RNA extraction 
procedure adapted for the recovery of small RNAs allows the use of RNA extracts for gene 
expression and miRNA expression beadarrays. The miRNA expression profile in our 
cancer cell lines may resolve whether the same JAK-STAT pathway induces both miRNA 
and the classical ISGs.
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Chapter 3 - Epigenetic alterations in colon cancer, cell lines treated with 
IFNα and knock-out phenotype of a DNA damage response gene 
involved in epigenetic stability in vivo
Interferon stimulated genes and DNA methylation in cancer
Epigenetic silencing of tumor suppressor genes is contributing to carcinogenesis and 
malign-transformation of cancer cells. CpG islands in the promoter region of the SOCS1 
gene get frequently methylated during carcinogenesis and promoter hyper-methylation 
correlates with protein levels in many cancer types such as HCC (Miyoshi et al. 2004; 
Nomoto et al. 2007; Okochi et al. 2003; Chu et al. 2010). Other ISG are also deregulated 
in cancer, but for IFITM3 for example, there is no well-defined CpG island the promoter 
region. However, when the definition for CpG island is relaxed some CpGs are found in the 
proximity of IFITM3. Silencing of IFITM genes promotes migration and growth in cancer 
cells and is associated with aberrant DNA methylation of the IFITM3 promoter. Methyl-
specific qPCR correlated DNA methylation in that region to the CpG island methylator 
phenotype (CIMP) defined in colorectal cancer (CRC) tissues (unpublished data from 
Stefan Weis, University of Basel). Further, SOCS1, SOCS2 and SOCS3 CpG mehtylation 
occurred over all probes in the CIMP CRC sample and only some SOCS probes in the 
non-CIMP sample were methylated. For this small sample size screen, SOCS2 promoter 
mehtylation showed better correlation to mutL homolog 1(MLH1) methylation than SOCS1 
(unpublished data). This finding documents the complexity in classifying CRC samples as 
CIMP+ or CIMP- phenotype. Hyper-methylation of SOCS1 in CIMP is well known and 
SOCS1 promoter methylation is part of the new CIMP definition set (Weisenberger et al. 
2006; Ogino et al. 2007a; Ogino et al. 2007b). This data set can be used for better 
determination of CIMP+ and CIMP- status than the original set of sequences (Teodoridis et  
al. 2008). Promoters of genes from this CIMP set, such as SOCS1, are found also in 
Illustration 13: Principal component analysis of CRC cell lines
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breast cancer (Van der Auwera et al. 2010). Therefore, clinical samples may be used to 
find a link from SOCS or IFITM expression and promoter methylation to therapeutic 
response to chemotherapy, for example using recombinant IFNα.
The use of gene expression arrays to screen changes in mRNA levels of genes that are 
methylated in CIMP samples may be limited by the low expression of these genes in 
control tissue. A preliminary screen of six CRC cell lines could in fact separate the CIMP 
(MHL1 methylated) from non-CIMP cancer cell lines (Illustration 13). Several genes are 
lower expressed in cancer cell lines and can be analyzed further by quantitative 
methylation specific PCR (qMSP). A gene that was highly expressed in non-CIMP colon 
cancer cell lines was intestinal trefoil factor family 3 (TFF3): This is a JAK-STAT induced 
gene and has been implicated with proliferation and migration in cancer (Jiang et al. 
2010a). Therefore, the direct analysis of promoter methylation of such genes is in the 
focus of current research and shed light on the association of DNA methylation and 
prognostic implications in cancer patients. Hypermethylator (CIMP) and micro-satellite 
instability phenotype in CRC are critical indicators for clinical outcome (Kim et al. 2009a; 
Issa 2008; Boland et al. 2010).
Beadarrays covering most of the cancer related genes are available to analyze 
methylation specific differences in patient specimens or in cell culture. Therefore, we have 
initiated a project to integrate transcriptome and epigenome analyzes in CRC samples. 
Early detection in ademomas before a cancer becomes malignant could improve benefits 
for the patients. Systematic analysis of the methylation fingerprint of CRC cancers may be 
used to sub-group patients, update CIMP methylation site diagnosis panel and provide an 
opportunity for personalized healthcare. Today, detection markers for early diagnosis of 
cancer risk in adenoma do not cover a large group of patients. Therefore, we are 
interested in finding a panel of candidate biomarkers by combination of different micro-
array technologies to address this task.
Adenomas are thought to generally precede a CRC stage and were screened in 32 
adenomas from 28 patients on Affymetrix Chips (GSE8671) (Sabates-Bellver et al. 2007). 
A key feature of in this study was remodeling of the Wnt pathway, which is also affected by 
the IFITM family proteins (Lickert et al. 2005; Siegrist et al. 2011). To identify candidate 
gene regions undergoing aberrant methylation at early stages of CRC, integration of 
different types of microarray data is reasonable. Gene expression profiles in colorectal 
adenomas and normal mucosa, gene expression analysis of CRC cell lines treated with 
demethylating agents and beadarray assisted comparison of DNA methylation in normal 
and CRC samples can generate a list of candidate genes for early detection of CRC 
malign-transformation.
We have observed specific methylation pattern of IFITM genes in CIMP patients and some 
of the CpGs may be important for IFITM deregulation in cancer in general. CpG sites in the 
promoter of IFITM genes may be therefore dynamically regulated and factors that promote 
gene induction from repressed genes in cancer cells may have a general influence on 
them. IFITM3 mRNA is not expressed in ME-15 cell but it is inducible by IFNα. Therefore, 
cytokine stimulation may contribute to dynamic DNA promoter methylation dependent on 
cellular factors.
IFNα regulates DNA damage repair pathways as well and nuclear SOCS1 plays a 
regulatory role in that (Calabrese et al. 2009). Thymine-DNA glycosylase (TDG) is involved 
in excision of mismatch GT nucleotides in the DNA repair mechanism of cells (Cortázar et 
al. 2007; Kunz et al. 2009). TDG may act as modifier in dynamic DNA methylation 
alterations as proposed for IFNα induced dynamic regulation of DNA methylation. Gene 
expression experiments in TDG knock-out animals promise to generate lists of genes that 
are regulated by mismatch-directed DNA glycosylase.
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Conclusion and Outlook
Chapter 1
Characterization of IFNα transcriptional responses in cancer cell lines
IFNα provides cellular defense mechanisms against cancer and viral infections and are 
used as drugs to improve health after tumor-surgery or together with antiviral formulations 
to fight viral infections. Many questions remain unanswered and more basic research is 
needed to understand the functional interaction of the ISGs to fully realize the potential of 
IFNα.
We have assessed cell type specific differences in gene expression of several cell lines 
used in basic research laboratories. Cytokine treatment of cells showed indirectly JAK-
STAT pathway activation. These results can be used to select the optimal cell line for a 
functional study of proteins or drugs. Small double strand RNAs can induce interferon 
production, one of the side effects that may appear when recombinant small interfering 
RNA is used, for example. Obviously, a cell culture model must be responsive to IFNα for 
the evaluation of both IFNα pathway activation and target mRNA silencing on the 
transcriptome level. Further, pericellular proteins, for example IFITM3, can be detected in 
cell culture supernatant and may indicate excessive IFNα signaling in treatment-naive 
individuals.
We have further characterized functional aspects of ISG, such as IFI44, the IFITM gene 
family and SOCS genes. This may help understand the specific cellular and clinical effects 
in response to IFNα. However, our results of ISG functionality are based on in vitro 
experiments only and have to be confirmed in a clinical setting. Further, the development 
of advanced methods for RNA preparation, to conserve the small RNA part for example, 
the evaluation of different in vitro transcription procedures and most of all the adaptation 
and development of bioinformatic and statistic methods for alternative microarray analysis 
could improve the scientific value of the results. Pioneer work in the analysis of miRNA and 
DNA methylation beadarray data introduced new prospects in the research for 
unappreciated aspects of cytokine signaling for example. Some of the technologies may 
disappear in the near future and be replaced by more sophisticated methods like next 
generation sequencing. We could show that microarray based detection of miRNA is 
useful to detect change in expression levels but is limited to estimate the expression ratio 
of miRNAs in the same sample. The bias towards certain small RNAs is as well an issue 
when using a deep sequencing approach to quantify miRNA levels and is not entirely 
comparable with qPCR. However, the expression ratios of miRNA sequencing and qPCR 
quantification methods are highly correlated (Linsen et al. 2009).
Chapter 2
Characterization of IFNα transcriptional responses in cancer cell lines 
overexpressing suppressor genes
We have assessed the role of SOCS proteins in repressing the functionality of IFNα 
signals in different cancer cell lines and concluded that SOCS1 is able to repress 
transcriptional response in cancer cell lines of different origin. However, transcripts of 
genes that are not dependent on JAK activation are less affected by the silencing. Among 
them are STAT1 and IRF9, well known players of the JAK-STAT pathway. SOCS3 
expressing cell lines did not show such an overmastering effect and may play a minor role 
in the translation of the IFNα signal to the antiproliferative effect in cancer cell lines. 
However, SOCS3 may limit antitumor action of IFNα in stimulation of immune effector cells 
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and in tumor-antigen presentation. Our results from SOCS overexpressing cancer cell 
lines extend our knowledge of the molecular causes of resistance to IFNα in HCV and 
cancer. The bias of SOCS proteins for a specific kinase may be dependent on the 
extracellular mediator or the cell type. This aspect is crucial for normalizing JAK activation 
in cancer cells in therapy with SOCS mimics. SOCS3 interacts with Tyk2 to silence TLR3 
signaling for example (Zeng et al. 2008). Moreover, SOCS1 can bind JAK2 and 
subsequently initiate ubiquitination and degradation of the kinase in IL6 signaling (Ali et al. 
2003). These are two examples that further reveal details of the functionality of SOCS-box 
mediated kinase degradation in general. Research on SOCS proteins will help to 
understand how SOCS deregulation promotes cellular growth in carcinogenesis and may 
help to design small molecules to restore growth control. On the one hand, mutations 
occur in SOCS1 genes with defective JAK2-degradation activity and this can be restored 
by insertion of wt SOCS1 in vitro (Melzner et al. 2005). On the other hand, in tumor cells 
with genetically based constitutive activation of JAK2 or SOCS1 mediated degradation can 
limit aberrant signaling (Kamizono et al. 2001; Frantsve et al. 2001; Haan et al. 2009). This 
indicates that hyper-methylation of SOCS1 promoter can induce lost of growth control in 
cancer cells with aberrant DNA methylation and SOCS mimics may be used in therapy.
All HuH-7 SOCS expressing cell-lines lost CD81 expression and cannot be used for HCV 
in vitro models because CD81 is a required co-receptor for HCV entry (Bartosch et al. 
2003; Cormier et al. 2004; Zhang et al. 2004). Moreover, CD81 is a tetraspanin protein that 
promotes HCV entry via its interaction with the viral E2 protein and can be associated with 
IFITM-proteins (Takahashi et al. 1990; Bradbury et al. 1992; Deblandre et al. 1995). 
Therefore, it is unlikely that the SOCS-modified HuH-7 cell lines can be used for 
experiments to address suppression of antiviral activity of IFNα Since this effect has not 
been observed in ME-15 cells, it must be a cell type specific response to either the 
selection procedure applied (Geneticin or response to singularization of the cells) or to a 
common genetic feature introduced by the plasmid containing either SOCS1, SOCS3 or 
the IFN non-responsive SOCS4 in HuH-7 cells. But this connectivity among ISGs shows 
how important the use of genome-wide gene expression experiments is to understand 
consequences of genetic mutations that occur during the cultivation of cell lines.
25 years after the introduction of IFNα in the clinics, the mechanism of resistance to IFNα 
remains a secret. Our project was initiated to describe a link between resistance in cell 
lines and SOCS proteins. Resistant cell lines with high SOCS expression could be used 
for screening drug libraries to find SOCS inhibitors that may prolong IFN treatment 
efficiency and thus reduces dosing interval in patients. However, we did not find high 
expression of SOCS mRNA in cell lines tested here. The generation of SOCS expressing 
cell lines enabled closer investigation of their transciptome profiles in response to IFNα 
treatment. However, concerns about the safety profile of SOCS inhibitors should be first 
clarified before entering drug development. The deletion of the negative feedback 
regulator SOCS3 enables excessive STAT3 activation and is associated with increased 
tumor numbers for example (Rigby et al. 2007). Potent SOCS1 antagonists have been 
described several years ago, for example a JAK2 peptide phosphorylated at Tyr1007 
(Waiboci et al. 2007). This small molecule exerts broad antiviral activities, synergizes with 
the IFNγ mimic IFNγ(95-132) at the level of transcription and enhances cellular and 
humoral immune response (Ahmed et al. 2010; Frey et al. 2009). Additionally, it shows 
also inhibitory function against SOCS3 when overexpressed and enhances IFNγ activity 
(Ahmed et al. 2010).
The opposite approach, to treat IFNα resistant HCV infected patients with activated IFNα 
cascade before treatment or cancer patients with constitutive JAK activation, SOCS 
agonist may be used to control JAK-STAT signaling. Peptides mimicking SOCS1, tyrosine 
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kinase inhibitor peptide Tkip or the kinase inhibitory region of SOCS1 (SOCS1-KIR) could 
be used as inhibitors of JAK2 activation (Waiboci et al. 2007). The main difference of the 
two peptides is that Tkip does inhibit JAK2 autophosphorylation and IFNγ-induced STAT1α 
phosphorylation, whereas SOCS1-KIR only inhibits STAT1α activation (Waiboci et al. 
2007).
The use of SOCS targeting drugs is probably limited to a certain subgroup of patients and 
factors determining the responsibility are needed. In our in vitro model, induction of 
SOCS3 protein expression had no significant effect on gene expression levels arguing for 
IFNα sensibility in melanoma cells regardless of both the SOCS3 expression and the 
status of STAT3 activation in the cells.
SOCS1 and SOCS3 mRNA expression levels are reduced in the HCC region of HCV 
infected patients and result in hyper-activated STAT3 (Ogata et al. 2006). This may be due 
to SOCS3 promoter methylation and is true for numerous cancer types including HCC 
(Weber et al. 2005; Niwa et al. 2005; He et al. 2004). However, reduction in SOCS 
expression levels can also occur without promoter methylation (Yoshida et al. 2004). The 
hyper-activation of JAK-STAT pathway is repressing pro-apoptotic genes and SOCS 
mimics may overcome resistance to apoptosis in cancer such as HCC (Jarnicki et al. 
2010). However, application of SOCS mimics may only find application in patients where 
the IFN response is studied thoroughly since general application could interfere with the 
constitutive 'weak' IFN signaling which is crucial for a strong response to the cytokine 
(Taniguchi et al. 2001).
In addition to systemic administration of SOCS inhibitors, to stimulate both antiviral or 
antitumor action of affected cells and cells of the immune system, development of 
antibody-drug conjugates (ADC) may deliver the inhibitors specifically to cancer cells for 
example with a HER2 positive phenotype. The first ADC from Roche submitted to the FDA 
is a similar conjugate: trastuzumab-DM1 is in clinical development; here HER2-antibodies 
are linked to a chemotherapeutic to increase specific anticancer activity (Lewis Phillips et 
al. 2008; Niculescu-Duvaz 2010). A crucial step in the development of SOCS targeting 
therapies is in my opinion the monitoring of SOCS levels in patients undergoing a IFNα 
therapy.
Chapter 3
Epigenetic alterations in colon cancer, cell lines treated with IFNα and 
knock-out phenotype of a DNA damage response gene involved in 
epigenetic stability in vivo
We have shown different localization of SOCS1 and SOCS3 proteins. Overexpressed 
SOCS1 is predominantly distributed in the nucleus of IFNα naive cells. However, there is 
no indication of JAK-STAT modulation by nuclear SOCS1. Recently, the function of nuclear 
SOCS1 has been linked to IFNα-induced senescence and depends on the formation of 
SOCS1-p53-ATM complexes (Calabrese et al. 2009). The nuclear function can be 
triggered by ATM DNA damage repair and results in stabilization of activated p53 
transcription factor and a prolonged cell cycle arrest. Clarification of the mechanisms that 
mediate SOCS1 nuclear localization and recruitment to DNA damage sites would be 
crucial to determine how SOCS1 mediates its tumor suppressor activity. An open question 
is if mutant SOCS1 proteins that do not localize to the nucleus are potent to inhibit 
cytokine signaling. Mutants could be generated by mutation of the nuclear localization 
signal or by insertion of a nuclear export signal.
The interaction of SOCS1 with the DNA damage pathway links this protein to epigenetic 
activities. Collectively we have found indications that the loss of a gene (Tdg) involved in 
29
DNA damage repair can induce remarkable epigenetic changes in embryonic cells. 
Furthermore, cell lines treated with cytokines dynamically modify the percentage of DNA 
mehtylation at unique CpG sites in the promoter of IFITM3. This result has to be confirmed 
for other ISGs and the mechanism of demethylation and the proteins involved in this 
process have yet to be identified. CpG sites in the promoter sequence of IFITM3 undergo 
aberrant methylation in CRC cancer specimens and SOCS1 CpG island methylation ratio 
is taken as one factor to classify CRC patients. Therefore, it would be interesting to screen 
clinical samples for IFNα sensitivity, especially from patients in a therapy with drugs that 
restore the normal, demethylated state of the SOCS1 promoter. Arsenic trioxide (A2O3) 
may be used as adjuvant therapeutics in multiple myeloma cells for example by 
counteracting hypermethylation (Wang et al. 2008). In addition, SOCS3 CpG promoter 
methylation status may be involved in the response rate and overall survival of cancer 
patients treated with therapeutic CD33 antibodies (Mylotarg®) and the outcome depends 
on the age of the patients (Middeldorf et al. 2010). This suggests that an age related 
cancer-selective change in CpG methylation patterns of SOCS and tumor suppressor 
proteins influences the survival of patients. Therefore we suggest to screen cancer 
patients for their CpG methylation pattern to correlate response rate and overall survival to 
cancer specific SOCS expression. The costs of such experiments will be marginal 
compared to the costs resulted from the Mylotarg® withdrawal for example, when 
combination of CD33 antibodies to chemotherapy resulted in higher death rates and no 
benefit for the study cohort (SWOG S0106). SOCS screenings may provide an advance in 
personalized healthcare by reducing risks and raise the benefits from anti-cancer 
medicines. Therefore, large prospective studies on SOCS1 and SOCS3 hypermethylation 
on response and outcome of anticancer drugs are warranted.
Personally, I recommend publishing raw data generated by microarray assays or deep 
sequencing in one of the public databases. This allows reusing clinical data and to perform 
meta-analyzes. This allows further analyzes of clinical trials that lack statistical power to 
generate valuable data for ongoing research. Further, the data can be validated, used as 
confirmation of the own data or used to generate new hypotheses in basic research.
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The Small Interferon-Induced Transmembrane Genes and Proteins
Fredy Siegrist¹, Martin Ebeling², Ulrich Certa¹
¹ Non-Clinical Safety and ² Computational Biology, F. Hoffmann-La Roche Ltd., Basel, 
Switzerland.
Abstract
Interferon-induced transmembrane (IFITM) genes are transcribed in most tissues and are 
with the exception of IFITM5 interferon inducible. They are involved in early development, 
cell adhesion, and control of cell growth. Most IFITM genes are activated in response to 
bacterial and viral infections, and the exact host immune defense mechanisms are still 
unknown. Elevated gene expression triggered by past or chronic inflammation could 
prevent spreading of pathogens by limiting host cell proliferation. Accordingly, induction in 
cells with low basal protein levels is sufficient to drive growth arrest and a senescence-like 
morphology. On the other hand, loss of IFITM levels in cancer is correlated with 
pronounced malignancy; thus, these genes are considered as tumor suppressors. 
However, several cancer cells have deregulated high levels of IFITM transcripts, indicating 
a tumor progression stage where at least one of the interferon-controlled antiproliferative 
pathways has been silenced. Phylogenetic analyses of the protein coding genomic 
sequences suggest a single interferon-inducible gene in the common ancestor of rodents 
and primates. Biological functions studied so far may have evolved in parallel, and 
functional characterization of IFITM proteins will provide insight into innate immune 
defense, cancer development, and other pathways.
Introduction
Interferon-stimulated genes (ISG) are abundantly expressed in many different tissue types 
shortly after administration of interferon (IFN) in vitro and in vivo. These proteins have 
multiple functions such as antiviral, antiproliferative responses to stimulants of the immune 
system. Although several activities are reported for most of the genes, open questions 
remain concerning the biological function of IFN-activated cascades. Some members of 
this class have been found significantly downregulated in cancer screenings for metastatic 
and nonmetastatic melanomas (Brem and others 2001b). The interferon induced 
transmembrane (IFITM) genes IFITM1, IFITM2, and IFITM3 (IFITM1-3) belong to the 
family of small ISGs. Its members are induced in response to viral infections (Martensen 
and Justesen 2004). The IFITM protein levels and their inducibility may play a crucial role 
in the IFN therapy in hepatitis C infections and in melanoma adjuvant therapy. We 
assessed the function of IFITM3, which encodes the human 1-8U protein, in melanoma 
cell cultures in an IFN- sensitive cell line (ME-15) (Zhang and others 2006) or in cell line 
D10 that shows no antiproliferative activity. In the responder line IFITM3 is induced 
together with antiproliferative activity, whereas IFITM3 shows constitutive expression in 
D10 (Brem and others 2003). IFN-activated antiproliferative signals can be transmitted 
from cell to cell in vitro (Lloyd and others 1983). The molecular basis of this mechanism 
has not been resolved yet, and a role of IFITM proteins in the transmission of the signals 
remains to be proven. In addition to the antiproliferative activity, several functions of the 1–
8 family members have been proposed, and published interactions are summarized in 
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Table 1.
Discovery of IFITM and Related Gene Products
The IFITM gene family was first identified in a cDNA screen from IFN-treated 
neuroblastoma cells back in 1984 (Friedman and others 1984). Other members, such as 
human IFITM5, were discovered by genomic homology searches soon thereafter. Upon 
publication of the first genome drafts from rodents and humans, we realized that the 
genetics of the IFITM family was more complex than expected. Their chromosomal 
arrangement is not conserved between human, mouse, and rat both in length and in 
number of genes present in the chromosomal locus (Fig. 1). IFITM5, also known as bone 
restricted IFITM-like (BRIL) protein, is situated upstream of the human 1–8 protein 
chromosomal locus. The protein has recently been described as bone-specific modulator 
of mineralization and is significantly expressed neither in immune cells nor by IFN 
stimulation of sensitive cells (Moffatt and others 2008).
Beside this heterogeneous family we find some considerably conserved proteins, tumor 
suppressor candidate 5 (TUSC5), and proline-rich transmembrane protein 2 (PPRT2) that 
are not IFN inducible but share the 2 dominant hydrophobic regions. The TUSC5 shares 
the CD225 domain and is predominantly expressed in human cultured adipocytes (Oort 
and others 2007) and was described as a potential tumor suppressor (Konishi and others 
2003). The closest relative to TUSC5 is the PRRT2 (Morrison and Farmer 1999). The 
proposed common function for these 2 proteins is an involvement in cell cycle control.
A small fraction of 14 kDa IFITM-like polypeptides turned out to be much more 
immunogenic in mice than the predominant lipids present in the electric organ plasma 
membrane of proteolipid extractions from Torpedo fish (Morel and others 1991). As 
expected the antibodies obtained recognized preferentially membrane structures and the 
antigen was postulated to be involved in cell–cell interactions based on the subcellular 
localization. IFITM-like proteins connected with leukocyte functions were also found in 
other fish after poly(I:C) stimulation, and IFITM is induced in sea urchins following bacterial 
challenge (Rast and others 2000; Johnson and others 2006; Wan and Chen 2008). The 
genetic arrangement in fish shows similarities to the human promoter organization with 
IFN- and immune and stress-related transcription factor binding sites (Johnson and others 
2006).
Proteins containing CD225 domains are known from humans to bacteria, and some, but 
not all, vertebrate genes are IFN inducible. Below we present for the first time a 
comprehensive analysis on the evolution of 100 IFITM genes across several species using 
a genome-based phylogenetic approach. This allows better understanding of shared 
properties of IFITM proteins and discrimination of their pleiotropic functions in an 
evolutionary context.
Amino Acid Conservation and Functional Domains
Our analysis focuses on sequence conservation in vertebrate proteins with clear homology 
to human and mouse IFITM proteins. About 14–17 kDa proteins were identified in various 
species in response to pathogen challenge or IFN exposure. The human IFITM family was 
originally found in screens for IFN alpha (IFNα)-inducible genes. The functional importance 
for developmental processes was assessed in rodents, whereas uterine formation was 
studied in ruminants. Similar IFN-induced proteins (IIP) were detected in liver of the marble 
electric ray. We have compiled sequences that share a significant number of amino acid 
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(AA) similarities with the human and mouse IFITM proteins (Supplementary Table S1).
This set of sequences forms a group of proteins with a conserved CD225 domain and 2 
exons encoding transmembrane spanning polypeptides (Fig. 1). The length of proteins 
included in the current analysis ranges from 102 to 157 AA with median length of 132 AA. 
The core AAs are highly similar in all sequences, whereas the length and identity of the 
distal residues is more variable. Among the sequences analyzed, mole salamander 
proteins have maximum length (157 AA residues), and the nonmammalian proteins show a 
certain degree of length polymorphism.
For easier interpretation, the AA frequency is shown graphically for BRIL-like, mammalian, 
and nonmammalian sequences separately in Fig. 2. This classification allows identification 
of a conserved aspartate-rich domain at the carboxy terminus of BRIL proteins (Fig. 2). 
The BRIL-specific structure is highly similar to calcium binding domains (Rigden and 
Galperin 2004) and may be crucial for mineralization of bones. There are some additional 
IFITM protein domain (IFITMD)-containing proteins. TUSC5 (IFITMD3) and PRRT2 
(IFITMD1) are the closest relatives of the IFITM family in human code for a CD225 domain 
and share the position of the single IFITM splice site. In TUSC5, the first intron and the 3'-
untranslated region are larger compared to IFITM genes and the mRNA has a second 
splice site just before the STOP codon. The PRRT2 gene has an intron before the start 
codon and the protein has a longer amino terminal domain. In conclusion, all functional 
CD225 proteins in vertebrates share a single exon–exon splice junction within the highly 
conserved domain and are probably derived from an early duplication event in the 
evolution of chordates.
Phylogenetic Analysis Reveals Recent IFITM Gene Duplication
In addition to the ancient gene relationships outlined above, the IFN-inducible IFITM family 
has also significantly evolved much more recently. Human IFITM genes all have 2 exons 
separated by a short intron and are located in a cluster on the left arm of chromosome 11 
(11p15.5). IFITM5 is located upstream of the first 3 IFITM genes and apparently lacks any 
IFN response elements (Fig. 1). The IFITM gene structure including a conserved splice 
site is highly similar in vertebrates. This allows us to estimate when gene duplications such 
as the recent duplication leading to human IFITM2 and IFITM3 occurred.
The exact human gene arrangement is only replicated in the chimpanzee and orangutan 
genomes. Two IFITM3-like genes in the rhesus macaque genome cannot be 
unambiguously assigned as orthologs to either human IFITM3 or IFITM2. In mouse, the 
fragilis gene cluster is located in the distal arm of chromosome 7 (Lange and others 2003). 
Four IFN-inducible protein coding genes are contained within a 60 kb region and the 
organization is entirely different from the human gene arrangement (Fig. 1b). The mouse 
proteins all have divergent termini and these distal regions may have limited relevance for 
protein function (Fig. 1a). We have collected sequence information for IFN-inducible 
IFITM-like proteins to calculate the evolutionary distance and relationships (Supplementary 
Table S1). Each candidate sequence was manually inspected for computational artifacts. 
For example, in the gorilla genome draft (gorGOR1 at EMBL), sequence gaps masked 
parts or entire coding exons and interfered with automatic splice site prediction. We 
excluded genes lacking the highly conserved S(V/T)K–(S/A)RD AA pattern together with a 
functional splice site in the center. Phylogenetic analysis of 100 IFITM like DNA sequences 
using a maximum likelihood approach (as implemented in the DNAML program of the 
PHYLIP package) identified separated branches for all IFITM5 sequences and for 
mammalian IFN-inducible IFITM sequences. Nonmammalian sequences (IIP) are joined to 
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the branch connecting the IFITM5 subtree to the rest of the main tree (not shown). Next, 
we refined the analysis by separating the 2 subfamilies IFITM1-3 and BRIL. The length of 
BRIL sequences is identical, and therefore full-length coding sequence was analyzed. In 
contrast, IFITM sequences were trimmed to the core region that could be reliably aligned. 
Bootstrap analysis of the mammalian IFITM tree provided unambiguous evidence for a 
single common ancestor gene before the divergence of the euarchontoglires from the 
remaining mammalian lineages (Fig. 3). There is only one BRIL gene in every species 
analyzed here, including the less conserved fish BRIL-like sequences (Fig. 3).
The evolutionary distance in IFITM5 (BRIL) sequences is comparable to that found for 
other genes. In contrast, some of the IFITM genes, in particular the rodent Ifitm6, show 
significantly higher sequence divergence (Fig. 3). This property is frequently found in 
genes that lost evolutionary pressure for maintenance of the AA sequence due to loss of 
function, or in genes that are under positive selection to adopt a new function. Ifitm6 and 
Ifitm3 are close paralogs with similar expression patterns across tissues except for total 
bone marrow extracts. Ifitm6 may have a special function in subsets of immune cells, 
including macrophages (Smith and others 2006). Mouse Ifitm7 maps to chromosome 16 
and is not part of the cluster on chromosome 7. It has no intron or reported functionality, 
but there is evidence for it being transcribed and translated, and therefore we have 
included this special case in the analysis. It was probably retrotranscribed from an Ifitm1 
transcript and has since then not acquired any nonsynonymous mutations or premature 
stop codons. As a result, this gene can be classified as a retrogen (Sakai and others 
2007). The evolutionary analysis of the gene family clearly suggests that human and 
rodent IFITMs share some functional properties, but the situation is complicated by some 
obvious species-specific adaption during evolution and unclear orthology relationships.
Copy Number Variations and Pseudogenes
Initially, we screened the available genomic sequence databases for genes with 
homologous sequences to IFITM3 to find genes with similar functions, expression 
patterns, or subcellular localization. Several hits on other human chromosomes, apart from 
chromosome 11, were detected. However, for none of these loci is there evidence for 
active transcription, and 4 copies are clearly pseudogenes due to premature stop codons 
or truncation of the primary sequence. Global genome analyses produced 10, 2, and 1 
pseudogenes for IFITM3, IFITM1, and IFITM2, respectively (Zhang and others 2003). This 
establishes an average of 4.3 pseudogenes per IFITM gene and IFITM3 made it to place 
115 in the list of top pseudogene carriers in this analysis (Zhang and others 2003). 
Pseudogene frequency is relatively high compared to 0.5 pseudogenes per active gene on 
average.
Processed pseudogenes (PPG), which are retrotransposed copies of gene transcripts, 
have been regarded as junk or selfish DNA for a long time. The ribosomal RNA and 
olfactory receptor genes are the main groups of pseudogenes in our genome. Ribosomal 
RNA genes contribute one-third of known pseudogenes and contain no introns. Olfactory 
receptor genes represent another third; these are non-PPG. In addition, genes involved in 
immune response account for about 10% of the total (Zheng and others 2007). IFN class I 
pseudogenes were already recognized decades ago (Henco and others 1985). The 
genomic locus contains 13 pseudogenes and 17 functional IFN genes (Chen and others 
2004). PPG and duplicated pseudogenic fragments are expressed in most tissues, 
including the germ line. They have small coding sequences (400–900 bp) and have GC 
contents below 53%. IFITM transcripts share the first 2 of these common properties with a 
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coding sequence length of 378–402 bp, but their GC content is 55%–59%. In addition to 
retrotransposition in the genome, exact copies of IFITM genes (probably originating from 
DNA repair events) represent an additional source involved in the generation of IFITM 
gene heterogeneity. Comparisons of individual human genomes identified hundreds of 
copy number variations in coding genes, including IFITM1 (Redon and others 2006). The 
copy number is in normal range for IFITM2/3 and IFITM5, but twice as high for IFITM1 
(3.4–4.1). However, the copy numbers of IFNα genes outrange it by far with values up to 
11.3 copies of IFNA7 for instance (Alkan and others 2009). Evidence for the presence of 
pseudogenes originating from IFITM genes was found already around the time of the first 
IFN pseudogene publication. In Northern blot experiments with 1–8 complementary DNA 
hybridized to multiple mRNAs between 650 and 900 nucleotides (Friedman and others 
1984; Kelly and others 1985). This finding suggests transcription of some PPGs or else 
variable transcription of IFITM1 and IFITM2/3. PPGs have few or no reported expressed 
sequence tags and proteins have not been detected. Therefore, IFITM-derived PPGs are 
considered to be nonfunctional (Lange and others 2003).
Both the origin and the function of transcribed PPG remain unclear, but they may influence 
cell cycle processes through interference in IFITM translation or transcription. Some 
pseudogene-derived small interfering RNAs are active in the regulation of gene expression 
during embryogenesis (Tam and others 2008). However, no IFITM homologous RNA 
sequence has been identified in screens for pseudogene derived RNAs involved in this 
process (Watanabe and others 2008). Therefore, IFITM-like PPGs are probably not 
involved in RNAi control of development and there is no evidence for interference on 
IFITM translation after infections.
This raises the question why there is such a high number of pseudogenes and what is 
their origin. IFITM proteins are abundant in germ cells and this could enable random 
integration of IFITM retropseudogenes in the genome. Another explanation is that IFITM 
transcripts have been induced by viral infection and subsequently integrated by viral 
reverse transcriptase in the genome (Brierley and others 2007). The best match to this 
recognition pattern for genomic integration is found in IFITM5 mRNA but not in IFITM3, the 
template of most IFITM-like PPGs (http://pseudogenes.org) (Zhang and others 2003). Note 
that this event requires viral infection in germ cells. Therefore, random integration of IFITM 
transcripts in the genome of germ cells or their progenitors currently appears more 
plausible. Random integration of active genes that encode antiproliferative proteins is 
posing a threat to the organism and the copies are found to undergo rapid inactivation. 
Ifitm7, for example, has recently been retrotranscribed from Ifitm1 in mice and has low 
transcriptional activity. The Ifitm6 sequence is most closely related to the one of Ifitm3 but 
has a much higher overall divergence compared to other members of the family and is not 
present in primate genomes.
The human IFITM2 and IFITM3 genes are very closely related and have been treated as a 
copy number variation (Alkan and others 2009). Copy number varies not only in inter-
species comparisons but also within human individuals (Zhang and others 2009). The 
IFITM gene locus contains sequence elements that may promote duplication events. 
IFITM1 is flanked by 2 inverted repeats of 1672 bp length each (Fig. 1b). The element 
consists of a unique CpG sequence in the core and an unspecific LTR/ERV1 repeat with 
only 1 bp mismatch between the 2 copies in the human reference sequence (NCBI Build 
36.1). The core of this element has a length of 736 bp and represents potential 
recombinogenic inverted sequences (PRIS) (Flores and others 2007). The PRIS are 
oriented in opposite direction and are thus potential targets for nonallelic homologous 
recombination, which could give rise to duplications and deletions of the IFITM1 locus. 
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Comparable PRIS have been found to be inverted at high frequency in human somatic 
cells (Flores and others 2007). IFITM1 inversions could lead to chromosomal 
rearrangements nearby and affect the inducibility of adjacent IFN-inducible genes. There 
are other marks of genetic rearrangements in this locus such as a tandem duplication in 
the 3'-untranslated region of IFITM2 (Lewin and others 1991).
Promoter Elements Stimulated by IFNs and Alternative Regulation
The main feature that discriminates these genes is the response of human IFITM1 and 
IFITM2/3 genes to IFN gamma (IFNγ) and IFNα stimulation. Thus, promoter analysis may 
reveal clues that explain the differential activation. After binding of IFNα to the receptor, 
signaling is initiated by receptor dimerization and recruitment of Janus kinases. 
Subsequent steps involve phosphorylation of these kinases and receptors as well as 
phosphorylation and dimerization of the signal transducers and activators of transcription 
(STATs). Activated STAT1 dimers form IFNγ-activated transcription factor and STAT1, 
STAT2, and IRF9 form the initial activator complex termed ISGF3 (ISG factor 3). ISGs 
have specific upstream promoter elements known as interferon stimulated response 
element (ISRE) and gamma-activated sequence, which are targets of ISGF3 and activated 
STAT1 dimers, respectively.
Here we will focus on the most relevant ISRE binding-site for ISGF3 “GGAAAN(N)GAAAC” 
(Lewin and others 1991), and other motifs were omitted for clarity (Meraro and others 
2002). RNA protection assays showed that IFITM1 and IFITM3 are inducible by IFNα or 
IFNγ signaling (McKendry and others 1991). All IFN response motifs are in proximity of the 
core promoter and the transcriptional start site. In addition, the recognition matrix tolerates 
single nucleotide insertion without significant loss in response to IFNs (Tanaka and others 
2004). Modern computational search algorithms using iterative refinement of hidden 
Markov models detect potential ISGF3 binding sites with reliability and accuracy 
(Tsukahara and others 2006). Combination of relaxed motive searches with microarray 
data collections confirm that essential all IFITM genes regardless of mouse or human 
respond to type I or II IFNs with the exception of IFITM5 (Samarajiwa and others 2009).
In relatively a recent duplication event of IFN-regulated IFITM genes the conserved ISRE 
evolved independently leading to differential responses to class I or II IFNs (Kelly and 
others 1985). All 3 human IFITM genes contain ISRE elements (Lewin and others 1991) 
and the IFITM1 promoter has a 17 bp insertion in the corresponding position that contains 
2 gamma-activated sequence elements “CTTAAGAGAAA” and “CTTCTGAGAAA,” which 
would explain inducibility by IFNγ.
IFN responsive sites have different relative positions in the rodent IFITM genes. ISREs are 
immediately adjacent to the Ifitm3 and Ifitm6 transcriptional start sites and not detectable 
in the core promoter of Ifitm1, but each mouse gene can be regulated by IFNs 
(Samarajiwa and others 2009). This indicates that an ISRE is not necessarily required in 
the core promoter for IFN responsiveness. Some potential enhancer elements have been 
identified in some distance to Ifitm1 in mice (Lange and others 2003). They may confer 
IFN responses by long-range interactions between regulatory elements, the so-called 
remote enhancers that are involved in the formation of chromatin loops in response to IFN 
beta (IFNβ), for example (Nolis and others 2009). IFN-induced gene expression depends 
strongly on regulation by chromatin remodeling, and Brahma-related gene 1 (BRG1) is a 
component of the chromatin-remodeling complex SWI/SNF, which interacts with STAT2. 
This interaction is required for IFNα-induced IFITM1 expression, suggesting an important 
role of this epigenetic mechanism in regulation IFITM genes and other ISGs (Huang and 
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others 2002). BRG1 and Brahma form together with BRG1-associated factors the SWI2-
SNF2 complex. This complex recruits TEAD1 resulting in IFITM3 gene transcription 
(Cuddapah and others 2008). Further, this complex is constitutively associated with the 
IFITM3 promoter in vivo and is involved in chromatin-remodeling during IFNα and IFNγ-
stimulated gene induction (Liu and others 2002; Ni and others 2005). BRG1-associated 
factors complex enables binding of transcription factor SP1 to its cognate site, which is 
crucial for efficient IFN-stimulated gene transcription (Ni and others 2005; Nolis and others 
2009). This suggests that the BRG1-containing SWI/SNF complex acts as co-activator of 
ISGF3, SP1, TEAD1, and CTNNB1 in the modulation of IFITM gene expression. In 
addition, CTNNB1 and bone morphogenetic protein 2 and 4 signaling is able to control the 
level of expression of IFITM genes in mouse embryonic germ cells (Saitou and others 
2003; Lickert and others 2005; Young and others 2010). Aside from that, phosphorylation 
of p38 mitogen-activated protein kinase and activation of Akt via mTOR/p70 is required for 
efficient ISG15 ISRE promoter regulation and seems to be involved in general IFN type I 
regulation (Kaur and others 2008). Moreover, ionizing radiation can induce IFITM1 
transcripts probably through upregulation of inactive STAT1 molecules (Clave and others 
1997; Tsai and others 2007). Taken together, several pathways and mechanisms control 
IFITM transcription and tissue-specific expression during development.
Interactions in Adhesion and Receptor Complexes
IFITM1 associates in many human cell types with the cell surface antigen CD81 
(Takahashi and others 1990; Bradbury and others 1992; Deblandre and others 1995). 
CD81 is expressed in a variety of tissues and cancers such as melanoma, and CD81-
targeting functional antibodies have adhesive and antiproliferative properties (Oren and 
others 1990). The IFITM1/CD81 complex is involved in the β1-integrin-mediated adhesion 
to extracellular matrix proteins (Behr and Schriever 1995) and interacts with the B-
lymphocyte antigen (CD19)/complement component receptor 2 (CR2) signal transduction 
complex (Tedder and others 1994). Antibodies against IFITM1 (αLeu-13) trigger homotypic 
aggregation of T cells (Chen and others 1984) and have an antiproliferative effect in 
leukemic B cells (Evans and others 1990, 1993). Therefore, IFITM proteins contribute to 
cell adhesion and growth control in lymphocytes and other cell types (Martensen and 
Justesen 2004). The CD81 interaction of Ifitm1 and Ifitm3 has also been shown in mice 
(Smith and others 2006). A role of Ifitm3 in cell adhesion seems to be important in rat and 
mice where the protein contributes to the organization of mammary glands and the germ 
cell niche, respectively (Zucchi and others 1998; Saitou and others 2002). Ifitm3 (Rat8) is 
involved in epithelial cell differentiation (Zucchi and others 1998) and 
coimmunoprecipitates with Fyn, a membrane-associated tyrosine kinase involved in cell 
cycle control (Zucchi and others 2004). The adhesive properties are partially based on an 
interaction of Ifitm3 with the extracellular matrix glycoprotein osteopontin (Opn) also known 
as secreted phosphoprotein 1 (El-Tanani and others 2010). Opn interacts with b1-integrins 
and is involved in the anchoring of hemopoietic stem cells within the endosteal niche as 
well as in their transmarrow migration. In addition Opn forms a complex with fibronectin 
and collagen within the extracellular matrix (Haylock and Nilsson 2006). Recombinant 
overexpression of IFITM3 in benign Rama-37 cells inhibits colony formation, cell adhesion, 
and cell invasion, whereas inhibition of IFITM3 in noninvasive cells enhances cell invasion 
(El-Tanani and others 2010).
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Involvement in Embryonic Development
Ifitm3 (fragilis protein) is a very early germline marker and has proposed functions in 
primordial germ cell (PGC) homing in mice. Single-cell analysis of differential gene 
expression between founder PGCs and their somatic neighbors at the embryoid bodies 
stage identified fragilis (Ifitm3) and stella (Dppa3) as genes strongly and specifically 
expressed in PGCs (Saitou 2009). Ifitm3 marks the onset of germ cell competence in the 
epiblast of pregastrula-stage mouse embryos (Tanaka and Matsui 2002). In vivo, Ifitm3 
levels start to increase in about 20 cells within the posterior proximal epiblast in late 
streak/early bud stage (E7.0–E7.5) embryos (Saitou and others 2002), and these cells 
undergo proliferation and migrate to the gonads. These results indicate that IFITM proteins 
are partial inhibitors of cell proliferation in pluripotent cells. Ifitm1 and Ifitm3 are differently 
expressed in migratory PGCs and it has been suggested that Ifitm1 is required for PGC 
transition from mesoderm into endoderm. Ifitm3 is sufficient to confer autonomous PGC-
like homing properties to somatic cells, an effect that was shown to be mediated by the N-
terminal extra-cellular domain (Tanaka and Matsui 2002; Tanaka and others 2005). In 
addition to PGCs, Ifitm genes are expressed in pluripotent embryonic stem cells and mice 
with RNAi-mediated reduced levels of Ifitm1 have a phenotype resembling Wnt mutants 
Thus, it appears that Ifitm1 is a key mediator of the Wnt response during gastrulation 
regulating epithelialization of the somites (Lickert and others 2005). In contrast to transient 
knockdowns of Ifitm1, deletion of the entire locus on chromosome 7 has no obvious effect 
on embryonic development, viability, or fertility (Lange and others 2008). These obviously 
conflicting data require further clarification until final conclusions can be drawn.
Antiproliferative Signaling and Antiviral Activities
The best documented function of proteins containing the conserved CD225 domain (such 
as the IFITM family) is antiproliferative and in some cases apoptotic activity, which can be 
enhanced by IFNs (Gutterman 1994). IFN-mediated proliferation control can be 
transmitted through administration of a 17 kD protein fraction from IFNβ-treated cells 
(Hillman and others 1987; Deblandre and others 1995). Functional antibodies against 
these peptides can activate antiproliferative signaling pathways through binding of IFITM1 
complexes on the cell surface (Evans and others 1990, 1993; Takahashi and others 1990; 
Bradbury and others 1992). We have shown previously that overexpression of IFITM3 
inhibits proliferation of IFN-sensitive melanoma cells (Brem and others 2003). Silencing of 
IFITM1 markedly reduced the antiproliferative action of IFNγ and IFITM1 expression leads 
to enhanced tumor suppressor protein 53 (p53) signaling with no effect on cell cycle 
progression in p53-deficient cells (Yang and others 2007). Cessation in cell growth acts 
through inhibition of extracellular signal-regulated kinases following activation of the 
mitogen-activated protein kinase p53 pathway (Xu and others 2009). IFNγ activates p53 
instantly through signaling of the ATM DNA damage pathway, whereas IFNα has delayed 
activity in this experimental system (Kim and others 2009). This is in accordance with 
delayed IFITM1 induction by IFNα compared to IFITM3 and in contrast to rapid inducibility 
by IFNγ. IFN-driven activation of p53 changes the morphology of cultured cells to a 
senescence-like stage (Siegrist and others 2009b) with distinct large flattened morphology 
(Kim and others 2009). We have observed a similar morphology upon recombinant 
expression of IFITM3 proteins together with an arrest of cell proliferation. In contrast, 
overexpression of IFITM2 leads to a rounded appearance typical for an apoptotic state 
(Joung and others 2003). FITM2 expression leads to G1 and subG1 phase arrest, which is 
independent on p53 activation (Daniel-Carmi and others 2009). In contrast, the IFITM1-
induced G1 phase arrest is p53 dependent (Xu and others 2009). Like IFNγ, IFNβ is able 
to activate the ATM DNA damage pathway together with high levels of reactive oxygen 
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species, which results ultimately in p53-mediated senescence (Moiseeva and others 
2006). Production of reactive oxygen species is affected by the IFITM3 interaction partner 
pre-B-cell colony-enhancing factor (Zhang and others 2008).
These findings suggest that additional pathways apart from the canonical Janus kinase 
(JAK)/STAT are involved in cellular senescence driven by IFITM proteins. Further, the 
antiproliferative action of IFITM proteins is limited in pluripotent cells and not effective in 
certain tumors. Elevated Ifitm3 levels induced by nuclear transfer in bovine embryos had 
no effect on cell division progress, indicating a specific role for Ifitm proteins in early 
development (Smith and others 2007). Cell cycle time increases from 6 to 16 h in mouse 
nascent germ cells with fragilis expression, compared to the nonexpressing surrounding 
somatic cells (Saitou and others 2002). In differentiated tissue such as mouse fibroblasts, 
the growth rate is significantly decreased in presence of Ifitm3 (Ropolo and others 2004). 
In addition to the cellular functions showcased above, IFN signaling is predominantly 
important for effective immune responses and host defense.
Viruses such as cytomegalovirus and herpes simplex are capable of inducing IFITM gene 
expression (Zhu and others 1997, 1998; Navarro and others 1998; Nicholl and others 
2000; Zhao and others 2009). Despite the efforts to find evidence for antiviral activity of 
IFITM family members, most results today are either ambiguous or not reproducible. 
Mouse cells are less permissive for vesicular stomatitis virus infection when human IFITM1 
is expressed, demonstrating that IFITM family members can possess intrinsic antiviral 
activity across species (Alber and Staeheli 1996). IFITM3 expression results in reduced 
hepatitis C viral RNA levels, indicating an association with the antiproliferative activity of 
the polypeptide (Zhu and Liu 2003). Only recently, genomewide RNAi screenings have 
identified IFITM3 as restriction factor for influenza and flaviviruses by inhibiting viral 
infection at cell entry (Brass and others 2009). Further evidence for the inhibition of 
flaviviruses by IFITM3 and IFITM2 proteins suggests disruption of viral molecular events 
before translation of viral genomic RNA (Jiang and others 2010). Variable activity against 
pseudoviruses coated with envelope proteins from diverse RNA-viruses suggests that 
rather the properties of envelope proteins than the nature of the viral genome determines 
the antiviral activity of IFITM proteins. However, blockage of retroviruses, positive- and 
negative-strand RNA viruses has been detected so far, and activity against DNA viruses 
needs further examination. However, a transmission of antiviral signals to noninfected cells 
by IFITM has not been demonstrated in these studies.
Pathogen infections lead to long-lasting upregulation of IFITM proteins, suggesting a 
function of IFITM3 in host defense. In addition, IFITM3 might be a suitable biomarker for 
past or chronic inflammation. IFITM transcripts have higher levels in certain neurological 
disorders, indicating an environmental insult during brain development (Arion and others 
2007).
Tissue Distribution and Localization
The subcellular localization of IFITM proteins varies in different tissues and cell types. 
Targeting of the proteins to their site of function probably depends on cellular factors that 
modify the proteins post-translationally or on protein interactions specific for transport 
vehicles such as caveolin vesicles (Xu and others 2009). Relocation to small vesicles is 
important for inhibition of virus entry (Brass and others 2009). IFITM1 localization is cell 
type dependent and various techniques have detected IFITM proteins in proximity to the 
endoplasmatic reticulum, the Golgi apparatus, or associated with the plasma membrane 
(Alber and Staeheli 1996; Zucchi and others 2004; Yang and others 2007). In melanoma 
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cell lines IFITM3 co-localizes with major histo-compatibility complex, class I (MHC-1) and 
tetraspanins of the cell membrane and exosomes were considered as transport rafts 
(Brem and others 2003). The membrane-bound fraction of IFITMs interacts with several 
other membrane proteins involved in adhesion and transmission of proliferation control 
signals (Table 1).
IFITM genes are transcribed in most adult tissues and the expression levels differ in 
specific cell types of the same organ (Yamashita and others 2000; Seo and others 2010). 
During development gene expression changes and is associated with the migratory 
behavior of germ cells (Saitou and others 2003; Lickert and others 2005; Tanaka and 
others 2005; Smith and others 2007). In melanoma cells, IFITM containing small vesicles 
like exosomes or the soluble form of IFITM proteins are found in culture supernatants 
(Siegrist and others 2009a). IFITM proteins can be processed by an unknown mechanism 
to be targeted for secretion or to change the subcellular localization. This mechanism 
probably involves cleavage of a small peptide fraction at both IFITM3 proteins ends and 
efficient translocation may depend on processing at the amino terminus (Siegrist and 
others 2009a). Tagged IFITM proteins for instance can display these degradation or 
modification processes occurring in 6xHis-tagged IFITM1, Ifitm6, and 3xflag-tagged BRIL 
proteins (Alber and Staeheli 1996; Smith and others 2006; Moffatt and others 2008).
This cleavage process is limiting localization studies because some cleavage products of 
IFITM fusion proteins are undetectable. In addition, the IFITM processing may regulate 
secretion of IFITM3 proteins and enable the transmission of antiproliferative responses in 
IFNα-sensitive cells or tissues (Brem and others 2003). However, an active or passive 
transfer of apoptotic or antiviral activity in vitro can be excluded based on recent 
experiments (Brass and others 2009; Daniel-Carmi and others 2009). A crucial step to 
discover an antiproliferative or antiviral signaling across cells is the identification of this 
processing factor. Signal transmission may involve immune cells or gap junction formation 
for communication apart from unknown signal transducers. Transgenic flies (Drosophila  
melanogaster) expressing human IFITM3 proteins showed no developmental defects, 
although the speckled subcellular localization resembled the pattern in human cells 
(unpublished results). This indicates that IFITM protein function requires interaction with 
proteins that are specific for mammalian organisms. Serial deletions or site-directed 
mutagenesis may lead to the identification of modified AA or sites required for protein 
interactions important for IFITM functions provided the protein scaffold is maintained after 
mutagenesis.
IFITM Antiproliferative and Antiviral Signaling and Discrimination of Subtypes
The antiproliferative and antiviral activity is shared between all IFITM proteins, but the 
efficiency can vary among different IFITMs, tissues, and cell types. A conserved function of 
all IFITM polypeptides is the apparent control of cell proliferation or apoptosis (Table 1). 
IFITM1 for instance interacts with the p53 signaling cascade, resulting in partial cell cycle 
arrest (Xu and others 2009). In contrast, the pro-apoptotic function of IFITM2 is largely p53 
independent although decreased efficiency has been noted in p53-deficient rodent 
fibroblasts cells (Daniel-Carmi and others 2009). IFITM3 is the most potent inhibitor of viral 
entry relative to IFITM2 and IFITM1, which points to functional differentiation of protein 
subtypes (Brass and others 2009; Jiang and others 2010). These different activities may 
reside in the amino termini that are specific for IFITM2 and IFITM3 and may direct specific 
protein interactions for example to interfere with virion uptake or uncoating. The next steps 
in unveiling the mechanism will involve the identification of IFITM-interacting proteins 
contributing to the innate antiviral activity.
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IFITM Expression and Implications in Cancer Development
IFITM expression levels are different from control tissues in many cancer samples, and 
upregulation and down-modulation occurs depending on the cancer type and may occur 
together with mutations. There are at least 5 variations in the IFITM3 promoter consisting 
of repeated sequences (Seo and others 2010). In addition, single-nucleotide 
polymorphisms as well as insertions are frequent in the IFITM2 coding region (Daniel-
Carmi and others 2009). This indicates either high genetic variability among humans or an 
enhanced somatic mutation rate in cancer necessary to deactivate the gene product. 
IFITM proteins have properties of tumor suppressors because they can control the cell 
cycle and they are modulated even before tumor formation. IFITM expression 
abnormalities occurs often in the transition from normal to premalign stages and are 
associated with viral infections, lesions, or inflammation.
The histological activity of hepatic steatosis in patent with chronic hepatitis C correlates 
with IFITM1 levels for example (Younossi and others 2009). Further, IFITM proteins are 
also associated with inflammatory diseases such as ulcerative colitis and inflammatory 
bowel disease (Hisamatsu and others 1999; Wu and others 2007; Seo and others 2010). 
In addition, IFITM genes have been associated with the cause of cytopenia in preleukemic 
conditions (Pellagatti and others 2006). In this case the proliferation inhibitory action of 
IFITM proteins may cause ineffective hematopoiesis by promoting apoptosis or 
senescence. In the early stages of oncogenesis IFITM abundance may promote selection 
of cells that are insensitive to tumor suppressor pathways like p53, but conclusive proof for 
the involvement of IFITM proteins in tumor formation is still missing. Elevated IFITM levels 
are found in adenoma compared to adjacent normal mucosa and they are even higher in 
colon carcinoma (Zhang and others 1997; Andreu and others 2006; Tirosh and others 
2007; Fan and others 2008; Nibbe and others 2009; Ma and others 2010). Cancer cells 
insensitive to the antiproliferative action of IFITMs are expressing higher amount of the 
molecule, which implies a benefit for the tumor by escaping the immune surveillance. 
Gastric cancer cell lines with elevated IFITM1 protein levels escape natural killer cell 
recognition (Yang and others 2005). Further, IFITM3 levels are upregulated in the invasive 
stage of breast carcinoma (Abba and others 2004) and overexpression of IFITM1 
promotes invasiveness of tumor cells in vitro (Yang and others 2005; Hatano and others 
2008). Expression of IFITM proteins can also be reduced in certain tumor types and 
IFITM1 transcription is repressed in most brain samples from astrocytoma patients (Huang 
and others 2000). Further, in vitro tumorigenesis by ras transformation results in 
downregulation of IFITM transcripts in rodent cells (Zuber and others 2000; Brem and 
others 2001a). Cells with deactivated IFITM function are probably selected during their 
cultivation and the co-expression of oncogenic transformation factors myc and ras together 
with IFITM2 results in diminished colony formation (Daniel-Carmi and others 2009). 
Consistent with these results, IFITM knockdown promotes cancer growth in vivo (Yang and 
others 2007).
The tumor suppressive in vivo effect may depend on the translocation of IFITM-derived 
peptides to exosomes that are involved in the transport of cancer antigens to dendritic 
cells. The high immunogenic potential of IFITM peptides supports this theory and they may 
act as tumor-associated antigenic peptides in MHC-1 presenting cells (Tirosh and others 
2007). Depletion of IFITM expression can change the adhesive properties of cancer cells 
and indicates malign-formation in some cancers. The assumption that IFITM expressing 
cells cannot escape cellular structures in benign tumors is based on the involvement of 
Ifitm3 in the formation of specific dome structures by breast adenocarcinoma cells (Zucchi 
and others 1998). Subsequently, the correlation of IFITM reduction with cancer 
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progression and metastasis was examined in gene expression studies of human 
melanoma cell lines. Indeed, IFITM1 and IFITM3 levels are downregulated in metastatic 
melanoma cells, indicating successful escaping from the cellular cohesion in these tumor 
samples (Brem and others 2001b). However, there is no convincing evidence for 
significant correlation of metastasis and IFITM depletion in every melanoma-derived cell.
IFITM expression levels can be both full transcriptional silenced or virtually unrestricted in 
cancer cells insensitive to growth inhibition through IFNα-activated pathways (Certa and 
others 2001). IFITM3 expression is deregulated in the nonresponder melanoma cell line 
D10 and overexpression of IFITM3 does not significantly reduce cellular growth (Brem and 
others 2003). However, cell lines derived from different cancer samples are highly variable 
in IFITM gene expression irrespectively of their ability to respond to IFNα (Siegrist and 
others 2010). Recent findings of IFITM3 interaction with Opn may explain some aspects of 
IFITM involvement in cancer although Opn expression is variable in different tumors. 
IFITM3 expression lowers apparently Opn levels and this may interfere with the function of 
Opn in migration and adhesion during cancer progression (El-Tanani and others 2010). 
The antiproliferative and adhesive properties of IFITM proteins qualify them as antagonists 
for tumor development provided that overexpression can be pharmacologically achieved.
There is good evidence for the involvement of positive and negative regulation of IFITM 
expression during the malignant transformation of tumors. IFN-sensitive cells may not 
benefit from higher IFITM levels due to the antiproliferative activity in these cells. It is 
feasible that IFITM gene levels are predictive for the outcome of IFN-based adjuvant 
treatment in cancer patients. IFITM1, usually more IFNγ associated, was not upregulated 
in IFNα-treated D10 but significantly in the IFNα growth-sensitive melanoma cell line ME-
15 (Certa and others 2001). This indicates a contribution of IFITM1 in the response to IFN. 
Subsequently, the IFNα response in these cells was evaluated with different platforms to 
detect global changes in gene expression, including microRNA genes (Certa and others 
2003; Siegrist and others 2009b, 2010). There are some differences in IFITM expression 
depending on the detection technology, and the similarities between the genes may 
complicate interpretation of results. ME-15 cells, for instance, have no detectable levels of 
IFITM3 in absence of JAK/STAT activation (Zhang and others 2006) and show a marked 
growth arrest by pegylated IFNα (Foser and others 2006). In addition, melanoma 
xenotransplants in mice are restricted in growth mediated by IFNα or pegylated IFNα, and 
IFITM levels are upregulated among other genes in these tumors (Krepler and others 
2004). In an analysis across many clinical settings, IFNα showed significant improvement 
of relapse-free survival for at least some melanoma patients (Garbe and others 2010). 
Activation of IFITM proteins by IFN administration could explain the therapeutic efficacy in 
cancer adjuvant therapy but there is no convincing proof so far. The correlation of IFNα 
sensitivity and low IFITM expression levels is cancer-type specific, and in contrast with our 
findings in melanoma cell cultures, IFITM1 is expressed low in high-risk leukemia patients 
who have reduced response to IFNα therapy (Akyerli and others 2005).
IFITM levels may indicate resistance to other therapeutics and are linked to treatment 
outcome. Tumor cells selected for radio-resistance have enhanced STAT1 signaling, 
including high IFITM1 levels, and therefore IFITM1 could contribute to survival in relapsing 
tumor cells (Khodarev and others 2004). In this case high levels of pluripotency markers 
such as IFITM genes indicate probably a state of slowly replicating cancer stem cells that 
have constitutively activated IFN pathways and are resistant to anticancer drugs as IFNs, 
radiotherapy, or any drug therapy that is selective for rapidly growing cells. Further, IFITM1 
is also induced by in vitro selection for cis-platinum resistance in lung cancer cells 
(Whiteside and others 2004). This is in contrast with the increase of cis-platinum 
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resistance in esophageal squamous cell carcinoma with experimentally reduced IFITM1 
levels (Fumoto and others 2008). Moreover, loss of IFITM2/3 expression is a predictive 
factor for bad response to chemotherapy in osteosarcoma patients (Salas and others 
2009).
In summary, IFITM may have different functions in different tumors and the exact role in 
tumorigenesis is complex. Tumorigenesis involves the inactivation of cell cycle control and 
attenuated DNA damage repair. Tumor suppressor protein 53 is necessary to maintain 
cells in an amplification-permissive state and can be regulated by IFITM proteins. Cancer 
cells proficient in p53 signaling may benefit from transcriptional silencing of IFITM genes, 
but virtually unrestricted IFITM levels in most cancer cells probably reflect resistance to 
IFITM-mediated proliferation control that is linked to deactivated p53 signaling. Further, 
amplifications in the tip of chromosome 11 are occurring frequently in tumors and affect 
IFITM, HRAS, and IRF7 genes. Deficiencies in nonhomologous end-joining DNA repair 
could lead to duplications, inversions, and chromosomal rearrangements involving IFITM 
genes.
Conclusions
We have shown here that at least some of the IFITM genes have evolved only recently, 
and this could be crucial for effective antiviral protection and host defense. IFITM proteins 
protect against viral challenges dependent on the type of virus in addition to the IFITM 
properties. An enhanced mutation rate of these genes is probably beneficial for adaptation 
to genetic changes in viruses. The phylogenetic analyses, a high number of pseudogenes 
representing frequent duplications, the presence of the PRIS, and frequent mutations in 
cancer demonstrate the high mutation rate of IFITM genes. Antiviral genes with an 
elevated mutation rate are beneficial for the evasion of viral countermeasures against 
human innate immunity actions. One plausible action is the proapoptotic effect that may kill 
the host cell before the virus is able to assemble into a fully functional virion (Joung and 
others 2003).
Due to the progress of functional characterization of IFITM class proteins, we are now able 
to highlight connections between the phenotypes observed and the presence of IFITM 
proteins. There are good indications that the mode of IFITM-controlled antiproliferative 
signaling is conserved in many chordates. We have addressed possible genetic 
implications of duplicated IFITM genes. IFITM genes with abundant expression acquired 
and conserved IFN inducibility after the duplication event of the ancient BRIL/IFITM gene. 
Only few functions such as antiproliferative activities are maintained in the IFITM proteins 
to BRIL, and new functions have evolved that are related to innate immunity. Due to the 
recent development of the IFITM genes at evolutionary scale, functional discrimination 
should be considered when conclusions across the species are drawn. IFITM3-derived 
pseudogenes are relatively frequent and complicate the genetic discrimination using 
amplification or hybridization assays. On the basis of our evolutionary analysis, IFITM 
pseudogenes are remnants of random integration during embryogenesis and IFITM 
proteins are expected to play a nonessential role in germ cell progenitors in humans and 
mice. Common antiproliferative action and variable response to related cytokines indicates 
a redundancy in the system and interchangeability of the IFITM proteins in response to 
pathogens. We anticipate a function of at least some of the IFITM genes beyond the 
intracellular activities because IFITM fusion proteins are processed to their natural size 
and detectable in the supernatant of cultured cells. The elucidation of inter-cellular 
antiproliferative pathways would therefore link some of the less-defined IFITM functions in 
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innate immunity and cancer development. Finally, IFITM activators could be useful as 
therapeutics against viral infections and cancer.
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Figure 1 (a) Structural display of human and mouse IFITM proteins 9–27/fragilis2 
(IFITM1), 1-8D/fragilis3 (IFITM2), 1-8U/fragilis (IFITM3), fragilis5 (Ifitm6), and 
BRIL/fragilis4 (IFITM5); mil4 (Ifitm7) is not shown. (b) Chromosomal localization of IFITM 
genes in human and mouse. There are 2 interferon stimulated response elements (ISRE) 
(red) in each promoter of human IFITM genes and additional gamma-activated sequence 
(yellow) in IFITM1. Two potential recombinogenic inverted sequence (PRIS) are indicated 
by red arrowheads, genes are shown as arrows, and protein coding sequence as vertical 
bars. IFITM, Interferon induced transmembrane; BRIL, bone restricted IFITM-like.
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Figure 2. Amino acid (AA) occurrence in putative homologs of IFITM1-3, IFITM5 (BRIL), 
and nonmammalian homologs of fish interferon-inducible proteins (IIP). Probability is 
calculated from 55 mammalian IFITM homologs, 27 IFITM5, and BRIL-like AA sequences 
in fish or 17 IIPs. Consensus AA sequences of human, mouse, and rat were used to 
search for homologs in complete genomes; whole genome shot-gun contigs and additional 
sequences were taken from publications. All sequences were manually screened for 
presence of a single 300–2500 base spanning intron (or up to 6,500 bases in lizard). 
Exceptions with no intron are Ifitm7 from mouse, IFITM from dasypus, 3 BRIL from fish, 
and 10 nonmammalian IIP sequences. Protein sequences, including an IFITM-like 
sequence from arrow-worms, were aligned with the CLUSTALW in MEGA 4. Global 
pairwise alignment is shown for the region 71 AAs before and after the conserved exon 
splice-junction. Potentially calcium binding domain of BRIL is highlighted by a yellow bar 
and predicted trans-membrane regions are indicated by a green bar. The CD225 domain 
has the same length in all but one (IFITM0 from horse) of the sequences analyzed. In 
human IFITM1, it corresponds to amino acid positions Pro34 to Thr97. Sequence logos 
were generated from translated coding sequences using the web-based program 
WEBLOGO 3.
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Figure 3. Phylogenetic tree for trimmed coding sequences of 55 mammalian variants of 
IFITMs (left) and 27 identified BRIL and related sequences (right). Fish IIP sequences and 
other ambiguous sequences were not taken into account for generation of these trees. 
Phylogenetic analyses were performed on the coding DNA sequences using the maximum 
likelihood method program DNAML in PHYLIP (Phylogeny Interference Package version 
3.68) distributed by the author. There were a total of 312 and 441 nucleotide positions in 
the final data sets. The evolutionary history was inferred using the maximum likelihood 
method for DNA sequences. Default settings were changed to “not rough” calculation and 
allowing global rearrangements. HMM rates were defined with 2 categories of rates one 
and 3 with probability 0.66 and 0.34. For each set the optimal tree with the sum of branch 
length IFITM = 4.56979 and BRIL = 4.58961 is shown as radiation tree with branch lengths 
in the units of expected nucleotide substitutions per site. The branches were colored by 
common biological classes (and orders) and human and mouse sequence names are 
colored. Bootstrap values are shown for branches of interest based on 100 replicates. 
Highlighted numbers indicate the high probability for gene duplication during speciation of 
primates. Sequence names were annotated in the following way: mammalian IFITM5 
sequences and unknown genes showing a similar, specific domain at the C-terminus were 
named BRIL, and similar sequences in other species BRILL (BRIL like proteins) 
accordingly. Species with only 1 detected gene were named IFITM in mammals and 
interferon-induced protein in others. Numbering of genes is based on the present analysis 
and does not claim to correspond to other databases and publications.
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Abstract
The interferon-α (IFN-α)-inducible protein IFI44 is associated with hepatitis C virus (HCV) 
infection, and its function is unknown. We show here in two human melanoma cell lines 
(ME15 and D10) that transcription starts 4 h after induction, and peak protein levels are 
reached 24 h after stimulation. We show by immunofluorescence, viral overexpression, 
and cellular fractionation that IFI44 is a cytoplasmic protein. Overexpression of IFI44 cDNA 
induces an antiproliferative state in vitro, even in cells that are not responsive to IFN-α. 
IFI44 contains a perfect GTP binding site but has no homology to known GTPases or G 
proteins. Based on these results, we propose a model in which IFI44 binds intracellular 
GTP, and this depletion abolishes extracellular signal-regulated kinase (ERK) signaling 
and results finally in cell cycle arrest.
Keywords: interferon-α; signaling; GTP binding proteins; IFI44
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Introduction
Chronic infection with hepatitis C virus (HCV) is the most common form of chronic viral 
hepatitis in the developed world with 170 million infected individuals worldwide. The 
chronic infection is often silent and may be discovered during routine blood screening. 
Symptoms are typically absent, and only liver biopsies demonstrate disease progress and 
severity. The therapy of chronic hepatitis is still unsatisfactory, and the only agent with 
proven benefit is cotherapy of pegylated interferon-2A (IFN-2A) with the viral polymerase 
inhibitor ribavirin (Feld and Hoofnagle, 2005; Hoofnagle, 1998; Zeuzem et al., 2001). Only 
50% of individuals infected with HCV genotype 1 respond to antiviral therapy, and the 
responders increase to 80% in nongenotype 1 infections. The host and pathogen factors 
that cause therapy failure are still unknown, and efforts have started to identify host-
encoded candidate genes using global transcriptional analysis in patient samples and cell 
lines (Bain et al., 2006; Basu et al., 2006; Certa et al., 2003; Foser et al., 2003; Patzwahl 
et al., 2001; Walters et al., 2006). One gene that is consistently upregulated following IFN-
α therapy or in vitro stimulation of cell lines was termed IFI44. It was initially discovered in 
association with microtubular structures in an HCV-infected chimpanzee, and more than a 
decade later, nothing is known about its possible function (Honda et al., 1990). Recently, it 
was included in a genetic screen aimed at discovering biomarkers for predisposition of 
responsiveness to therapy for chronic hepatitis C (Hwang et al., 2006). Most genes 
included in this study had about 10 single nucleotide polymorphisms (SNPs) in the 
noncoding promoter region, with the exception of IFI44, where a nonsynonymous amino 
acid change (Arg/Trp) occurs in the ninth position of the protein sequence, which points 
perhaps to a role in HCV pathogenesis or host defense. This feature and its consistent 
high-level induction by IFN-α and HCV raise the possibility that IFI44 has antiviral activity. 
In this paper, we assess the function of IFI44 by studying its induction kinetics in a number 
of human cell lines as well as its subcellular localization, and we demonstrate 
antiproliferative activity.
Materials and Methods
Antibodies
Antibodies against a peptide conjugate of IFI44 (amino acid residues 271–285, 
GLCRDDIFYILNGNIRDRYQFNPMESIKLNHHDYIDSPSL) were raised in rabbits using 
standard immunologic techniques (Eurogentec/ LIEGE Science Park, Belgium). Anti-IFI44 
serum (rabbit 247) was used at 1:1000 dilution for Western blots and diluted 1:100 for 
immunofluorescence. Preimmune serum was used as a control to establish the assay 
conditions (data not shown). Goat antirabbit IgG (HL) horseradish peroxidase (HRP) 
conjugate was obtained from BioRad (Basel, Switzerland), and Alexa Fluor 488 goat 
antirabbit IgG (H+L) and Alexa Fluor 568 goat antirabbit IgG (HL) were purchased from 
Invitrogen (Basel, Switzerland).
Cell lines.
ME15 and D10 have been described previously, and all other cell lines were purchased 
from the ATCC cell culture collection (Rockville, MD) and cultured at 37°C in a 5% CO2 
atmosphere in RPMI 1640 medium (GIBCO Life Sciences, Paisley, U.K.) supplemented 
with 10% fetal bovine serum (FBS), L-glutamine (2 mM), sodium pyruvate (1 mM), 
nonessential amino acids, antibiotics, and 10 mM HEPES buffer (Certa et al., 2003).
Cell proliferation assay.
Cells from each line (5000 cells) were grown in triplicate over a period of 5 days in 96-well 
plates with the appropriate treatment. Cell density was measured using a commercial 
colorimetric assay as described. (Foser et al., 2003). The mean of the OD reading was 
determined and used to calculate the standard deviation (SD) from the mean value. The 
averaged data were used to calculate the percent of control to obtain comparable values 
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within the set of experiments. The maximal deviation from the mean at day 4 was 3.2% 
(data not shown).
Immunefluorescence and immunoblotting.
Immunodetection of IFI44 was carried out as described with the serum dilutions indicated 
(Brem et al., 2003).
Recombinant expression of IFI44 in semliki forest virus.
The IFI44 coding sequence was amplified with total cellular ME15 cDNA as template by 
PCR using primers with internal BglII cloning sites (forward primer 5-
GTACAACAATCAAGATCTAGGCAGTGAC-3; position 71–100 in NM_006417; backward 
primer 5-GAATTTACGTGAACCTTTCAGATCTCTAT-3; position 1388–1418 in 
NM_006417). The BglII-digested PCR fragment was subcloned into pCR 2.1-TOPO for 
sequence verification. The correct IFI44 cDNA was cloned into SFV-PD for expression 
(SFVIFI44), and viral stocks were prepared as describe (Lundstrom et al., 2001). The 
SFVIFNα viral stock was a gift from Dr. S. Clure (Biocenter of the University of Basel).
Cell fractionation
ME15 and D10 cells were lysed and fractionated using a commercial kit and the 
instructions supplied (Qiagen Qproteome Cell Compartment Kit, Qiagen AG, 8634 
Hombrechtikon, Switzerland).
mRNA quantification
The cell lines A549, LS174T, HCT116, MIA PaCa-2, AsPC-1, D10, and ME15 were grown 
without (control) or with 100 U/mL human IFN-2A (Roferon, F. Hoffmann-La Roche Ltd., 
Basel, Switzerland) for 4 or 24 h. Total RNA was extracted with TRI reagent (Molecular 
Research Center, Inc., Cincinnati, OH), and biotin-labeled using a commercial kit and the 
protocol supplied (Agilent Technologies, Basel, Switzerland). Labeled, unfragmented 
cRNA (500 ng) of each cell line was hybridized to commercial microarrays using the 
manufacturer’s protocol (Sentrix HumanRef-8 Expression BeadChips; Illumina, Inc., San 
Diego, CA). Data were collected using a confocal scanner (Illumina beadstation), and data 
analysis was performed using Illumina Beadstudio (www.illumina.com) and RACE-A 
software (Certa et al., 2003).
Results and Discussion
Expression mode of IFI44
Inhibition of HCV replication by IFN-α occurs within hours after stimulation, which implies 
that host defense genes show immediate-early induction (Guo, Bichko and Seeger, 2001). 
In Figure 1, we analyze the kinetics of IFI44 mRNA and protein induction by IFN-α relative 
to control genes in a panel of IFN-α-sensitive and resistant cell lines. Four hours after 
cytokine stimulation, efficient induction of IFI44 mRNA occurs in ME15, D10, and AsPC-1, 
whereas A549, LS174T, HCT116, and MIA PaCa-2 are poor responders (Fig. 1A). A 
similar induction pattern appears for the early induced control gene IFIT3, with the 
exception of MIA PaCa-2, where this particular gene is efficiently induced after 4 h 
(Fig. 1B). In contrast to IFI44 and IFIT3, 6-16 shows peak levels of mRNA 8 h after 
stimulation, which eliminates it as an immediate-early host defense gene (Fig. 1C). At this 
point, we found it important to show induction of IFI44 at the protein level by probing 
immunoblots of IFN-α-treated ME15 and D10 cells (for details, see Materials and 
Methods). Induction of IFI44 protein is clearly evident 8 h after stimulation in both lines 
(Fig. 1D), which is consistent with the mRNA induction kinetics. Removal of IFN-α 24 h 
after induction results in clear decline of IFI44 protein, which classifies IFI44 as a bona fide 
IFN-α response gene.
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Cellular localization of IFI44
IFI44 was originally found in microtubular aggregates in hepatocytes of non-A, non-B 
(NANB) virus-infected chimpanzees (Honda et al., 1990). Nothing is known about the 
subcellular localization of IFI44 in human tissues or cell lines. To address this question, we 
chose the human melanoma cell lines ME15 and D10 because IFN-α stimulation induces 
significant amounts of IFI44 protein (Fig.1). In both lines, fluoresecent patch-like structures 
are consistently detected in the nuclei in nonstimulated cells (Fig. 2A, B). Upon IFN-α 
treatment, the nuclear signal fades, and a uniform cytoplasmic fluorescence appears, 
which is consistent with the data shown in Figure 1D. When untreated ME15 cells are 
transfected with an SFV that overexpresses IFI44 protein (SFVIFI44), a similar diffuse 
cytoplasmic fluorescence with higher intensity appears, which proves specificity of the anti-
IFI44 rabbit serum (Fig. 2C). Control infection with virus vehicle alonedoes not cause any 
changes in the IFI44 detection pattern (data not shown). The immunofluorescence with 
anti-IFI44 serum clearly differs from a typical microtubular staining pattern obtained with 
serum against -tubulin (Fig. 2C, right).
We thus applied cell fractionation as an independent approach to confirm this conclusion 
(Fig. 3). In fractionated ME15 and D10 cell lysates, IFI44 is detectable only in the 
cytoplasmic fraction and is absent in the membrane, nuclear, and particularly the 
cytoskeleton fraction, where it would be expected as a microtubule-associated protein. In 
this assay, we failed to confirm the nuclear localization of IFI44 in uninduced ME15 or D10 
cells, which might be related to insufficient sensitivity, shedding during the preparation of 
nuclei, or other technical issues (Figs. 2 and 3). We conclude based on two independent 
assays that IFI44 is a cytoplasmic protein in human melanoma cell lines and is associated 
with microtubular structures. IFI44 was first identified in density gradient-enriched 
microtubular aggregates with a monoclonal antibody (mAb) from HCV-infected 
chimpanzee livers, and, therefore, any protein present in these complexes is microtubule 
associated. This is the first report describing in situ detection of IFI44, and detection in 
microtubular aggregates might be cross-contamination related to the high abundance of 
IFI44 in HCV-infected liver cells. Alternatively, although less likely, subcellular localization 
of IFI44 might be cell type specific.
Comparative genomics analysis of human IFI44
With the availability of complete genome sequences of a number of relevant organisms, it 
became possible to identify functional domains of any protein by sequence homology. 
Such an analysis can provide important clues for the potential function of an 
uncharacterized protein. We performed a computer-aided homology search with human 
IFI44 in the genomes of bat (Myotis lucifugus), cow, dog, rabbit, mouse, amphioxus, and 
rat. In all species analyzed (including some fish species, for which no data are shown), we 
identified IFI44 homologs with 80% sequence identity (Fig. 4). However, none of the 
conserved sequence blocks corresponded to any known functional protein domain motif, 
with the exception of the sequence GP(I/V/T)GAGK, which is a GTPbinding site. This now 
classifies IFI44 as a potential GTP-binding protein, and its overall high interspecies 
conservation points to an important biologic function.
Antiproliferative activity of IFI44
A hallmark of IFNs is the ability to induce antiproliferative activity. Transfection of the small 
IFN-α-inducible protein 1-8U, for instance, leads to a complete arrest of cell division (Brem 
et al., 2003). On the other hand, GTP-binding proteins, like the IFN-α-inducible GTPase 
p47, are involved in host defense against such viruses as HCV and HIV (MacMicking, 
2004). Cell cycle arrest of infected cells is an important aspect of virus defense because it 
inhibits spread of the pathogen through blocking of cell division. To test whether IFI44 has 
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antiproliferative activity, we overexpressed IFI44 in ME15 and D10 cells by infection 
withSFVIFI44 or SFV as control and measured cell proliferation over a period of 4 days (Fig. 
5A). In both cell lines,SFVIFI44 infection induced significant growth inhibition of about 20% in 
ME15 and D10 at day 4 relative to the control virus-infected cultures. As an additional 
control, we infected ME15 and D10 cells with SFVIFNα, which is a recombinant virus that 
expresses secreted recombinant IFN-2A. We also included reference cultures in the 
analysis that received standard treatment with 100 U/mL IFN-α (Fig. 5B). As expected, 
proliferation of SFVIFNα infected or IFNα-treated ME15 cells was strongly inhibited 
regardless of the IFN-α delivery, whereas growth of D10 cells was essentially unaffected 
by either treatment. This also eliminated the concern that viral infection might cause 
growth arrest. Thus, recombinant expression of IFI44 alone is sufficient to inhibit cell 
proliferation regardless of the IFN-α response state of the cell. This finding points to a 
direct mechanism of action that does not require the presence or activity of any additional 
IFN-α-inducible proteins. Our sequence analysis (Fig. 4) opened the possibility that the 
highly conserved GTP-binding site present in all IFI44 orthologs has functional 
significance. In mouse, the p47 group of IFN-inducible GTPases with antiproliferative 
activity has been strongly implicated in host defense against bacterial, viral, and protozoan 
pathogens (MacMicking, 2004). The molecular weight range of 47–50kDa of these 
enzymes is similar to that of IFI44 (50461 Da), which opened the attractive possibility that 
IF44 is perhaps a novel member of this group. To our surprise, only the GTP binding motif 
(GXXXXGKS) is shared between IFI44 and the GTPase panel,and rest of the IFI44 amino 
acid sequence has no homology to this group of enzymes (data not shown). In particular, 
the G3 (DXXG) and G4 (TKXD) motifs that are found in all p47 type GTPases at 
equivalent positions are absent in IFI44 (MacMicking, 2004). Another category of GTP-
binding proteins are the well-studied G proteins, which transmit signals of G protein-
coupled receptors (GPCRs) to the adenylate cyclase signaling cascade. One well-studied 
downstream enzyme associated with cell proliferation is the mitogen-activated protein 
kinase (MAPK), also termed extracellular signal-regulated kinase (ERK). ERK cascade 
activity couples cytokine or growth factor signaling to proliferation through G proteins. 
(Stork and Schmitt, 2002). We relied again on sequence alignment for the possible 
classification of IFI44 as a G protein. However, typical G proteins, such as Ras, are 
smaller and plasma membrane associated, and known G proteins are not inducible and 
less abundant than IFI44. Finally, G proteins form trimeric complexes, and no protein 
interaction is documented for IFI44 in the Database of Interacting Proteins 
(www.dip.doembi.ucla.edu/dip).
We conclude that it is unlikely that IFI44 is a GTPase or G protein, and its high abundance 
after IFN-α induction might be key to its function. Pharmacologic GTP depletion induces 
apoptosis and cell cycle arrest of insulin-secreting cells by inhibition cAMP signaling to 
downstream cascades, such as ERK.(Li et al., 1998). The relatively high abundance of 
IFI44 after IFN-α stimulation together with its cellular localization lead to the following 
hypothesis. IFI44 binds intracellular GTP and depletes the cytoplasmic pools, which would 
cause inhibition cAMP-mediated signaling downstream of the ERK cascade and the 
ultimate arrest of cell division. The fact that IFI44 levels decline without IFN-α stimulus 
(Fig. 1D) would allow normal cell growth after successful virus defense. We are currently 
testing this plausible hypothesis experimentally by analyzing G protein signaling in stable 
IFI44-transfected cells. Strikingly, the most potent drug known against HCV, the guanosin 
analog ribavirin depletes intracellular GTP pools, and IFI44 might be its natural homolog 
(Leyssen et al., 2005). 
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Figures / Legends
Figure 1. Kinetics of IFI44 induction in IFN-α-sensitive and resistant human cell lines. (A) 
IFI44 induction with 100 U/mL IFN-α in a panel of human cell lines. In AsPC-1, ME15, and 
D10, efficient expression of IFI44 mRNA occurs early, 4 h after stimulation, whereas the 
IFI44 gene is virtually noninducible in A549, LS174T, HCT116, and MIA PaCa-2. (B) 
Induction kinetics of the primary response gene IFIT3 and of the secondary gene 6-16 (C) 
in the same panel of cell lines. mRNA abundance was measured in parallel using 
commercial DNA microarrays. (D) Immunoblot detection of IFI44 protein in ME15 and D10 
4 or 24 h after IFN-α stimulation. As expected for a bona fide response gene, continued 
cultivation without IFN-α results in protein decay. IFI44 protein was detected with rabbit 
serum raised against an immunogenic peptide fragment of IFI44. The serum crossreacts 
with a larger, unknown protein, which is not IFN-α inducible. The position of IFI44 is 
marked by an arrow.
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Figure 2. Cellular localization of IFI44 by immunofluorescence. (A) ME15 or (B) D10 cells 
were incubated with 1000 U IFN-α for 24 h, followed by fixation and staining with a 
polyclonal rabbit antibody raised against an immunogenic peptide of IFI44. 
Antibody/antigen complexes were labeled with a secondary antibody conjugated with red 
(ME15) or green (D10) fluorochromes. In noninduced cells, some fluorescent patches are 
consistently detectable in the nucleus of ME15 and D10 cells (left). After IFN-α stimulation, 
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red (ME15) or green (D10), the nuclear signal fades, and diffuse fluorescence of the 
cytoplasm appears. (C) ME15 cells infected with an SFV that expresses recombinant IFI44 
(left) or a typical microtubular staining pattern obtained with antitubulin antibodies in ME15 
cells as reference (right).
Figure 3. Immunoblot detection of IFI44 in cellular fractions of ME15 (top) or D10 (bottom) 
cells. Uninduced cells (co) and cells induced with IFN-α or K134 for 24 h (a lysine 134 
monopegylated form of IFN-α) were lysed and fractionated by differential centrifugation 
into cytoplasm (CP), membranes (MEM), nuclei (NUC), and cytoskeleton (CS) using a 
commercial kit (for details, see Materials and Methods). Equal amounts of total protein 
were separated by SDS-PAGE, immobilized on membranes, and probed with IFI44 rabbit 
serum. Consistent with Figure 2, IFI44 is detectable only in the cytoplasm and virtually 
absent in the remaining fractions, including cytoskeleton and nucleus.
Figure 4. Comparative genomics analysis of IFI44. The coding sequences of IFI44 
orthologs of human, mouse, rat, cow, dog, bat, and fish were aligned, and conserved 
amino acid blocks are highlighted in blue. A GTP-binding motif found in all known 
GTPases and G proteins is showcased in yellow (Pavlovic et al., 1993).
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Figure 5. Antiproliferative activity of IFI44. (A) ME15 (IFN-α sensitive) or D10 (IFN-α 
resistant) cells were infected either with SFV vector control or with a virus stock that 
overexpresses IFI44(SFVIFI44) Proliferation was measured in triplicate cultures over a 
period of 4 days using a calometric assay and expressed as percent of control (for details, 
see Materials and Methods). (B) As reference, ME15 and D10 cells were stimulated with 
IFN-α and, in addition, infected with an SFV that expresses secreted recombinant IFN-α 
(SFVIFNα). Control cells in B were grown without IFN-α or viral stock. Consistent with the 
literature, both IFN-α formulations inhibited only the growth of ME15 cells, whereas D10 
proliferation was essentially unaffected. Notably, SFVIFI44 infection affected the growth of 
both cell lines to a similar extent.
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Abstract
Interferon inducible transmembrane (IFITM) proteins 
are involved in early development, cell adhesion and 
the inhibition of cell growth in response to interferons 
(IFN). These genes can be transcribed in most 
tissues capable of IFN signaling with the exception 
of bone-specific IFITM5/BRIL. They are clustered 
within a distinct region in the vicinity of IFITM5 which 
shows highest homology to corresponding genes in 
most other vertebrate species. Some processed 
pseudogenes lacking the single intron are spread 
over investigated genomes and apparently do not 
code for functional proteins. Phylogenetic analysis of 
the protein coding sequences point to the presence 
of a single interferon inducible IFITM in the ancestor 
of rodents and primates. The distinct functions 
studied so far in primates and rodents may have 
evolved in parallel but should not be casually 
inferred based on identical gene names. Cancer 
cells tend to have deregulated levels of IFITM 
transcripts. IFITM3 reintroduced into cell lines with 
low basal levels is sufficient to drive growth arrest 
and a senescence-like morphology. Overexpressed 
IFITM3 proteins are moved from inner cell 
organelles to the membrane in small 
caveolae-like compartments. 
Nevertheless they can be isolated from 
the culture medium and show intracellular 
processing when attached to a protein 
tag. IFN alpha-induced growth inhibitory 
signals are transmitted from mouse to 
human cells and may be carried by IFITM 
proteins. According to our results, IFITM3 
protein expression alone is not sufficient 
to transfer growth-inhibitory signals. 
However, high IFITM levels in tumor cells 
may point to a progression state where 
one of the IFN-controlled antiproliferative 
pathways has been switched off.
IFITM genes in cancer
IFITM gene expression levels are 
altered in cancer cells (Brem et al, 
2001). We have found both full 
transcriptional silenced and virtually 
unrestricted expression of IFITM3 
genes in melanoma cells. IFITM3 is 
important for development (Smith C 
et al, 2007) and underlies epigenetic 
regulation by DNA methylation. 
Cancer patients with a 
hypermethylator phenotype show an 
aberrant methylation status of IFITM 
promoter sequences. Tumor 
suppressor protein p53 proficient 
cancer cells may benefit from 
transcriptional silencing of IFITM 
genes and p53 deficient cells may 
even profit from high abundance of 
IFITM transcripts by potential anti-
proliferative signaling to adjacent 
normal cells or by regulation of the 
immune system. 
Abbreviations
BRIL: Bone marrow restricted IFITM like 
(protein) 
CDS: Coding sequence
IFITM: Interferon inducible transmembrane 
(gene)
IFN (IFNα): Interferon (alpha)
IIP: Interferon induced protein (in fish)
IQR: Inter quartile range
GAS: (Interferon) gamma activated 
sequence/site
ISRE: Interferon-stimulated response 
element
SNAP-tag®: Small protein based on human O6-
alkylguanine- DNA-alkyltransferase
9-27 / 1-8D human IFITM 1/2/3 protein synonyms
 / 1-8 U: (see figure legend 2)
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CD225 domain proteins and consensus sequence of IFITM and BRIL
Figure 1
Amino-acid occurrence in putative homologues of IFITM1-3 (top) and IFITM5 (BRIL) proteins  
(bottom). Probability is calculated from genomic sequences of 55 mammalian (IFITM1-3 and 
homologous) or 17 different mammals and one bird (IFITM5) genes. The conserved exon splice-
junction is indicated by a vertical line. Potentially calcium binding domain of BRIL is highlighted by a  
yellow line above and predicted trans-membrane regions are underlined in orange.
Figure 2 A) Structural diagram of human and mouse IFITM proteins 9-27 / fragilis2 (IFITM1), 1-8D /  
fragilis3 (IFITM2), 1-8U / fragilis (IFITM3), fragilis5 (ifitm6) and BRIL / fragilis4 (IFITM5), mil4  
(ifitm7) is not shown.B) Mapping of IFITM genes to human and mouse chromosome locus. There  
are 2 ISRE promoter elements (red) in IFITM1-3 and an additional GAS (yellow) in IFITM1 (Lewin  
et al, 1991).
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Phylogenetic analysis
The interferon induced protein family members in humans IFITM1, IFITM2 and IFITM3, 
share more DNA homology within their taxonomic order than to homologues in other 
vertebrates, suggesting one common ancestor of these sequences when rodents and 
rabbits separated from primates (figure 3). 
IFITM5, also described as bone marrow restricted IFITM like (BRIL, Moffatt et al, 2008), 
Figure 3 Phylogenetic tree (maximum likelihood approach) for trimmed CDS sequences of 55 
mammalian variants of IFITMs. Identified BRIL sequences, fish IIP sequences and other,  
ambiguous sequences were not taken into account for this analysis. Bootstrap values based on 
100 replicates are shown for branches of interest. Enlarged numbers indicate the high probability  
for occurrence of a singe common ancestor for all primate interferon induced transmembrane 
genes and one for all Old World rats and mice (Murinæ).
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has homologs in many species among the jawed vertebrates (not shown). In contrast to 
IFITM1-3, BRIL has a highly conserved aspartate-rich domain of probably calcium ion 
binding function at its C-terminus (see figure 1). 
A clear ordering of the rodent-specific IFITM6 fails within the interferon regulated IFITM 
proteins. This gene shows higher mutation rates when assuming descent from the same 
ancestor, thus its evolution resembles that of an antiviral gene with positive selection 
pressure or reflects the mutation rate of a dying gene. The sequences of primates and 
rodents look clearly separated, suggesting a single gene in the ancestor of placental 
mammals.
Cellular localization, secretion and processing of IFITM3 fusion proteins
IFITM proteins are transferred in caveolae like vesicles to the cell membrane (Xu et al, 
2009) and can be detected in the supernatant of constitutively expressing cells and IFN-
treated cells at comparable levels to ISG15 (d'Cunha et al, 1996). Fusion proteins in 
human cells were processed to endogenous protein size (figure 4a), similarly to the mouse 
model (Smith RA et al, 2006). Processed IFITM proteins may act as tumor-associated 
antigenic peptides (Tirosh et al, 2007) in all MHC class I presenting cells. We have 
suggested that secreted IFITM3 proteins could interact with receptors on other cells (Brem 
et al, 2003), but so far we could not demonstrate transfer of 1-8 protein.
Processed amino-terminal and intact carboxy-terminal SNAP-tagged fusion proteins could 
be found in concentrated supernatants (figure 4b). IFITM3 sensitive cell lines with 
knocked-in fusion protein are initially blocked in proliferation and adopt a senescence like 
morphology. The majority of these cells regain proliferative ability only when IFITM3 
expression is strongly diminished. This effect is stronger when the protein is tagged at the 
C terminus and predominantly processed to endogenous protein size.
Figure 5 Live cell imaging of TMR star labeled human IFITM3 SNAP tag fusion (N-tag) proteins.  
ME-15 (melanoma) cells were labeled 16 hours after transfection of plasmid and incubated for 4  
hours to allow protein trans-location. Overlay of fluorescence and phase contrast (25%) channels  
is shown.
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Co-cultures – no observable effect of growth arrest signal transduction
Anti-proliferative signals can be transmitted from one cell to the other when the interferon 
system has been activated (Lloyd et al, 1983). IFITM1-3 proteins are able to inhibit cell 
growth (Hillman et al, 1987, Deblandre et al, 1995, Brem et al, 2003, Ropolo et al, 2004). 
IFITM proteins are also known to interact with receptor complexes (Smith RA et al, 2006). 
1-8 proteins are able to bind viral proteins and induce apoptosis in infected cells (Joung et 
al, 2003). IFITM proteins drive cells to senescence by interaction with the ATM-p53 
pathway (Kim et al, 2009) . Overexpression of IFITM3 genes in tumor cells is sufficient to 
drive them into senescence.
We investigated the potential of 1-8U protein to be transmitted from one cell to the 
adjacent and to act as a co-receptor, by blocking with antibodies. A transfer of protein or a 
significant change in the proliferation rate was not observed in our experiments. In 
addition, there was no significant benefit for growth sensitive tumors cells when anti-serum 
against 1-8 proteins was added to the culture medium. In conclusion,  we have 
demonstrated that expression of IFITM3 genes is not sufficient for the transfer of interferon 
induced anti-proliferative signals in our model system.
Figure 4 A) Degradation pattern of amino-terminal SNAP-tagged (N-tag) and carboxy-terminal  
SNAP-tagged IFITM3-fusion proteins (35 kDa) and unspecific antibody binding (wt). B) Detection 
of processed IFITM3 (15 kDa), fusion-proteins (35 kDa) and endogenous ISG15 protein (15 kDa)  
in the supernatant (sup) and cytosolic protein (cyt) levels under IFN alpha (+) or PBS treatment (-  
control).
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Venus protein was a gift from the Miyawaki lab (Nagai et al, 2002).
Conclusions
IFITM gene locus is a hot spot of gene duplications and mutations
IFITM1-3 multiplied and evolved only recently 
► shared functions in all mammalian variants
IFITM proteins are processed and found in extracellular compartments
IFITM3 expression is sufficient for cellular senescence
but not for anti-proliferative cell to cell signaling
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Abstract
MicroRNAs are positive and negative regulators of eukaryotic gene expression that 
modulate transcript abundance by specific binding to sequence motifs located prevalently 
in the 3′ untranslated regions of target messenger RNAs (mRNA). Interferon-alpha-2a 
(IFNα) induces a large set of protein coding genes mediating antiproliferative and antiviral 
responses. Here we use a global microarray-based microRNA detection platform to 
identify genes that are induced by IFNα in hepatoma- or melanoma-derived human tumor 
cell lines. Despite the enormous differences in expression levels between these models, 
we were able to identify microRNAs that are upregulated by IFNα in both lines suggesting 
the possibility that interferon-regulated microRNAs are involved in the transcriptional 
repression of mRNA relevant to cytokine responses.
Introduction
The gene expression patterns of tumor-derived cell lines differ greatly, as do their 
responses to antiproliferative effects of interferons (IFNs). The cause of this variation has 
been under investigation for more than 40 years, but only basic regulatory mechanisms of 
interferon signaling are understood today. Small regulatory genome encoded RNAs, such 
as microRNAs, have recently attracted attention in genomic research. New methods to 
analyze the levels of these regulatory elements are now commercially available, but the 
power of these techniques is still discussed extensively. Our study was designed to 
compare two methods for microRNA detection with respect to usefulness in defined cell 
culture assays. The experimental design assesses variation between the two cell lines and 
the treatment effects of IFNα.
A hallmark of the therapeutic activity of type I interferons is the induction of antiproliferative 
activity mediated by the upregulation of several hundred response genes with pleiotropic 
functions (1). These genes can be divided into two major classes based on the kinetic 
properties of induction (2). Primary response genes (PRGs) are upregulated within 24 h 
after the cytokine signal and the secondary response genes (SRGs) are induced following 
day1 when the activity of the PRGs decays. In contrast to SRGs, all PRGs studied to date 
contain bona fide interferon response elements in the promoter region, which are required 
for binding of the interferon-stimulated gene factor 3 (ISGF3) complex and for janus 
kinase/signal transducer of transcription (JAK/STAT)-pathway-mediated signaling.
Expression of PRGs is turned off by proteins termed suppressors of cytokine signaling 
(SOCS) (3). As the nomenclature indicates, this class of polypeptides has the capacity to 
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interfere and silence other cytokine-induced signaling cascades (for review see (4)). 
SOCS1 for instance is part of the early inducible PRG cluster and down modulation occurs 
together with the other genes before onset of SRG expression. It is believed that feedback 
inhibition of JAK/STAT signaling by SOCS1 represses transcriptome modulation of IFNα 
signaling (5). Regulation of SOCS protein translation by interferon-regulated microRNAs 
(IRmiRs) would enhance the potential of cytokine fine regulation. It has been reported that 
miR-19 antagonists lead to higher SOCS1 levels and miR-19 mimics can repress SOCS1 
reporter constructs, thus obviously supporting the bioinformatic predictions that SOCS1 is 
a direct target of miR-19 (6). Inhibition of SOCS activity could for instance prolong the 
duration of cytokine activity, which has obvious clinical implications.
Following the discovery of microRNAs in virtually all higher eukaryotic organisms 
significant research efforts were initiated to address the function of these catalytic 
oligonucleotides which are the natural counterparts of synthetic small inhibitory RNAs 
(siRNAs) used for experimental gene silencing (for review see (7)). MicroRNAs are 
positive and negative modulators of the expression of entire gene clusters that contain 
complementary microRNA recognition sequence motifs in the 3′-UTR. Today, prediction of 
microRNA target genes by homology-based algorithms is still ambiguous (8). The activity 
of one or several microRNAs could explain suppression of the entire PRG cluster provided 
that microRNA abundance is regulated by IFNα. Alternatively, microRNA-mediated 
degradation of transcripts encoding negative regulatory proteins would also abolish PRG 
expression and restore IFNα responsiveness.
Some recent reports showed that interferon beta (IFNβ) stimulation can boost microRNA 
levels in cell culture together with inhibition of viral replication (9). At this point it is an open 
question whether this induction is IFNβ specific or a shared feature of all type I interferons. 
To investigate whether microRNA are also involved in regulation of IFNα response, we 
used two human-tumor-derived cell lines: the melanoma line ME-15 (10) and the 
hepatoma line HuH7 (11). We have chosen these cell lines as models, because we have a 
good understanding of the IFNα responses at the mRNA and the protein levels in these 
cell lines. Further we chose to use a melanoma cell line because IFN is also used for 
treatment of this cancer type. HuH7 is commonly used as a model for testing antiviral 
effects of IFN in the HCV replicon system. In both models efficient responses to IFNα have 
been shown at the functional and transcriptional level. IFNα response genes carry 
response elements in their promoter region and these motifs are responsible for gene 
expression with similar efficiency in many cell types. Therefore we expected to find a 
similar regulated set of genes in both lines given that IRmiR genes are regulated by the 
same mechanism, whereas some constitutively expressed microRNA genes were 
expected to be cell type specific for functional reasons. We have chosen a DNA-
microarray-based technology (Illumina) for the multi-parallel expression analysis of all 
known human microRNAs (http://microrna.sanger.ac.uk/; Release 10.0: August 2007). This 
method allowed us to process total RNA as template, allowing the possibility of mRNA 
gene expression profiling in further experiments. Briefly, annealing of microRNA specific 
primers combined with enzymatic polyadenylation allows multi-parallel polymerase chain 
reaction (PCR)-mediated amplification of individual microRNAs. The output of this step is a 
DNA amplicon library that reflects to a large extent the original stoichiometry of mature 
microRNAs in a cell or tissue (12). PCR amplification is performed with fluorescently 
labeled primers, which allows quantitative signal detection by conventional confocal laser 
scanning.
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Materials and Methods
Cell Culture, Interferon Treatment, and RNA Precipitation
Melanoma cells (ME-15) were cultured in RPMI 1640 with L-Glutamine supplemented with 
non-essential amino acids and sodium pyruvate (1 mM) and hepatoma (HuH7) cells were 
cultured in DMEM + GlutaMAX. Both media contained 10% FBS. All cell culture reagents 
were purchased from Invitrogen (GIBCO®). Roferon (Interferon alpha2a, ROCHE) was 
diluted in fresh medium to a final concentration of 1,000 U/mL and control cultures were 
grown without cytokine. Cells were cultured at 37°C in a humidified atmosphere containing 
5% CO2. Total RNA preparation was carried out using TRIZOL (Invitrogen) total RNA 
extraction using 1/2 volume of 1-bromo-3-chloro-propane (molecular biology grade, 
SIGMA) as chloroform substitute. For efficient recovery of small RNAs, DNA LoBind tubes 
(Eppendorf) were used and all centrifugation steps were performed at maximum speed 
and 4°C in an Eppendorf 5417R centrifuge. Total RNA was precipitated with 2 vol of 2-
propanol (Fluka) at −20°C for at least 16 h. The RNA pellet was washed with 75% ethanol 
(Merck), dried, and dissolved in DEPC-treated water (Ambion). The RNA was quantified 
with Quant-iT™ RiboGreen® RNA Assay (Invitrogen) as suggested by Illumina.
Illumina Bead Array MicroRNA Detection
Starting with 500 ng/sample of total RNA, mature microRNAs were amplified with the 
Illumina human v1 MicroRNA expression profiling kit containing primers for 743 human 
microRNAs. The resulting amplicons were hybridized to a 96 sample universal probe 
capture array and fluorescent signals were detected by confocal laser scanning. All steps 
were performed according to Illumina’s instructions manual.
Data Processing and Statistical Analysis
The data was processed with Beadstudio software (version 3.1.3, gene expression module 
3.3.8) including the calculation of detection p values based on negative control bead 
signals. Log-transformation, loess normalization (13) and statistical analysis were 
performed with R (2.8.1) (14) using the package lumi (1.8.3) (15) and software contained 
therein, in particular limma (2.16.4) (16). Statistical models were chosen as follows: a 
linear model (limma t statistics) with two separate coefficients for HuH7 and ME-15 cells 
was used for the selection of differently expressed genes shown in Fig. 1 and Table 1. 
Statistics represented in the tables were calculated by testing the two indicated conditions 
as independent factors. In Table 1, p values were adjusted by the false discovery rate 
method (17). Treatment effects shown in Table 2b and Fig. 3a were modeled with two 
coefficients (cell line, treatment) for time point 4 h, p values arise from t statistics. 
Normalized relative fluorescence levels were calculated by 2^mean (of log2 transformed, 
loess normalized values). Change factors (CHF) were calculated as fold change on the 
linear scale minus 1 as previously described (2). Raw data, non-normalized, and 
normalized microRNA expression data have been submitted to the Gene Expression 
Omnibus with accession number GSE16421.
Quantitative PCR and Data Processing
microRNA levels were measured using TaqMan® microRNA assays (Applied Biosystems) 
using the TaqMan® MicroRNA reverse transcription (RT) kit with TaqMan® 2× universal 
PCR master mix (No AmpErase® UNG) as recommended by the supplier. Ten nanograms 
of total RNA was used as input for amplification using the samples used for microarray 
analysis. Reversed transcriptase products were diluted 1:15 and measured on an ABI 
7900HT fast real-time PCR system. Technical replicates were run on three different plates 
(one with 40 cycles and two with 50 cycles) and threshold for cycling time (CT) calculation 
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was set for all probes to 0.2. For estimation of endogenous small RNA content, the 
nucleolar RNA RNU48 was used as control and reference.
Standard error (Δx) was calculated by the average standard error of treated and untreated 
MNE for biological replicates.
Results and Discussion
The following technical aspects have to be considered for result interpretation. The dataset 
of the microRNA bead array assay is not directly comparable to gene expression arrays 
where in vitro translated transcripts are directly hybridized to the probes. Moreover 
Illumina’s bead array technology tends to have higher background fluorescence levels and 
lower change factor values than Genechips from Affymetrix. Background (average of 
negative control signals) and noise (standard deviation of negative probes from each 
sample) were 528 ± 60 and 229 ± 67, respectively. The density of all samples shows a 
bimodal distribution peaking around the background fluorescent levels and the robust 
levels (approximately 12,000). The curve is skewed to the right and peak density height is 
found in the ratio 4:1 considering all probes (data not shown). The distribution of probes 
detected in all samples (detection p value threshold at 0.01) has a plateau ranging from 
about 2,000 close to the detectors maximum capacity of 2^16 relative fluorescent units 
(12). As expected, the correlation of data coming from biological replicates r² = 0.952 ± 
0.028 (not normalized) and r² = 0.956 ± 0.022 (after loess normalization and log-
transformation) was lower than for technical replicates r² > 0.97 (12). We preferred loess 
normalization to quantile normalization because the later was too aggressive for the given 
small probe numbers.
As a first step we wished to address the robustness of the microRNA array in probe 
detection by selecting microRNA genes that are detected under all experimental conditions 
with high statistical significance in all biological triplicates (detection p value < 0.01). In 
each set of triplicate samples (control, 4 h or 24 h, IFNα stimulation) we detect 
approximately 270 genes that fulfill the above criteria. This corresponds to roughly a third 
of microRNAs available for detection in the assay system. Furthermore, this result 
suggests indirectly that IFNα treatment does not induce global changes in microRNA gene 
expression, but it modulates rather the expression of individual genes.
Today it is well established that microRNA expression patterns are cell and tissue type 
specific, which is consistent with a role in cell differentiation and biological function (8). 
Thus we expected to detect genes with preferential expression in either hepatoma or 
melanoma cells as these cell lines are derived from different tumors. Indeed, when all 
experimental conditions and data points are included in the data analysis about 150 
microRNAs genes show preferential expression in either HuH7 or ME-15 cells (Fig. 1).
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Fig. 1 Differential microRNA expression in human melanoma (ME-15) and hepatoma  
(HuH7) cells. microRNA expression levels were compared in two cell lines at two different  
time points and corrected for the treatment effect. The 50 most significant (p value below  
10−¹²) microRNA expression values from untreated samples are shown in a heat diagram  
including hybridization controls as reference for technical variance. White indicates noise  
levels, yellow indicates the first quartile, orange the median, red the third quartile, and  
black maximum expression levels. The intensity data, significance values and the IFNα-
dependent expression levels are summarized in Table 1.
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Control Interferon-alpha treated
4 h 24 h 4 h 24 h
ME-15 HuH7 CHF ME-15 HuH7 CHF ME-15 HuH7 CHF ME-15 HuH7 CHF
microRNAs rated higher in HuH7
hsa-miR-122a 685 30,912 44.14*** 704 32,058 44.51*** 717 30,459 41.46*** 876 29,044 32.17***
hsa-miR-224 359 10,085 27.07*** 345 7,358 20.31*** 358 8,183 21.87*** 333 7,483 21.44***
hsa-miR-483 915 23,671 24.87*** 811 18,073 21.29*** 849 17,784 19.95*** 802 17,554 20.88***
hsa-miR-200a 517 8,392 15.22*** 667 13,543 19.29*** 722 11,317 14.68*** 500 12,649 24.30***
hsa-miR-218 405 5,654 12.96*** 417 6,527 14.64*** 419 5,764 12.76*** 431 6,155 13.29***
hsa-miR-618 700 7,549 9.78*** 649 8,128 11.52*** 651 8,042 11.35*** 616 7,416 11.03***
hsa-miR-215 638 6,826 9.71*** 829 6,013 6.25*** 663 6,641 9.02*** 723 6,501 7.99***
hsa-miR-192 3,956 34,724 7.78*** 3,401 34,181 9.05*** 4,021 29,382 6.31*** 3,343 33,293 8.96***
hsa-miR-194 4,410 32,950 6.47*** 4,142 32,991 6.96*** 4,700 33,182 6.06*** 4,410 32,422 6.35***
hsa-miR-182 1,575 11,480 6.29 *** 2,541 13,088 4.15*** 2,227 12,512 4.62*** 3,067 13,907 3.53***
hsa-miR-452 434 2,284 4.27*** 707 3,326 3.70*** 530 3,378 5.37*** 636 3,028 3.76***
hsa-miR-183 1,763 8,748 3.96*** 2,123 8,945 3.21*** 2,000 8,984 3.49*** 2,129 8,258 2.88***
hsa-miR-200b 1,934 7,551 2.90*** 1,692 9,633 4.69*** 1,705 9,393 4.51*** 1,911 10,855 4.68***
hsa-miR-143 1,355 5,087 2.75*** 1,775 7,167 3.04*** 1,698 5,688 2.35*** 1,765 7,519 3.26***
hsa-miR-624 4,852 13,418 1.77** 4,188 11,593 1.77*** 4,479 11,718 1.62** 3,872 10,539 1.72**
hsa-miR-99a 8,653 20,232 1.34** 8,887 20,645 1.32*** 9,064 18,019 0.99** 8,870 19,506 1.20**
hsa-miR-27b 10,067 22,544 1.24** 11,924 23,914 1.01*** 11,564 23,044 0.99*** 12,182 24,515 1.01**
microRNAs rated higher in ME-15
hsa-miR-146a 36,976 15,721 −1.35** 33,410 16,103 −1.07*** 35,166 15,137 −1.32*** 35,688 19,962 −0.79***
hsa-miR-422b 19,264 7,759 −1.48** 19,962 7,832 −1.55*** 20,641 7,462 −1.77*** 17,453 7,152 −1.44***
hsa-miR-149 5,868 2,246 −1.61** 6,195 2,030 −2.05*** 6,061 1,743 −2.48*** 5,477 2,418 −1.26**
hsa-miR-510 1,051 368 −1.86*** 1,489 396 −2.76*** 1,435 366 −2.92*** 1,053 384 −1.74***
hsa-miR-30a-5p 10,664 3,717 −1.87** 10,223 3,700 −1.76*** 10,686 3,477 −2.07*** 10,466 4,538 −1.31***
HS_98 3,274 1,065 −2.08** 3,225 859 −2.76*** 3,445 965 −2.57*** 2,850 750 −2.80***
hsa-miR-340 4,583 1,443 −2.18** 4,218 1,220 −2.46*** 4,664 1,061 −3.40*** 3,078 933 −2.30***
HS_182.1 1,965 615 −2.2** 1,687 606 −1.79** 1,903 562 −2.39*** 1,844 534 −2.45***
hsa-miR-378 4,619 1,371 −2.37** 4,975 1,364 −2.65*** 4,994 1,213 −3.12*** 4,188 1,237 −2.38***
HS_305_b 4,105 1,207 −2.40* 3,853 833 −3.63*** 4,278 977 −3.38*** 3,688 1,076 −2.43***
hsa-miR-505 1,312 343 −2.83*** 2,070 342 −5.05*** 2,050 360 −4.70*** 2,030 362 −4.60***
hsa-miR-10a 1,570 350 −3.48** 1,592 350 −3.55*** 1,828 360 −4.07*** 1,880 352 −4.34***
hsa-miR-10b 1,695 378 −3.49** 2,929 371 −6.89*** 3,564 411 −7.67*** 4,297 382 −10.26***
hsa-let-7g 10,720 2,302 −3.66** 16,046 3,077 −4.21*** 13,792 2,854 −3.83*** 15,435 2,568 −5.01***
hsa-miR-584 11,643 2,261 −4.15*** 12,717 1,873 −5.79*** 12,394 1,912 −5.48*** 12,616 1,674 −6.54***
hsa-let-7i 11,701 2,255 −4.19** 16,410 2,707 −5.06*** 15,319 2,251 −5.80*** 15,718 2,563 −5.13***
hsa-miR-330 9,029 1,653 −4.46*** 9,684 1,670 −4.80*** 9,432 1,397 −5.75*** 7,773 1,380 −4.63***
HS_307_b 2,453 444 −4.52*** 4,188 443 −8.45*** 3,669 407 −8.01*** 3,318 448 −6.41***
hsa-miR-34c 2,292 412 −4.56** 3,303 426 −6.75*** 3,524 381 −8.25*** 2,403 404 −4.95**
hsa-miR-133a 9,270 1,594 −4.82*** 7,942 1,662 −3.78*** 8,488 1,435 −4.92*** 6,495 1,783 −2.64***
hsa-miR-361 5,234 828 −5.32*** 7,641 755 −9.13*** 7,356 875 −7.41*** 7,904 706 −10.19***
hsa-miR-508 2,552 325 −6.86** 4,280 376 −10.39*** 3,965 357 −10.09*** 4,013 336 −10.96***
hsa-miR-9* 8,372 1,039 −7.06*** 10,114 940 −9.76*** 10,027 1,263 −6.94*** 9,948 843 −10.81***
hsa-miR-31 5,967 661 −8.03*** 5,742 720 −6.97*** 6,619 657 −9.07*** 5,978 728 −7.21***
hsa-miR-506 5,855 625 −8.37*** 6,125 713 −7.59*** 5,916 665 −7.90*** 5,602 675 −7.30***
hsa-miR-211 5,147 476 −9.81*** 3,218 490 −5.57*** 3,833 471 −7.14** 5,575 464 −11.01***
hsa-miR-296 6,194 570 −9.86*** 5,913 504 −10.72*** 6,441 557 −10.57*** 4,369 532 −7.21***
hsa-miR-598 4,445 401 −10.09*** 4,475 386 −10.59*** 4,934 424 −10.63*** 4,127 367 −10.24***
hsa-miR-199b 9,081 775 −10.71*** 9,478 916 −9.35*** 9,629 865 −10.13*** 8,059 911 −7.85***
hsa-let-7b 8,236 539 −14.28*** 12,563 475 −25.44*** 12,150 500 −23.30*** 12,309 452 −26.24***
hsa-miR-509 10,413 536 −18.44*** 10,346 512 −19.22*** 9,966 548 −17.20*** 9,311 529 −16.62***
hsa-miR-9 12,587 422 −28.85*** 15,870 447 −34.50*** 15,502 418 −36.09*** 16,402 429 −37.26***
hsa-miR-514 12,065 364 −32.16*** 13,112 358 −35.64*** 12,201 315 −37.74*** 12,355 355 −33.83***
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Control Interferon-alpha treated
4 h 24 h 4 h 24 h
ME-15 HuH7 CHF ME-15 HuH7 CHF ME-15 HuH7 CHF ME-15 HuH7 CHF
Hybdridization controls
array_hyb_con4 6,404 7,110 0.11 7,724 6,684 −0.16 7,031 6,739 −0.04 6,964 6,746 −0.03
array_hyb_con3 6,923 7,681 0.11 7,833 7,368 −0.06 7,422 7,054 −0.05 6,906 7,365 0.07
array_hyb_con1 10,779 11,868 0.10 11,812 11,728 −0.0.01 11,436 11,382 0.00 11,059 11,522 0.04
array_hyb_con2 10,258 11,145 0.09 11,382 10,829 −0.05 11,075 10,650 −0.04 9,997 10,283 0.03
Table 1 Cell line differences in microRNA expression
Table 1 shows the expression data for the most significant genes including change factors 
and significance score as reference. Among these differentially expressed genes there are 
three members of the let-7 family, which has properties of tumor suppressor genes (for 
review see (18)). Therefore it is not surprising that the members of this well-known 
microRNA gene family are deregulated in the analyzed cancer cells too. Furthermore, the 
different developmental stage of our cancer cell lines is expected to have left a genomic 
fingerprint where some microRNA genes are expressed in one but not the other cell line 
(19). Consistent with this, expression of some microRNAs is strictly cell type specific and 
barely detectable in the other cell type (Fig. 2a), for example the liver-specific miR-122a 
and miR-192 (20).
Fig. 2 Cell line specific microRNA expression Volcano plot (a) display demonstrates the  
multi-variant biological diversity of microRNA expression in ME-15 or HuH7 cells. The  
estimated fold-change value (change factor) is plotted on the X-axis against the p value  
(limma t statistics) in logarithmic scale on the Y-axis. A linear model, using the expression  
values of untreated ME-15 cells at 4 h as base together with three parameters to estimate  
differences in time, treatment, or cell line. The top ranked and qPCR measured  
microRNAs are annotated. b Quantitative PCR validation of microarray data using eight  
selected microRNAs. Input total RNA came from independent cell cultures. Data are  
shown as relative cycling times (ΔCT) calculated with endogenous control RNU18 for ME-
15 (color-filled bars) and HuH7 (gray). Error bars represent ΔCT±Δx (standard deviation of  
biological replicates). ΔΔCT are noted above the bars together with the significance codes  
for t statistics (0 ‘***’, 0.001 ‘**’, 0.01 ‘*’, 0.05 ‘.’, and 0.1 ‘‘ 1).
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Control Interferon-alpha treated
4 h 24 h 4 h 24 h
a ME-15 HuH7 CHF ME-15 HuH7 CHF ME-15 HuH7 CHF ME-15 HuH7 CHF
Validated microRNAs
hsa-miR-19a 13,617 6,726 −1.02 18,318 17,178 −0.07 19,226 17,409 −0.10 14,425 14,079 −0.02
hsa-miR-19b 13,365 9,406 −0.42 25,463 22,438 −0.13 21,532 20,625 −0.04 18,039 17,440 −0.03
hsa-miR-30e-5p 9,497 6,838 −0.39 13,045 11,321 −0.15 12,643 10,887 −0.16 13,230 11,809 −0.12
hsa-let-7a 15,244 4,335 −2.52. 28,304 6,181 −3.58 *** 22,226 6,386 −2.48*** 30,449 5,612 −4.43***
hsa-let-7b 8,236 539 −14.28*** 12,563 475 −25.44*** 12,150 500 −23.30 *** 12,309 452 −26.24***
hsa-miR-203 907 325 −1.79** 1,155 348 2.32*** 1,302 359 −2.63*** 1,186 5,757 −1.07**
hsa-miR-130b 5,700 8,316 −0.46 13,023 13,880 0.07 9,994 14,055 0.41 12,053 12,432 0.03
hsa-miR-455 2,677 2,604 −0.03 3,944 5,285 0.34* 3,437 5,927 0.72** 3,262 5,342 0.64*
b
ME-15 HuH7
4 h 24 h 4 h 24 h
−IFNa +IFNa CHF −IFNa +IFNa CHF −IFNa +IFNa CHF −IFNa +IFNa CHF
Interferon-regulated microRNAs
hsa-miR-33b 1,226 3,484 1.84** 2,888 2,318 −0.25 476 1,113 1.34** 1,306 1,851 0.42***
hsa-miR-33 2,631 7,352 1.79 9,774 5,764 −0.70* 1,887 6,645 2.52. 8,893 2,726 −2.26
hsa-miR-126* 2,221 5,409 1.44* 5,578 6,111 0.10 4,749 6,410 0.35. 5,687 5,803 0.02***
hsa-miR-10b 1,695 3,564 1.10* 2,929 4,297 0.47** 378 411 0.09 371 382 0.03
hsa-miR-551b 2,085 4,169 1.00* 4,423 3,419 −0.29 1,804 4,979 1.76* 5,221 4,865 −0.07
hsa-miR-137 1,037 1,966 0.90 2,523 2,872 0.14 1,613 3,155 0.96** 3,429 3,598 0.05
hsa-miR-138 2,158 4,074 0.89* 4,709 3,701 −0.27 725 828 0.14 903 859 −0.05
hsa-miR-130b 5,700 9,994 0.75 13,023 12,053 −0.08 8,316 14,055 0.69** 13,880 12,432 −0.12
hsa-miR-101 6,701 11,387 0.70 13,088 11,688 −0.12 3,569 10,871 2.05** 10,445 10,796 0.03
hsa-miR-140 7,339 12,236 0.67 15,512 15,931 0.03 3,058 5,976 0.95* 6,135 7,221 0.18
HS_92 829 1,356 0.64. 1,246 1,179 −0.06 407 587 0.44 492 478 −0.03
hsa-miR-362 1,382 2,234 0.62* 2,144 2,276 0.06 1,907 2,737 0.43* 2,456 2,519 0.03
hsa-miR-19b 13,365 21,532 0.61** 25,463 18,039 −0.41 9,406 20,625 1.19* 22,438 17,440 −0.29
hsa-miR-130a 13,031 20,878 0.60. 27,571 23,048 −0.20 17,884 31,012 0.73* 33,801 28,875 −0.17
hsa-miR-579 552 816 0.48. 992 1,053 0.06 729 1,362 0.87* 1,250 1,308 0.05
hsa-miR-29b 23,138 34,148 0.48. 32,691 29,710 −0.10 8,737 17,989 1.06* 20,599 17,405 −0.18.
hsa-miR-19a 13,617 19,226 0.41* 18,318 14,425 −0.27 6,726 17,409 1.59. 17,178 14,079 −0.22.
hsa-miR-338 1,298 1,813 0.40. 1,870 1,603 −0.17 2,363 4,603 0.95. 5,109 4,088 -0.25
hsa-miR-590 1,403 1,949 0.39. 1,545 1,367 −0.13 669 1,068 0.60. 884 847 −0.04
hsa-miR-545 1,455 1,973 0.36. 2,149 1,720 −0.25* 829 1,371 0.65** 1,573 1,393 −0.13
hsa-miR-30e-5p 9,497 12,643 0.33 13,045 132,030 0.01 6,838 10,887 0.59* 11,321 11,809 0.04
hsa-miR-570 1,989 2,576 0.30. 2,397 2,610 0.09 2,213 3,739 0.69* 4,312 3,708 −0.16
hsa-miR-301 13,621 17,531 0.29* 16,321 15,142 −0.08 5,646 10,460 0.85* 10,925 10,295 −0.06.
hsa-miR-561 517 621 0.20 568 464 −0.22** 683 1,157 0.69** 1,149 941 −0.22
HS_250 4,284 1,813 −1.36. 740 983 0.33 3,688 2,337 −0.58 1,195 1,303 0.09
c
ME-15 HuH7
4 h 24 h 4 h 24 h
−IFNa +IFNa CHF −IFNa +IFNa CHF −IFNa +IFNa CHF −IFNa +IFNa CHF
Validated microRNAs
hsa-miR-19a 13,617 19,226 0.41* 18,318 14,425 −0.27 6,726 17,409 1.59. 17,178 14,079 −0.22
hsa-miR-19b 13,365 21,532 0.61** 25,463 18,039 −0.41 9,406 20,625 1.19* 22,438 17,440 −0.29.
hsa-miR-30e-5p 9,497 12,643 0.33 13,045 13,230 0.01 6,838 10,887 0.59* 11,321 11,809 0.04
hsa-let-7a 15,244 22,226 0.46 28,304 30,449 0.08 4,335 6,386 0.47. 6,181 5,612 −0.10
hsa-let-7b 8,236 12,150 0.48* 12,563 2,309 −0.02 539 500 −0.08 475 452 −0.05
hsa-miR-203 907 1,302 0.44* 1,155 1,186 0.03 325 359 0.10 348 575 0.665**
Table 2 Modulation of microRNA expression by IFNα — 4 and 24 h after stimulation
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Bead-array-based microRNA detection technology, including the bio-statistic analysis, is 
currently not well established or widely used and we have applied a commercial PCR-
based assay to confirm the array data for some microRNAs that cover different expression 
levels and change factors. In contrast to mRNA profiling, where RT-PCR-based assays are 
considered as gold standard for data validation, new generation deep sequencing is 
considered as the method of choice for microRNA quantification but is not available in our 
research institute. For the microRNAs let-7 a/b, miR-19 a/b, and miR-203, the PCR-based 
quantification method (Fig. 2b) confirmed the direction of change found with microarray 
technology (Table 2a). Expression of miR-130b and miR-455 was at similar levels in both 
assays. The correlation calculated for the eight tested microRNAs was acceptable: 
multiple r² from f test of mean relative cycling times (ΔCT) to mean log2 microarray 
expression values was 0.9279. Differences of absolute levels between the microRNA 
targets probably results from different hybridization properties of the microarray probes 
and variation in the performance of Taqman primers for the specific microRNA on the other 
side.
Assuming that any IFNα relevant microRNA will have the same kinetics as the mRNA for 
PRGs, we looked at the regulation of microRNA genes in our experiment. These IRmiRs 
should respond to IFNα stimulation preferentially in both cell lines, because this would be 
a good indication of a general mechanism in the IFNα response. Within the 25 most 
significantly regulated genes (Table 2b), only one gene (HS_250) is downregulated. A 
general upregulation of transcripts is consistent with classic IFNα signaling seen for 
mRNAs. However, the maximal observed change factor with high significance was 1.84 
(miR-33b in Table 2b) which is clearly lower than the values seen for protein coding 
mRNAs (2). We also included an expression analysis 24 h after IFNα stimulation in order 
to detect microRNA genes that show either delayed induction or remain activated at 
comparable levels to the 4 h stimulus. Based on our data set, the majority of the microRNA 
response genes show no further induction, but rather moderate downregulation 24 h after 
induction. This finding is not surprising as we expected immediate early impact of IFNα-
mediated primary signaling.
We also measured the IFNα response in the same experiment and for the same 
microRNAs (Table 2c). When we analyze the IFNα effect at the early time point in both cell 
lines we find all the validated microRNAs to be upregulated (Fig. 3a). The magnitude of 
upregulation and the basal expression levels of the microRNA-19a and 19b are similar in 
both cell lines (Fig. 3b, top). This and the finding that miR-19 regulates SOCS1 (4) may be 
relevant for the regulation of cytokine signaling. let-7a and let-7b had higher levels in the 
melanoma-cell-line-derived samples compared HuH7, but the induction by IFNα in ME-15 
could not be reproduced by RT-PCR (Fig. 3b, bottom). In both assays accurate fold 
changes are difficult to calculate, if the baseline expression level is close to background 
noise or the detection limit. An example of a gene at the detection limit is miR-203, which 
is not detectable without IFNα treatment in HuH7 cells (Table 2c). Upon IFNα stimulation 
(24 h in HuH7) the microRNA is detectable above background suggesting minimal 
induction. Consequently a solid change factor cannot be calculated, which is consistent 
with the high variance obtained by qPCR (ME-15). This result is in fact not surprising, 
because both technologies rely on logarithmic PCR amplification of microRNA templates. 
At low expression levels, both technologies show relatively high variation in biological 
replicates, which should be considered for data interpretation. Interestingly, miR-203 has a 
putative binding site for ISGF3 in the promoter region, which would enable IFNα-
dependent upregulation. miR-30 has been reported to be IFNβ inducible, although the 
subclass measured was not specified by the authors (9). We decided to analyze the most 
promising candidate (miR-30e-5p) present in our microarray dataset (Fig. 3a in gray). 
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Detection of miR-30e failed in ME-15 cells due to technical problems, but induction in 
HuH7 was similar to miR-19a/b.
Fig. 3 IFNα-dependent modulation of microRNA expression. a Volcano plot display of IFNα  
induced microRNA upregulation 4 h after induction. The change factor values (2^log factor  
change −1) are plotted on the X-axis against the p value in logarithmic scale on the Y-axis.  
Top-rated microRNAs are annotated together with the let-7 family members. b  
Confirmation of IFNα effect for selected microarray data by qPCR. The CT-values are the  
average of three technical and three biological replicates and changes were calculated  
with 2^ΔMNE (mean normalized expression values). Error bars show 2^ΔMNE±Δx  
(average standard error of treated and untreated MNE) from biological triplicates. miR-30e  
failed to amplify in ME-15 and miR-203 was below the detection limit in HuH7. Expression  
values were normalized against endogenous snoRNA RNU48 levels.
Some technology-related questions remain open. The microRNA assay measures 
essentially the number of amplicons generated by RT-PCR for each transcript. Thus the 
signal is an indirect measurement of transcript abundance as compared to classical mRNA 
microarray platforms, where the target mRNA is directly labeled during linear amplification 
by in vitro transcription. As a consequence, change factor calculations for amplicon-based 
assays are ambiguous.
In summary, Illumina’s bead array technology is well suited for multi-parallel profiling of 
microRNAs expressed in different cell types or tissues. We were also able to detect IFNα-
inducible microRNA genes although the changes observed were moderate and biological 
significance remains to be proven. Like most microarray-based detection technologies the 
technical variability among identical samples is low compared to biological variations of 
individual cell cultures. At this point it is important to note that variation among biological 
samples occurs and is independent of the parameters that are measured. Consistent with 
IFNα-dependent induction of mRNAs we find that virtually all modulated microRNA genes 
are upregulated. However, the IFNα-induced changes detected in our study are relatively 
small compared to the changes induced by IFNβ in HuH7 cells (9). Finally, it is noteworthy 
that IRmiRs have similar kinetic properties to their mRNA counterparts. miR-10b for 
instance is induced early in ME-15 and remains upregulated, while miR-19 abundance 
1D11
ceases after 24 h. In general, the majority of IRmiR genes were reset to basal levels after 
24 h and further studies are needed for kinetic classification. Thus, our study adds another 
level of complexity to the dynamic regulation IFNα signaling and other mechanisms like 
epigenetic promoter methylation are currently under intense investigation in our 
laboratories.
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Abstract
Suppressors of Cytokine Signaling (SOCS) Family Proteins are rapidly transcribed after 
Interferon alpha 2a (IFNa) treatment. They are involved in silencing the general pathways 
induced by Interferon, especially the Janus kinase / signal transducers and activators of 
transcription (JAK/STAT) pathways. SOCS1 and SOCS3 mRNA is barely detectable in 
most cultured cells but upon IFNa stimulation their levels increase rapidly. Their maximal 
expression levels differ markedly in cultured cancer cell lines, perhaps due to their 
epigenetic status. Peak SOCS3 mRNA are reached three hours after IFNa induction 
followed by rapid degradation within a few hours. These results suggest post-
transcriptional regulation of SOCS3 mRNA expression. In addition to various protein 
coding genes, also levels of certain micro RNA’s (miRNA) are modulated by IFNa. The 
3’ UTR of SOCS1, SOCS3 and SOCS6 share conserved binding sites for IFNa inducible 
miRNAs. Here we propose a model of how the SOCS dependent negative feedback 
pathway of Interferon may be influenced by RNA interference. This regulation suggests an 
important role in controlling the suppressor’s protein levels. Moreover, the involvement of 
miRNAs may contribute to an Interferon mediated cytokine memory.
Predicted miRNA binding sites for SOCS1 and SOCS3
Conserved binding sites for miRNA 
families were scanned using 
Target-Scan. Especially the 
miRNAs lying at the very 3’ end: 
let-7, miR-30, miR-19, miR-203 
were upregulated after Interferon 
challenge. 
A genome wide scan for the 
occurrence of miR-30 and miR-19 
sites in close proximity in 3’-UTRs 
showed that only 41 transcripts had a 
gap of less than 150 base pairs 
between these two sites, including 
SOCS1, SOCS3 and SOCS6 
mRNA.
2A2
Genomic context of miRNA-203 has a conserved ISRE transcription factor binding  
site
The miR-203 gene shows a similar context as an interferon stimulated gene. The miR 
coding site is covered by a CpG island. There are several transcription start sites and 
transcription factor binding sites, including one for ISGF3, upstream and 11 polyA sites 
downstream. 
Model of miRNA mediated cytokine memory 
Model showing the induction of the negative feedback loop of Interferon alpha (SOCS 
protein expression), the action of their presumed negative regulators (miRNAs) and their 
potential to contribute to long term cytokine memory through epigenetic regulation.
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miRNA levels after Interferon stimulation
Mature miRNA levels 
were affected early 
(after 4 hours 
incubation) by 
Interferon alpha 
addition to cell culture 
media. This effect 
was washed out after 
24 hours, when only 
few, specific miRNAs 
were regulated (see 
table on the lower 
right). The effect is 
spread over many 
miRNAs and every 
single expression 
level needs 
confirmation by 
qPCR.
The tables show 
upregulated miRNA 
which have target 
sequences in the 
very 3’-UTR regions 
of SOCS1 or 
SOCS3. Both, miR-
30 and let7 levels 
have been reported 
to increase after 
cytokine stimulation. 
Pedersen IM et al. 
(2007) showed a 
three fold 
upregulation of miR-
30 when HuH7 cells 
were stimulated with 
Interferon beta. This 
miR had no effect on 
their studied effect 
(viral replication). 
Meng F et al. (2007) 
postulated that the 
let-7 miRNA 
enhancement after 
Il-6 treatment may 
target SOCS1 to 
degradation and by 
that interfere in the 
Stat-3 pathway.
2A4
miRNA mediated degradation of SOCS1
After cytokine stimulation SOCS1 mRNA is produced and translated. Let-7 binding is 
inhibited or is not sufficient for degradation. The presence of several miRNA bound to the 
transcript will lead to translational blockage and degradation of the mRNA.
Discussion – Interfering in the SOCS pathway
A rapid degradation of SOCS-proteins after their induction is needed to restore cell 
responsiveness to cytokine stimulation. Restricted SOCS proteins levels are crucial to 
control their suppressing function (Lee KH, 2007). An insertion in the SH2 domain of 
SOCS3 is accountable for destabilizing the protein (Babon JJ, 2006), but this would be 
unprofitable unless its mRNA levels peak shortly after cytokine signalling.
In contrast to the large screening study (Landgraf P, 2007) that has not found any 
substantial changes in miRNA profiles after Interferon alpha, beta and gamma treatment, 
we have found evidence for a global change of miRNA expression after stimulation with 
IFNa supplemented medium. Therefore we propose a model where several miRNA are 
needed for a potent decay of SOCS mRNA and consequently their protein levels.
Systems where changes of a single miRNA against SOCS were analyzed showed positive 
results (Pichiorri F, 2008, for the regulation of SOCS1 3’-UTR by miR-19). Others had 
brought no measurable effect, thus these miRs have been claimed not to act as negative 
regulators (Lena AM, 2008, no regulation of SOCS3 levels by expressing pre-miR-203). 
Our microarray analysis depicted immediate regulation of many miRNAs followed by 
restoration to mock treated levels after 24 hours, similar to expression of early response 
genes (Hallen LC, 2007). Accordingly, we conclude that several miRNA, bearing the 
potential to target SOCS transcripts to degradation, are involved and hence needed for a 
fast restoration steady-state SOCS protein levels. This may be achieved by rapid 
transcription of primary miRNAs derived either from intergenetic regions, that carry 
Interferon response elements (eg. miR-203) or from introns of early response genes. 
Alternatively, maturation of pre-miRNA could be influenced by Interferon regulated genes.
Our previous findings (Brem R, 2003) suggested an epigenetic genome alteration following 
prolonged Interferon alpha exposure. Our model proposes contribution of Interferon 
regulated miRNAs to long term epigenetic gene silencing.
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Summary
Suppressors  of  Cytokine  Signaling  (SOCS)  Family  Proteins  are  rapidly  induced  by 
interferon alpha 2a (IFN ) treatment. SOCS1 and SOCS3 mRNA is barely detectable in  
most  cultured cells  but  upon IFN  stimulation transcript  levels  increase rapidly.  Peak  
SOCS3 mRNA levels are reached three hours after  IFN  induction followed by rapid  
degradation within a few hours. These results suggest post-transcriptional regulation of 
SOCS3 mRNA expression. In addition to various protein coding genes, also the levels of  
certain  micro  RNAs  (miRNA)  are  upregulated  by  IFN .  Interestingly,  the  3’  UTR  of  
SOCS1, SOCS3 and SOCS6 share conserved binding sites for IFN  inducible miRNAs.  
Here we propose a model in which the SOCS dependent negative feedback pathway of 
type I interferons may be controlled by RNA interference.
Introduction
SOCS are involved in silencing the general pathways induced by cytokines like interferon, 
especially the Janus kinase / signal transducers and activators of transcription (JAK/STAT) 
pathways. Their maximal expression levels differ markedly in cultured cancer cell  lines.  
Protein  and  mRNA  levels  of  SOCS  are  decreasing  rapid  after  induction.  The  fast 
degradation  of  SOCS-proteins  after  their  induction  is  needed  to  restore  cell  
responsiveness to  cytokine stimulation.  Restricted SOCS proteins  levels  are  crucial  to 
control  their  suppressing  function.  An  insertion  in  the  SH2  domain  of  SOCS3  is 
accountable for destabilizing the protein (Babon, 2006), but this would be inefficient unless 
its mRNA levels peak shortly after cytokine stimulation. A large screening study (Landgraf, 
2007) showed no substantial changes in miRNA profiles after interferon alpha, beta and 
gamma treatment.  Recently,  several groups have now reported miRNA regulation after 
cytokine  stimulation:  Pedersen  et  al.  (2007)  showed  upregulation  of  miR-30  when 
stimulated with interferon beta, yet this miR had no effect on viral  genome replication.  
Meng et al. (2007) postulated that the let-7 miRNA enhancement after Il-6 treatment may 
result  in  SOCS1  degradation.  In  a  model  system  miR-19  was  able  to  downregulate 
SOCS1 3-UTR bearing reporters (Pichiorri, 2008). Endogenous systems are more difficult:  
Lena AM et al. (2008) have not observed any regulation of SOCS3 levels by expressing 
pre-miR-203.
Materials and Methods
Cell  culture  and  interferon  treatment:  Melanoma  cell  lines  (ME-15)  were  cultured  in 
modified RPMI 1640, Hepatoma cells (HuH7) were cultured in  DMEM + GlutaMAX each 
supplemented with 10% fetal bovine serum.  Roferon (interferon 2a) was diluted in fresh  
medium to a final concentration of 1000 U/ml, for mock treatment medium w/o interferon 
was used. Total RNA was extracted with TRIZOL. 
Microarrays: miRNA expression was profiled using Illumina technology (MicroRNA Panel 
v1) which detects 743 human miRs.
Bioinformatics: Conserved binding sites for miRNA families were scanned using Target-
Scan (Release 4.2).  The expression data were processed with beadstudio 3.1.3, gene 
expression module 3.3.8 (Illumina), log2 transformed, loess-normalized and statistically (t-
test linear model) analyzed with R using lumi (Du, 2008) and packages used therein.
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Results
Figure 1 - Predicted miRNA binding sites for SOCS1 and SOCS3
Figure 1 shows that both, SOCS1 and SOCS3 have at the very 3’ end shared miRNA 
binding sites: miR-30, miR-19. SOCS1 have in addition a let-7 and SOCS3 binding sites 
for miR-203 and miR-455. A genome wide scan for the occurrence of miR-30 and miR-19 
sites in close proximity in 3’-UTRs showed that only 41 transcripts had a gap of less than 
150 base pairs between these two sites, including SOCS1, SOCS3 and SOCS6.
Table 1 - SOCS1 / 3 targeting miRNA levels after interferon stimulation
Mature miRNA expression (log-2 transformed levels showed) was upregulated 4 hours 
(n/d  no  detectable  levels,  *miRNA  only  detected  after  24h)  after  interferon  alpha 
stimulation. In Table 1 only miRNAs are listed which have predicted and conserved target 
sequences in the very 3’-UTR regions of either SOCS1 or SOCS3 or both of them.
Conclusions
We found evidence for a global change of miRNA expression after stimulation with IFN .  
Basal  levels  of  SOCS  targeting  miRNAs  are  constitutively  expressed  and  interferon 
stimulation further boost their expression levels. Consequently we propose a model where 
several miRNA are needed for a potent decay of SOCS mRNA and consequently their 
protein levels. After cytokine stimulation SOCS1 mRNA is produced and translated. The 
binding  of  the  ubiquitously  expressed  let-7  is  inhibited  or  is  not  sufficient  for  SOCS1 
degradation.  Our  microarray  analysis  depicted  immediate  regulation  of  many miRNAs 
followed  by  reset  to  uninduced  levels  after  24  hours,  similar  to  expression  of  early 
response genes (Hallen, 2007). Accordingly, we conclude that several miRNA, with SOCS 
target sites are involved and hence needed for a fast restoration of steady-state SOCS 
protein levels (Figure 2).
2A8
Primary  miRNAs  are  rapidly  transcribed  either  from  intergenetic  regions,  that  carry 
interferon response elements (as for miR-203) or from introns of early response genes.  
Alternatively,  maturation  of  pre-miRNA could  be  influenced  by  the  product  of  other 
interferon regulated genes.
In conclusion, our data strongly suggest that interferon inducible miRNAs contribute to the 
fine-tuning of cytokine signaling.
Figure 2 - Model for miRNA mediated degradation of SOCS1
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Introduction
Type I interferons (IFN) find therapeutic application against HCV infection in combination 
with anti-viral chemical drugs. Recently, meta-analysis of IFN adjuvant therapy trials has 
demonstrated benefits for relapse-free survival in melanoma patients. Although cure 
occurs in some patients, others either do not benefit from the treatment or tend to develop 
a resistance to the therapy. One class of putative effector proteins is the family of 
suppressors of cytokine signalling (SOCS) acting in a classical negative feedback loop. In 
order to understand the mode of JAK-STAT signalling pathway suppression by SOCS 
proteins, we profiled gene expression in hepatoma and melanoma cells with constitutive 
SOCS protein expression and IFN-alpha-2a treatment. We found unequally enhanced 
SOCS1 and SOCS3 mRNA levels shortly after IFN alpha treatment of human melanoma 
and hepatoma model cell lines. According to the literature, SOCS1 plays an important role 
in suppressing IFN alpha signalling, whereas the relevance of SOCS3 is disputed. Our 
results indicate a potential for full range inhibition of IFN alpha-induced gene expression in 
different tissues by SOCS1, whereas SOCS3 mediated suppression occurs in a cell- and 
gene-dependent manner. These findings suggest a relationship between SOCS 
expression levels and response to IFN alpha / PEGASYS® treatment for HCV and cancer.
1 – Eight suppressors of cytokine signaling (SOCS) proteins are regulated by a plethora of 
cytokines, hormones and growth factors as well as PAMPs (1). CIS and SOCS1-3 are well 
characterized in their response to these factors. SOCS proteins interfere often in the same 
pathways in negative feed-back loops. However, regulation of some factors is ambiguous. Here, 
we have investigated the role of interferon α induced SOCS in regulation of the JAK/STAT 
pathway.
2B2
SOCS mRNA induction by IFNα
2b – SOCS and PIAS 
induction by IFNα in 
melanoma cells, RT-PCR 
[fold].
2a – SOCS1 induction by 
IFNα in melanoma and 
hepatoma cells, Gene-array 
[light units]. 
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SOCS mRNA levels were elevated in several whole genome micro-array studies in 
combination with recombinant interferon α or pegylated interferon α (2a). SOCS1 and 
SOCS3 mRNA levels were induced highest among the SOCS and PIAS genes in our 
melanoma cell model (2b). SOCS1 and SOCS3 mRNA levels were highest at 2-6 and 1-4 
hours, respectively (2c). SOCS1 fold induction was more pronounced in melanoma cells 
whereas SOCS3 was moderately changed therein, while SOCS3 was induced heavily in 
hepatoma cells compared to SOCS1 induction (2c). SOCS1 level in control cultures was 
higher in HuH7 cells partially explaining the lower fold induction.
2d – SOCS1 and SOCS3 induction by IFNα in melanoma 
and hepatoma cells, RT-PCR time-course [cycling times]
2c – SOCS1 and SOCS3 induction by IFNα in melanoma and hepatoma cells, RT-PCR time-
course [fold].
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Generation of SOCS expressing cell lines and IFITM3 protein response
3a – Study design: SOCS proteins and IFNα response in cancer cell lines.
3b – SNAP labeled SOCS proteins in melanoma cell lines, confocal microscopy.
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Whole genome expression analysis of interferon response
3c – ISG (IFITM3) protein induction by IFNα in melanoma and hepatoma cells,
4b – Number of probes significantly changed by 4 
hour IFN treatment, Gene-expression arrays 
[count].
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Induction of interferon stimulated genes (4a) and their proteins (3c) is blocked in SOCS1 
expressing hepatoma and melanoma cells, whereas only SOCS3 in HuH7 cells  partially 
interfere with IFNα gene induction (4b). SOCS3 dependent ISGs have weak IFNα 
response elements and they are classed rather to IFNγ and late IFNα response genes 
(4c). 
4a – Induction levels by IFN treatment, Illumina Gene-expression arrays [log2 factor change].
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MicroRNA profiling of SOCS expressing cell lines
IFNα inducible microRNAs have small changes in detection levels shortly after treatment. 
SOCS expressing cell lines do not differ significantly in their response (5a). However, 
some of the IFNα inducible microRNAs are targets or have conserved binding sites on 
SOCS1 and SOCS3 mRNA. SOCS translation may be hindered by these microRNAs 
followed by deadenylation and decay of the messenger RNA (5b). Prolonged interferon 
treatment (several days) results in deactivation of the microRNA maturation factor DICER. 
Our data strongly suggest that interferon inducible microRNAs contribute to the fine-tuning 
of cytokine signaling.
4c – Classification of SOCS3 responder genes colored by numbers of conserved ISRE-like 
sequences [log factor change].
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5b – Proposed mechanism of SOCS1 degradation by IFNα induced microRNAs resulting in 
blockage of SOCS mRNA level. SOCS induction by interferons is followed by interferon regulated 
microRNA maturation supporting the degradation of SOCS mRNA and thus rapid turn-over of 
SOCS proteins.
5a – Induction mature microRNA levels by IFNα treatment (4 hours) in melanoma and hepatoma 
cells expressing SOCS, Illumina microarrays [log2 factor change].
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Conclusions
• SOCS1 is a strong inhibitor of  IFNα gene induction in both melanoma and 
hepatocellular carcinoma cells.
• Inhibition by SOCS3 depends on specific cellular factors
• and is marginal after prolonged treatment in vitro.
• Elevated SOCS3 levels interfere with IFNα signaling in hepatocellular carcinoma 
cells.
• SOCS3 levels are higher in patients with insulin resistance,
• thus either factor can be a negative indicator for interferon therapy success in the 
treatment of hepatitis viruses.
• SOCS3 levels do not interfere with IFNα signaling in growth sensitive melanoma 
cells (ME-15), thus SOCS3 may not be a prognostic marker for interferon alpha 
response in cancer therapy.
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Abstract: Type I interferons (IFN) have therapeutic applications in treating hepatitis C virus 
(HCV) infections and as adjuvant drugs in cancer treatment. A weak antiviral and antitumor 
response to IFN treatment correlates with the transcriptional expression of suppressor of 
cytokine signaling (SOCS) gene family members, which act in a classical negative feedback 
loop. We show stronger induction of SOCS1 and less induction of SOCS3 mRNA levels after 
IFN-alpha treatment in a human melanoma cell line (ME-15) compared to a hepatoma cell line 
(HuH7). In order to identify which INF-induced genes (ISGs) are suppressed by SOCS protein 
expression, we defined the genome-wide gene expression profiles of hepatoma and melanoma 
cells engineered to constitutively express one SOCS protein following IFN-alpha-2a treatment. 
We show full repression of IFN-alpha-induced gene expression in cancer cells by SOCS1, 
whereas SOCS3 mediated suppression is cell type specific and affects only a subset of 
inducible genes. Our data further support the negative correlation of SOCS expression levels 
and transcriptional response to IFN-alpha. Inhibitors of SOCS signaling could therefore prolong 
the IFN-alpha responses in clinical applications such as HCV or cancer therapy.
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Introduction
The suppressors of cytokine signaling (SOCS) protein family, comprising eight members, is 
regulated by a wide variety of cytokines, hormones, growth factors and pathogen associated 
molecular patterns (PAMP) (Greenhalgh et al. 2001). Among them, SOCS1, also known as JAK-
binding protein (JAB) or STAT-induced STAT-inhibitor 1 (SSI-1), and SOCS3 can interfere in 
interferon (IFN) signaling through their kinase inhibitory region (KIR), whereas SOCS2 and 
cytokine inducible SH2-domain containing human protein (CISH) and the larger SOCS4-7 lack 
this domain. SOCS proteins generally downregulate the pathway that triggered their expression. 
They act by classical negative feedback loop mechanisms functioning as inhibitors of upstream 
signaling proteins including cytokine receptors (Fujimoto et al. 2003; Yoshimura et al. 2005). 
SOCS-mediated regulation of receptors, kinases and signal transducers, including those 
involved in interferon-alpha (IFNα) signaling varies dependent on cell type. The classical IFNα 
signaling pathway is well known and consists of a few components, which act in a serial 
cascade (Stark et al. 1998). IFNα activates the IFNα receptors (IFNARs), triggering receptor 
dimerization allowing the phosphorylation of the receptor-associated Janus family tyrosine 
kinases (JAKs). Activated JAKs regulate the activation and dimerization of the signal transducer 
and activator of transcription (STAT) proteins (Darnell et al. 1994). The STATs translocate to the 
nucleus to induce interferon stimulated gene (ISG) expression. STAT activation, one of the 
crucial steps in IFNα signaling, can be downregulated by SOCS proteins, protein tyrosine 
kinases and transcriptional activity can be inhibited by protein inhibitors of activated STATs 
(PIAS) (Shuai 2006). Among other IFNα early response genes, SOCS1 and SOCS3 are 
transcribed and translated to suppress JAK-STAT signaling concurrently through the SH2 
phospho-tyrosine-binding domain, the SOCS-box and the kinase inhibitory region (Croker et al. 
2008). SOCS1 blocks interferon signaling by binding to the INFα receptor (INFAR1), thereby 
masking the JAK-recognition site (Sakamoto et al. 1998; Fenner et al. 2006; Walsh et al. 2006). 
SOCS1 suppresses also interferon gamma (IFNγ) signaling through IFNγ-receptor binding, KIR 
dependent inhibition of JAK2 activation and binding of phosphorylated JAK2 through the SH2 
domain (Starr et al. 2009; Endo et al. 1997; Yasukawa et al. 1999; Qing et al. 2005). Important 
for IFNα signaling through JAK1 / tyrosine kinase 2 (TYK2) is the fact that both the N-terminus 
and SH2 domain of SOCS1 are required for inhibition of JAK1, in contrast to JAK2 inhibition 
where either of these two domains alone is sufficient for kinase inhibition in vitro (Nicholson et 
al. 1999). Furthermore, SOCS1 is involved in kinase degradation in IFNγ-signaling through its 
SOCS-box motif with E3 ligase functionality leading to ubiquitination of JAK2 (Piessevaux et al. 
2008). An unpublished report suggested TYK2 ubiquitination and consequent TYK2 degradation 
when overexpressing ubiquitin, TYK2 and SOCS1 in vitro (Nguyen et al. 2006) However, a 
recent report demonstrate the destabilization of TYK2 through SOCS1-box independent 
inhibition of TYK2 activation by blocking the activating ubiquitination on Lys-63 (Piganis et al. 
2011). The degradation of the JAK1 is mediated through SOCS3 activity, in contrast to passive 
JAK1 inhibition by SOCS1 (Boyle et al. 2009). Recently, the ability of SOCS3 (KIR and SH2 
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domain) to inhibit JAK1, JAK2 and TYK2 has been shown in vitro implying that over-expressed 
SOCS3 is able to inhibit the kinases of classical IFNα signaling (Feng et al. 2012). However, this 
inhibition occurs with poor affinity, especially for TYK2, and is limited at physiological levels to 
cytokine pathways utilizing receptors with SOCS3 binding sites (Babon et al. 2012). SOCS1 and 
SOCS3 inhibit IFN mediated antiproliferative action in cancer cell lines and the expression of 
IFNα inducible antiviral proteins in liver cell lines (Song et al. 1998; Vlotides et al. 2004). This 
suggests that both SOCS1 and SOCS3 proteins are able to interfere with the IFNα signaling 
pathway and therefore limit the ability of IFNα therapy to control viral infections and expansion 
of cancer.
IFNα is used as standard therapy to treat chronic hepatitis C virus infections in combination with 
the antiviral nucleoside pro-drug ribavirin. The response to this treatment varies from patient to 
patient, and depends on the selected population, the viral genotype and other factors including 
steatosis, insulin resistance and high SOCS3 expression levels in the liver (Persico et al. 2010; 
Moucari et al. 2008; Petta et al. 2008; Persico et al. 2007). Factors that are predictive for 
treatment outcome, such as HCV genotype and insulin resistance directly correlate with SOCS3 
expression (Persico et al. 2009; Vanni et al. 2009). As a result, SOCS3 expression correlates 
with drug resistance in patients with chronic hepatitis C (CHC) (Walsh et al. 2006; Huang et al. 
2007; Kim et al. 2009; Miyaaki et al. 2009). Beside of SOCS3, other interferon-stimulated genes 
(ISGs) are abundantly expressed in the liver of non-responding patients (Feld et al. 2007; 
Sarasin-Filipowicz et al. 2008). More non-responding HCV patients may be cured by reversal of 
this pre-activation of the endogenous IFN system in the liver (Sarasin-Filipowicz 2010). 
Therefore, strategies to modify SOCS activity may have therapeutic benefits (Starr et al. 2009).
IFNα is also administered as adjuvant therapy in patients with metastatic melanoma after 
surgical removal of the tumor and in a meta-analysis patients revealed a significant benefit in 
relapse-free survival (Garbe et al. 2010). SOCS1 and SOCS3 expression is inversely correlated 
with cellular sensitivity to IFNα and may contribute to the resistance to the growth-inhibitory 
action of pro-inflammatory cytokines in clinical applications (Yoshikawa et al. 2001; Evans et al. 
2007; Sakai et al. 2002; Roman-Gomez et al. 2004; Brender et al. 2005; Takeuchi et al. 2005). 
In line with this, high SOCS1 and SOCS3 levels indicates poor prognosis in metastatic 
melanoma (Li et al. 2004). The mechanism by which SOCS1 and SOCS3 impacts on IFNα 
resistance may be through STAT1 serine phosphorylation that correlates with SOCS3 levels 
(Fojtova et al. 2007). However, IFNα mediated STAT1 tyrosine phosphorylation is reduced by 
overexpression of SOCS1 or SOCS3 and SOCS suppression in melanoma cells results in 
restored sensitivity to IFNα signaling (Lesinski et al. 2010).
Here, we analyzed effects of SOCS1 and SOCS3 on gene transcription in IFNα signaling using 
genome wide profiling. We constructed SOCS1 and SOCS3 overexpressing melanoma and 
hepatoma cell lines to identify genes that are controlled by these suppressors and the potential 
therapeutic impact of our findings is discussed.
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Material and methods
Plasmids
SOCS1, 3 and 4 coding sequences were cloned from RNA of ME-15 or HuH7 cells treated for 
two hours with INFα. Total RNA was isolated with the RNeasy Kit using QIAshredder columns 
for cell homogenization (Qiagen AG, Hombrechtikon, Switzerland). RNA was converted into 
cDNA with first strand RT-PCR kit using poly-p(dT)15 primers (Roche Applied Science, 
Rotkreuz, Switzerland). Protein coding sequences were amplified using SOCS specific primers 
(supplementary table 1). cDNA was sub-cloned in pCR2.1-TOPO vector and SOCS coding 
sequences were inserted in mammalian expression vector pcDNA3.1 NEO+ (Invitrogen, Basel, 
Switzerland) and pSEMS1-26m an expression vector with insertion of mammalian SNAP-tag 
(26m) coding sequence (Covalys Biosciences AG, Witterswil, Switzerland). Sequences coding 
for C terminally fused SNAP tag (Covalys Biosciences AG, Witterswil, Switzerland) were sub-
cloned using 'non-stop' primer with deleted STOP codon (supplementary table 1) and Phusion 
High-Fidelity DNA Polymerase (New England Biolabs, BioConcept, Allschwil, Switzerland). 
From cDNA template SOCS1, SOCS3 and SOCS4 sequences were amplified with Advantage®-
HF 2 PCR kit (BD Biosciences Clontech, Allschwil, Switzerland). Gel-purified DNA was sub-
cloned in pCR2.1-TOPO plasmids and cut by standard restriction enzymes (Roche Applied 
Science, Rotkreuz, Switzerland). The expression vector pSEMS1-26m and pcDNA3.1 were cut 
and dephosphorylated with shrimp alkaline phosphatase (Roche Applied Science, Rotkreuz, 
Switzerland). Vector DNA and insert DNA were ligated with Rapid DNA Ligation Kit (Roche 
Applied Science, Rotkreuz, Switzerland) in a ratio of 1:3 and transformed in Dh5α chemically 
competent cells. Plasmid constructs were sequenced over the entire trans-gene region.
Cells and interferon treatment
Melanoma cells (ME-15) were cultured in RPMI 1640 with L-glutamine (2 mM) containing 10 % 
FBS and supplemented with non-essential amino acids (0.1 mM) and sodium pyruvate (1 mM) 
(RPMI culture medium). Hepatocyte-derived cellular carcinoma cells (HuH7) were cultured in D-
MEM with GlutaMAX™-I containing 10 % FBS (D-MEM culture medium). All cell culture 
reagents were purchased from Invitrogen (Gibco®, Invitrogen, Basel, Switzerland). Roferon 
(Interferon-alpha-2-a, Roche Pharmaceuticals, Basel, Switzerland) was diluted in fresh culture 
medium to a final concentration of 100 or 1,000 U/ml and control cultures were grown without 
added cytokines. Cells were cultured at 37 °C in a humidified atmosphere containing 5 % CO2. 
For the generation of stable SOCS expressing cells, ME-15 and HuH7 cells were transfected 
with Optifect (Invitrogen, Basel, Switzerland), split one day post transfection and cultured in 
culture medium containing geneticin (selective medium; 800 μg/ml for ME-15 or 1.5 mg/ml for 
HuH7). Antibiotic-resistant clones were obtained by cultivation in selective medium for three 
weeks and single cells were plated in hybridoma cell culture dishes (Greiner bio-one, St. Gallen, 
Switzerland) and expanded to SOCS-transduced cell lines of approximately one million cells. 
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Cell cultures were screened for SOCS mRNA expression and three cell lines for each plasmid 
were cultured up to approximately 20 million cells. Then, induction of interferon induced 
transmembrane protein 3 (IFITM3) was measured to verify ISG stimulation.
Transfection and confocal microscopy
SNAP tag fusion proteins were transfected into cells with Optifect transfection reagent 
(Invitrogen, Basel, Switzerland), followed by a minimal incubation of 6 hours. SNAP-cell TMR-
Star photostable substrate was added at a concentration of 2 μM (Covalys Biosciences AG, 
Witterswil, Switzerland). Cells were washed according to the manufacturer’s protocol and 
fluorescent pictures were taken with a Leica confocal microscope DMI4000B.
Western blot analysis
Cell lysates containing protease and phosphatase inhibitory tablets (Roche Applied Science, 
Rotkreuz, Switzerland) were quantified with BCA protein assay (Pierce, Rockford, IL, USA), 
separated and blotted using the Xcell II™ system (Invitrogen, Basel, Switzerland). IFITM3 
proteins were detected with primary antibody against 1-8 protein peptide (1:1000 dilution) 
described in (Brem et al. 2003), followed by horseradish peroxidase conjugated secondary 
antibodies (Biorad, Reinach, Switzerland). Immune complexes were detected with Supersignal 
West Pico chemiluminescent substrate (Pierce, Rockford, IL, USA) on Lumi-Film 
Chemiluminescent Detection Film (Roche Diagnostics AG, Rotkreuz, Switzerland). Pictures 
were digitalized on a transmitted light scanner and plot intensity profiles of probe-lanes were 
calculated by image processing method in ImageJ (Wayne Rasband, National Institute of 
Mental Health, Bethesda, MD USA). Protein levels were estimated by calculation of the area 
under the curve (AUC) of the IFITM3 protein signal peak using the statistical program R and the 
package msProcess for data preparation, baseline correction, intensity normalization and peak 
detection.
RT-PCR analysis
250 ng of total RNA from IFNα (1000 U/ml) treated ME-15 or HuH7 cells was analyzed with 
QuantiTect SYBR Green RT-PCR reagent (Applied Biosystem, Rotkreuz, Switzerland) using 
SOCS and PIAS specific primers (Microsynth AG, Balgach, Switzerland - supplementary 
table 2). Optical data were generated using a 7500 Real-Time PCR system and analyzed using 
the manufacturers software package SDS (Applied Biosystem, Rotkreuz, Switzerland) to 
generate cycling time (ct) values. Fold induction (2^ΔΔct values) were calculated in R as ration 
of mean normalized expression values of sample to untreated controls as described previously 
(Siegrist et al. 2009). Significance was assessed by analysis-of-variance (ANOVA) tests 
comparing ct values.
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Gene expression microarray analysis
Total RNA was extracted from independent triplicates using the Trizol reagent (Sigma, Buchs, 
Switzerland). RNA was quantified using the Quant-iT™ RiboGreen® RNA Assay (Invitrogen, 
Basel, Switzerland) and 500 ng total RNA subjected to cDNA synthesis and subsequently in 
vitro transcribed to biotin labeled cRNA using the Illumina® TotalPrep RNA Amplification Kit 
(Ambion - Applied Biosystem, Rotkreuz, Switzerland). The protocol of miRNA microarray 
detection has been described previously (Siegrist et al. 2009). For genome-wide expression 
analysis 750 ng of cRNA was hybridized to HumanRef-8 v3 Expression BeadChips (Illumina, 
CA, USA) according to the manufacturer’s protocol. Replicates were randomly distributed 
among slides and positions. Bead arrays were washed and stained using FluoroLink Cy3 
Streptavidin (GE Healthcare AG, Glattbrugg, Switzerland). Fluorescent signals were imaged by 
laser scanning using the iScan system (Illumina, CA, USA). Scanner images files were 
processed by software supplied from the manufacturer to probe intensity files and further 
processed with the genome studio software (Illumina, CA, USA) without normalization and 
background correction. Illumina probe intensity data was processed by variance stabilization 
transformation (VST) (Lin et al. 2008) using R/Bioconductor software (lumi library) (Du et al. 
2008), followed by quantile normalization. Significance of effects for probes was tested in 
R/Bioconductor (limma library) (Smyth 2004) using moderated t-test and the false discovery rate 
(FDR) correction method by the Benjamini and Hochberg for multiple testing. No unspecific filter 
was applied and multiple probes per gene were retained. Raw and normalized data is 
accessible at NCBI GEO database, series accession number GSE22801.
Results
SOCS expression in IFNα treated cell lines
We have previously shown variation in induction of ISG through IFNα stimulus among different 
cancer derived cells and reanalyzed the data for SOCS and PIAS induction (Hallen et al. 2007). 
SOCS1 was found to be induced in most of ten cancer cell lines tested when treated with 
recombinant IFNα, whereas other SOCS and PIAS transcripts were not significantly regulated 
or not detected (NCBI GEO database, series accession number GSE21158). Eight out of ten 
cell lines showed induction of SOCS1 mRNA four hours following IFNα treatment 
(supplementary figure 1). We confirmed the induction of SOCS1 by IFNα in the melanoma cell 
line ME-15 using a more sensitive assay. Moreover, we examined all SOCS and PIAS 
transcripts by semi-quantitative reverse-transcription polymerase chain reaction (RT PCR). 
Among the genes analyzed by RT-PCR (CISH, SOCS1-7 and PIAS1-4), SOCS1 (16.2 fold) and 
SOCS3 (7.4 fold) mRNA levels were most significantly (p-value < 2e-16) induced by IFNα and 
their increase was considerably higher compared to the other SOCS and PIAS genes 
(figure 1a). A moderate upregulation of CISH, SOCS7 and PIAS4 genes (1.2-1.4 fold, 0.0025 > 
p-value > 0.05) was detected, but we considered that to be biologically irrelevant relative to 
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SOCS1 and SOCS3. In addition to the level of induction, we have evaluated by RT-PCR the 
time dependent induction levels and duration of SOCS1 and SOCS3 expression that may be as 
important for the attenuation of cytokine signaling as their maximal induction levels. SOCS1 and 
SOCS3 mRNA levels reach peak levels between two and four hours after IFNα treatment 
(figure 1b). In contrast to HuH7, SOCS1 induction was more effective in melanoma cells 
whereas SOCS3 induction was ten times stronger in hepatoma cells. In both cell lines SOCS1 
levels reached similar maximal induction levels in response to IFNα (Δct = 5.7±0.1 and 5.5±0.4 
for ME-15 and HuH7, respectively). Typically, STAT activation declines in the first hours implying 
that JAK-STAT activation drives IFNα induced SOCS1 and SOCS3 transcription as induced 
levels were observed here already one hour after treatment (Maher et al. 2008).
Subcellular localization of SOCS proteins
Unlike the classical IFN signal regulation by SOCS1 at the cell membrane, SOCS proteins can 
also be found in the nucleus, where their function in cytokine signal inhibition remains unclear 
for many SOCS (Ben-Yair et al. 2002). A nuclear localization signal (NLS) sequence was 
identified in SOCS1 and mutations do not affect but nevertheless impair the inhibitory function of 
IFNγ-induced gene expression but not STAT1 activation (Baetz et al. 2008; Koelsche et al. 
2009).
To assess SOCS localization in ME-15 cells, we cloned the SOCS1, SOCS3 and SOCS4 
cDNAs from IFNα treated cell lines for recombinant expression. We generated constructs in 
which SOCS fusions proteins with a SNAP tag are expressed that allow fluorescent labeling at 
different time points for dynamic subcellular localization. When labeled 16 hours after plasmid 
transfection, SOCS1 proteins are located in the nucleus, whereas SOCS3 proteins are equally 
distributed in the cytoplasm (figure 2). Attachment of the tag at the amino- or the carboxy-
terminus had no influence on the subcellular localization of SOCS1 and SOCS3. Tagged 
SOCS4 proteins were expressed at the detection limit whereas SOCS1 and SOCS3 proteins 
are found express in the cytoplasm already six hours after plasmid transfection (not shown). 
The proteins are then translocated to their primary localization site and can be detected after 
36 hours associated with compartments near the nucleus where the proteasome is localized 
(not shown). Our results demonstrate SOCS1 nuclear localization whereas SOCS3 is present 
predominantly in the cytoplasm when overexpressed in ME-15 cells.
Interferon-stimulated gene response in SOCS cell lines
To analyze the effect of SOCS1 and SOCS3 on interferon induced protein and gene expression 
without challenging the cells with DNA-transfection, we have generated clones of ME-15 and 
HuH7 cells overexpressing untagged SOCS proteins. Expression of SOCS mRNA and protein 
was confirmed by qPCR and western blot and had no visible effect on cell morphology or growth 
rate. We examined cell clones with high SOCS expression for the potential of IFNα in inducing 
IFITM3 protein levels to determine the functionality of the expressed SOCS proteins in this 
pathway. IFITM3 response levels are dependent on duration of IFNα stimulus and on the 
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amount of IFNα used. Therefore, monitoring of IFITM3 protein levels can be used as model ISG 
in these cells to control impact of SOCS proteins for both retardation and efficacy of IFNα 
signaling. In ME-15 cells, IFITM3 protein levels are detectable only after IFNα stimulation, 
whereas HuH7 cells express this protein at low basal levels (figure 3). SOCS1 expression 
suppresses IFITM3 protein production in both cell lines whereas the effect of SOCS3 is far less 
distinct. Quantification of the chemiluminescent signal shows suppression of IFITM3 protein 
synthesis in five out of six SOCS1 expressing clones. One clone has a similar response as the 
progenitor cell line, maybe due to spontaneous mutation in the SOCS1 gene during single cell 
selection. In contrast, SOCS3 expressing ME-15 cells and all cells generated with SOCS4 
plasmid respond similar to the parental cell lines. Relative IFITM3 protein levels are lower in all 
three SOCS3 expressing HuH7 cells lines, each derived from a single cell clone, indicating a 
limited effect on IFNα signaling in these cells (figure 3). However, reduced IFITM induction does 
not correlate with the amount of SOCS3 in these hepatoma cells (not shown). In conclusion, we 
were able to generate SOCS1 expressing cell lines that fail induction of ISG protein expression 
in response to IFNα and SOCS3 expressing cell lines with at most partially effect on IFITM3 
induction.
Genome-wide expression analysis of interferon responses in SOCS over-
expressing cells lines
There are hundreds of genes induced by IFNα with different promoters and induction time. To 
address the question to what extend the negative impact of SOCS expression on IFNα 
transcriptome responses varies in different cell lines we monitored mRNA levels by Illumina 
gene expression microarrays. Genome-wide expression levels were analyzed in SOCS 
overexpressing cell lines with the corresponding two parental lines as reference and with non-
stimulated controls for each condition for 2 different time points. We chose to analyze gene 
expression four hours after IFNα treatment, because induction of ISGs was maximal at this time 
in vivo and was followed by down-regulation of many genes (Lanford et al. 2006). In addition, 
we analyzed gene expression at 24 hours after treatment to estimate if secondary response 
genes are activated that are not dependent on SOCS regulated pathways such as JAK-STAT.
In total, 8'658 unique genes were expressed in the majority of the samples significantly above 
background levels. The effect of IFNα was estimated by an analysis of variance that take into 
account the cell-type, time and the presence of overexpressed SOCS, IFNα treatment as well 
as its interaction with time and SOCS type as co-factors. This analysis generated 1'708 
significantly changed probes representing more than 1'500 individual genes. Cluster-analysis of 
genes affected by SOCS proteins shows an overall suppression of ISG induction in SOCS1 
expressing hepatoma and melanoma cells (figure 4). As a consequence, SOCS1 expressing 
cells clustered together on the sample axis due to the suppression of ISG induction. In SOCS1 
expressing hepatoma cells, no probe was significantly upregulated four hours after IFNα 
treatment (adjusted p-value < 0.05) and only 11 probes at 24 hours (supplementary figure 2). 
Similarly, 36 and 12 probes were significantly changed in ME-15 SOCS1 cells at 4 hours and 
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24 hours, respectively. By comparing induction of ISGs in control and SOCS1-expressing cells, 
components of the IFNα signaling pathway themselves, IRF9 and STAT1, are less affected by 
SOCS1 overexpression than classical interferon-stimulated response element (ISRE) bearing 
genes for example IFIT1, IFIT2, IFITM3 or OAS2 (supplementary figures 3 and 4). In contrast to 
SOCS1, high SOCS3 levels in melanoma cells (ME-15) do not alter the clustering of these 
samples (figure 4). The effect of SOCS3 in ME-15 is comparable with the one in the SOCS4 
control cells and thus too marginal to draw further conclusions (supplementary figure 3). In 
contrast, SOCS3 expressing HuH7 cells four hour after treatment cluster with control cells of 
one day IFNα treatment and some probes for early ISGs are not changed in these samples 
(figure 4). Probes for IFITM1, GBP1, IRF1 or CXCL10 genes, more responsive to IFNγ than 
IFNα, are not significantly inducible at four hours in presence of SOCS3 (supplementary 
figure 4). This suggests stronger impact of SOCS3 on IFNγ activated promoter response 
element driven ISG expression. However, genes without ISRE element are not significantly 
enriched in SOCS3-suppressed probes in HuH7 cells (not shown). SOCS3 expression in the 
hepatoma cell line has no impact on induction of primary response genes such as MX1, 
EIF2AK2 (PKR), OAS1 and OAS2 (supplementary figure 4).
Cell lines transformed with the SOCS4 expression plasmid have low SOCS4 mRNA levels and 
the IFNα response is normal (data not shown). However, transformation and selection of cell 
lines with any SOCS expressing vectors did change a panel of genes including EFEMP1, 
NRP1, MAGEA8, IPO8, CD81, CTPS2 and RPS6KA3.
In conclusion, SOCS1 is potent to suppress globally ISG induction in vitro, whereas suppression 
of IFNα-induced genes by SOCS3 could only partially be observed in hepatoma cell lines. 
MiRNA expression profiles in SOCS overexpressing cells
In addition to classical ISG induction, evidence is accumulating that cytokine stimulation induces 
miRNA transcription or maturation involved in the regulation of translation of target mRNAs. We 
have profiled miRNA induction by IFNα in ME-15 and HuH7 cells and detected small changes in 
expression levels (Siegrist et al. 2009). In addition to these cell lines, we have evaluated here 
the miRNA profiles of SOCS1, SOCS3 and SOCS4 genetically modified cell lines. As expected, 
principal component analysis revealed that the sample variation could be best explained by the 
different cell type (data not shown). During genetically modification and selection of SOCS 
expressing cell clones, miRNA expression patterns were largely maintained and ME-15 cells 
and descendants were clearly separated from the HuH7 cells. The effect of IFNα treatment was 
only observable at 4 hours. This result indicates that the influence of IFNα is limited to a short 
period after treatment and that this effect is present in all cells regardless of SOCS expression. 
Therefore we screened the data for miRNA genes significantly changed after 4 hours 
incubation. Most of the IFNα induced miRNAs that are modulated in ME-15 cells are also 
upregulated in SOCS expressing clones, for example miR-10b, miR-551b, miR-137 and 
miR-101 (figure 5). This indicates that miRNA regulation by IFNα is independent of regular JAK-
STAT activation for many miRNAs. However, miRNAs that are clearly upregulated by IFNα in 
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ME-15 and HuH7 cells such as miR-19a, miR-19b and miR-33 are not significantly upregulated 
in SOCS over-expressing cells. Interestingly, not only miR-98 seems to be regulated by IFNα 
but the entire let-7 family cluster to which miR-98 belongs. Their fold changes imply only a 
moderate modulation of the normally ubiquitous available let-7 miRNAs (supplementary 
figure 5). To conclude, IFNα treatment results in moderate modulation of miRNA abundance 
which was in contrast to mRNA regulation SOCS1 independent. This suggests that a passive or 
alternative pathway controls the transcription or maturation of miRNAs and that the response 
decays 4 hours after treatment.
Discussion
Efficient induction by IFNα genes requires JAK-STAT pathway signaling and stimulation of 
transcription factors. Here we have shown that SOCS1 overexpression results in significant 
suppression of ISG mRNA expression in vitro. In contrast, the impact of SOCS3 overexpression 
on IFNα signaling is moderate and secondary response genes are less affected.
SOCS EXPRESSION:
We evaluated SOCS expression in ME-15 cells and detected early, strong and significant 
upregulation of SOCS1 and SOCS3 mRNA. These genes are inducible by IFNα in our cell lines 
suggesting that the negative feedback loop in IFNα signaling is initiated. The inducibility of 
SOCS3 in ME-15 cells does not reflect the situation in other melanoma cell lines, in which the 
SOCS3 gene is not responsive to IFNα (Kovarik et al. 2005). This may reflect an inability of 
STAT3 to be activated in these cells, because STAT3 is important for IFNβ driven induction of 
SOCS3, whereas SOCS1 induction depends on STAT1α and not on STAT3 or STAT2 (Qin et al. 
2008). The promoter of SOCS1 contains active ISRE and GAS elements that are responsible 
for STAT1-mediated gene transcription (Schlüter et al. 2000). Inducibility of SOCS1 is not 
surprising since ME-15 and HuH7 cells are able to modulate many genes with ISRE and GAS 
elements upon IFNα stimulation. Peak upregulation of SOCS1 and SOCS3 occurred 4 hours 
and 2 hours after IFNα stimulus, respectively. This correlates perfectly with IFNβ treated cancer 
cells (astrocytes) with equivalent peak induction times (Qin et al. 2008). Here, SOCS3 levels 
declined 4 hours after stimulation, which explains why we failed to detect significant SOCS3 
induction in our cancer cell line panel after 4 hours (GSE21158). The reduction of the SOCS 
response to basal levels in the liver after IL6 injection occurred after 4 hours and 8 hours for 
SOCS1 and SOCS3, respectively (Starr et al. 1997). This indicates a different induction period 
for distinct cytokines and cell-type-specific differences in the expression of SOCS genes in 
response to the same cytokine. Other SOCS proteins are also modulated by IFNs depending in 
a cell type dependent manner. For example, SOCS2 is upregulated in healthy donor PBMCs 
after one hour IFNα treatment (Zimmerer et al. 2008). Moreover, SOCS4 downregulation can be 
observed by IFNλ1 (IL29) in human melanoma cell lines, whereas SOCS6 and SOCS1 are 
upregulated (Guenterberg et al. 2010). The induction of SOCS proteins is not restricted to 
cytokines but may also be regulated by pathogens themselves. SOCS7 levels are upregulated 
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in HuH7 cells expressing HCV genotype 3a core protein for example (Pazienza et al. 2007; 
Pazienza et al. 2009). This SOCS7 upregulation is not mediated by IFNα alone in HuH7 cells 
and HCV core protein-expressing hepatocytes, in line with the results presented here (Pazienza 
et al. 2010). In their study, SOCS1 and SOCS3 expression levels were also determined in a 
time course experiment in HuH7 cells but IFNα was used at lower concentration (500 U/ml) 
compared to this experiment. The mRNA levels stayed elevated for several days and reached a 
plateau after 4 hours in the case of SOCS3 or peaked at 8 hours for SOCS1 transcripts. We 
refined this study by calculating fold changes compared to non-treated levels instead of the ratio 
to pre-treatment levels. This may be important since undefined components in the serum-
complemented medium alone such as cytokines have an impact on SOCS expression levels 
(figure 1b).
In conclusion, SOCS1 and SOCS3 levels are influenced in our melanoma and hepatoma cell 
lines and may play a role in the negative regulation of therapeutic IFNα treatment. For a better 
understanding of the impact of SOCS levels in adjuvant cancer treatment and resistance to 
treatment, we would suggest assessing SOCS1 and SOCS3 pretreatment levels and induction 
during clinical trials to investigate the correlation between SOCS levels and treatment success.
LOCALIZATION:
SOCS dependent negative feedback mechanisms is not only triggered by expression changes 
but also altered subcellular localization of SOCS proteins influence their function and may play a 
critical role in cancer (Rossa et al. 2012). We examined the cellular distribution of SOCS 
proteins in our cell lines and followed the protein localization from its synthesis to degradation 
by kinetic fluorescent tagging using SNAP-tag (Keppler et al. 2004). We favor this labeling 
technique because in contrast to proteins linked to a conventional fluorophore, the pool of 
labeled proteins is not replenished by newly synthesized proteins and the relocation of proteins 
during signaling processes can therefore be assessed in a time-dependent manner. Our results 
suggest that SOCS3 proteins are distributed throughout the cytoplasm and that in SOCS1 
proteins shuttle to the nucleus early after translation in the cell lines used here. Activation of 
JAKs can then trigger the re-localization of SOCS1 proteins to the plasma membrane where 
they modulate the kinase activity (Haan et al. 2009). It has been shown that SOCS1 can be 
readily found in the nucleus (Ben-Yair et al. 2002), where it could interact with NFκB as part of a 
multimeric ubiquitin ligase complex (Maine et al. 2007). Other nuclear functions involve 
activation of DNA damage responses through binding of ATM and successive activation of p53 
transcription factor mediating cellular senescence (Calabrese et al. 2009). Many SOCS proteins 
(SOCS1, SOCS2, SOCS4, SOCS5 and CISH) are upregulated in a p53 senescence state 
induced by constitutive STAT5 signaling. Therefore, it has been suggested that in tumor cells 
with aberrant and sustained STAT signaling SOCS1 may be highly abundant and localize to the 
nucleus. There, it may localize to DNA damage spots and activate p53 in an ATM-dependent 
manner. SOCS1 is believed to be the link between DNA damage signals stimulated by 
oncogenic activity and p53 (Mallette et al. 2010). Here, we have shown, that over-expressed 
SOCS1 can localize to the nucleus in ME-15 cells.
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PROTEIN EXPRESSION AND IFITM3 EXPRESSION IN CLONES:
In order to investigate the impact of SOCS expression on IFNα signaling we have generated 
clones from HuH7 and ME-15 cells by transfection of SOCS expressing vectors and selection in 
antibiotic medium. Similar to the marginal expression of SOCS4 tagged proteins, no 
upregulation of SOCS4 mRNA or proteins could be detected in the antibiotic resistant clones. 
IFITM3 was readily inducible in SOCS4 clones and gene expression patterns after IFNα 
treatment showed no obvious difference to the progenitors. There is no evidence that SOCS4 
has an inhibitory effect on IFNα, therefore the SOCS4 transfected cell lines act here as 
transfection control. A factor that may disturb the efficient expression of SOCS4 may be miRNAs 
of the let-7 family (Hu et al. 2010). They are highly expressed in both ME-15 and HuH7 and are 
upregulated after IFNα treatment (Siegrist et al. 2009). This may explain why there was no 
induction of SOCS4 mRNA detected some hours after treatment. However, this does not 
exclude an important function for SOCS4 in the signaling of other cytokines for example IL6 and 
in STAT3 and STAT6 phosphorylation, which is not under control of SOCS1 (Hu et al. 2010).
IFITM3 is an ISG that is not expressed in ME-15 control cell cultures and is induced in virtually 
all cultured cells competent in IFNα signaling. In SOCS1-expressing clones this induction was 
reduced almost to control levels. In contrast, IFITM3 expression was not substantially altered in 
SOCS3-expressing derivatives. This is probably due to the dependence of IFITM3 on interferon-
stimulated gene factor 3 activation. Thus, we conclude that the activation of STAT1-STAT2 
complexes is less affected by SOCS3 in our cell lines. We addressed this question in a 
genome-wide approach to define gene-sets that are regulated by SOCS3 interaction in IFNα 
activated pathways.
TRANSCRIPTOME ANALYSIS:
Liver cell cultures (HepG2) with stable SOCS1 and SOCS3 expression inhibit STAT1 and 
STAT3 phosphorylation and the expression of antiviral IFNα response genes such as Mx A, 
OAS1, OAS2 and OAS3 (Vlotides et al. 2004). Our results confirm efficient suppression of IFNα 
mediated transcriptional changes in SOCS1-overexpressing cell lines, but we did not observe 
an inhibition of the upregulation of these antiviral genes in SOCS3-overexpressing HuH7 cells. 
This indicates that over several weeks of SOCS3 expression, HuH7 cells adapted to the new 
situation and partially reduced the impact of the suppressor gene. Here we show that the effect 
of SOCS proteins is more pronounced in the first hours than after one day. In SOCS3 knockout 
mice, ISG expression is higher after cytokine stimulus, probably due to an increased duration of 
STAT1 activation (Croker et al. 2003). Thus, it may be feasible to expect a decrease in duration 
of STAT1 activation in SOCS3 overexpressing cell lines given that STAT3 activation is not 
altered. This results in the regulation of both the quantity and type of STAT signal generated 
from the IFNAR observed here. However, since only HuH7 cells could be classified as 
responders to SOCS3 overexpression this type of signaling seems either to be absent in ME-15 
cells or was silenced during clonal selection.
In contrast to the diffuse regulation of gene expression in SOCS3 HuH7 cells, SOCS1 
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expression in both cell lines affected all IFNα induced genes. However, a small number of genes 
resisted the negative regulation of SOCS1 in all cell lines, to some extent. Genes participating in 
the JAK-STAT pathway downstream of IFNα themselves, including STAT1 and IRF9, were over-
represented in this group. IFNβ driven induction of IRF9 in SOCS1 overexpressing cells does 
not depend on STAT-phosphorylation and this explains that IRF9 induction is less affected by 
SOCS1 negative regulation (Rani et al. 2010). We conclude from this and from our data that 
SOCS1 blocks JAK-STAT signaling pathway more specifically than accessory signals 
independent of IFNAR phosphorylation.
In order to generate a gene list with less than 5 % of false negatives we applied false discovery 
rate correction to the p-values of the moderated limma statistics. We observed that most of the 
probes that are upregulated in SOCS1-expressing cell lines and that do not met the 
p-value < 0.05 criteria are well known ISGs or are clearly upregulated in the control cells. This 
implies that the moderate t-statistics and false discovery rate adjustment may underestimate the 
total number of ISGs in our experiment. Consequently, even more than 1'500 genes are likely to 
be regulated by IFNα in our cell culture model. Additionally, only a very few genes are 
downregulated after IFNα treatment and one-tailed p-value calculation may be closer to reality 
and would result in more significantly upregulated genes.
MIRNA INDUCTION BY IFNΑ AND SOCS TARGETING
In the last years several miRNAs have been shown to be regulated by various pathogens and 
cytokines including IFNs. As an example, the miRNA expression profile of HuH7 cells treated 
with IFNβ revealed miR-30 as an interferon induced gene (Pedersen et al. 2007). Our results 
confirmed upregulation of this miRNA by IFNα (Siegrist et al. 2009) and SOCS1 and SOCS3 
have each a conserved miR-30 binding site in their 3'-UTR mRNA region (Siegrist et al. 2008). 
The miRNA profile of IFNβ treated HuH7 cells expressing the HCV replicon has been published 
after generation of our data (Gong et al. 2010). In comparision, no significant downregulation of 
miR-550 by IFNα is detected here and IFNβ-upregulated miRNAs were not induced. These 
disparities may be due to differences between IFNα and IFNβ, the detection method or the 
absence of an HCV replicon in our system.
In addition to modulation of miRNA gene expression, prolonged IFNα treatment deactivates the 
miRNA maturation factor DICER (Wiesen et al. 2009). This may have a direct impact on HCV 
replication since viral replication is inhibited by targeting DICER using siRNAs in HuH7 cells 
(Randall et al. 2007). Our data strongly suggest that interferon inducible miRNAs contribute to 
the fine-tuning of cytokine signaling as part of a rapid response. Several miRNAs have been 
reported to influence SOCS mRNA, which may represent an effective mechanism of limiting 
SOCS mRNA expression for a limited period after the IFN stimulus. Therefore, SOCS1 
degradation may be triggered by IFNα-induced miRNAs resulting in a reduction of SOCS mRNA 
level. We have thus hypothesized that SOCS induction by IFNs is followed by IFN-regulated 
miRNA maturation supporting the degradation of SOCS mRNA and therefore leading to fast 
turn-over of SOCS proteins (Siegrist and Certa 2008). We show there that the regulation of 
miRNA is not pronounced and we conclude that several miRNAs must be involved for efficient 
2C14
SOCS mRNA targeting. A miRNA family that is induced by IFNα in our experiment is the let-7 
family cluster including miR-98. These miRNAs (let-7d, let-7f-2 and let-7i) have been 
associated with SOCS1 and SOCS3 targeting (Meng et al. 2007; Zhang et al. 2011a; Bakre et 
al. 2012). Additionally, other SOCS genes (CISH and SOCS4) are targeted by the let-7 and 
miR-98 family after pathogen challenge (Hu et al. 2009; Hu et al. 2010). In addition, SOCS1 is 
targeted by miR-19 and this regulation is associated with pathogenesis of multiple myeloma 
(Pichiorri et al. 2008). Interestingly, miR-19a and miR-19b are significantly regulated in ME-15 
and HuH7 cells but less so in SOCS-expressing derivatives based on our data. Moreover, 
overexpressed miR-30b and miR-155 target SOCS1 in T-cells and miR-155 is also induced by 
IFNβ in macrophages during osteoclastogenesis (Chang et al. 2012; Zhang et al. 2012). This is 
important, because miR-155 is upregulated by lipopolysaccharide (LPS), regulates a wide 
range of regulatory pathways and promotes cytokine production (Tili et al. 2007; Xiao et al. 
2009; Cardoso et al. 2012). IRF3 may play a negative feedback role by suppression of miR-155 
and counteracts the induction of SOCS1 by IL1/IFNγ treatment (Tarassishin et al. 2011). In 
agreement with published data we were not able to detect any regulation of miR-155 (Lu et al. 
2009; Wang et al. 2009; Jiang et al. 2010). However, miR-155 gets induced by LPS and may 
therefore act as the limiting factor in the SOCS1 negative feedback loop in reaction to LPS 
(Androulidaki et al. 2009). In addition to bacterial infections, viral induction of miRNA-155 
promotes type I IFN signaling through targeting of SOCS1 by miRNA-155, finally suppressing 
viral replication (Wang et al. 2010). However, since miR-155 levels were not significantly 
changed in our experiment, the destabilizing effect on SOCS1 levels was unaffected by IFNα.
There are also conserved patterns in the SOCS3 3'-UTR mRNA, which contain target-
sequences recognizable by miR-203 (Sonkoly et al. 2007). Based on the negative correlation of 
miRNA expression and SOCS3 expression in psoriasis, a biological regulation has been 
suggested (Sun et al. 2008), but results of SOCS3 targeting experiments by miR-203 remain 
controversial. On the one hand, overexpression of miR-203 does not decrease SOCS3 mRNA 
levels in vitro (Lena et al. 2008). However, recent findings show efficient targeting of SOCS3 
luciferase reporter constructs by miR-203 or miR-483 in mice (Wei et al. 2010; Ma et al. 2012). 
In human cells, miR-203 is bound to SOCS3 5'-UTR and antagomir for miR-203 have a positive 
effect on SOCS3 levels and enhances chemosensitivity of breast cancer cells (Moffatt et al. 
2011; Ru et al. 2011). 
In summary, there are many miRNAs that have an impact on SOCS mRNA stability and even 
more may be involved in interfering with SOCS translation according to bioinformatic analyses 
(Friedman et al. 2009). Targeting of mRNA is followed by deadenylation and decay of the 
messenger RNA. This regulation supports other control mechanism for SOCS protein 
expression levels. First, SH2 domain of SOCS3 for instance contains an unstructured PEST 
(proline-, glutamic-acid, serine- and threonine-rich) motif, which negatively affects protein 
stability (Babon et al. 2006). Second, the N-terminal region of SOCS3 is also involved in protein 
instability through the presence of Lys-6, a major ubiquitination site (Sasaki et al. 2003). Last, 
the functions and stability of SOCS1 and SOCS3 proteins are modulated by the SUMO-
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modifying protein PIM1 (Chen et al. 2002; Peltola et al. 2004). This clearly indicates how 
important SOCS regulatory factors are for unimpaired cytokine signaling
POTENTIAL OF MIRNA REGULATION AS THERAPY
Antagomirs (anti-sense oligonucleotides) or miRNA mimics may be activated to limit SOCS 
proteins due to their importance in regulating SOCS expression. Despite the fact that miRNAs 
control SOCS translation it is not clear whether IFN-regulated changes in miRNA levels have an 
impact on the IFN antiviral effect. The most important miRNA for efficient HCV replication is 
miR-122 in HuH7 cells (Jopling et al. 2005; Jangra et al. 2010). Here, we could not detect a 
significant effect of IFNα on miR-122 expression in HuH7 cells neither at 4 nor at 24 hours. This 
is also true for mouse livers where miR-122 does not belong to the early ISG (Sarasin-
Filipowicz et al. 2009a). Besides acting as proviral agent, miR-122 has been linked to target 
SOCS3 responsiveness by modulation of SOCS3 promoter methylation status and silencing of 
miR-122 increases expression of IFNα response genes (Yoshikawa et al. 2012). Interestingly, 
non-responder patients have significant lower miR-122 levels (Sarasin-Filipowicz et al. 2009a) 
and supplementation with miR-122 does not increase production of the core protein or virus 
particles (Jangra et al. 2010). This supports the hypothesis that even low levels could allow 
HCV replication in vivo. Therefore, marginal reduction of miR-122 levels may not be limiting for 
HCV replication in HuH7 cells. It is therefore very unlikely that miRNAs mediate antiviral IFN 
responses against HCV (Sarasin-Filipowicz 2010). However, a total blockage of miR-122 in 
chimpanzees lowered HCV titer without effect on viral resistance and resulted in normalization 
of ISG levels. Moreover, it has been shown that miRNA-122 positively regulates a step in the 
life cycle of HCV other than its translation (Jangra et al. 2010). Thus, antagonizing miR-122 
could be used to convert IFN non-responders to responders (Lanford et al. 2010). 
In conclusion, we propose that miRNAs can limit the duration of SOCS expression. However, 
antagonizing this effect may only make sense where certain SOCS-targeting miRNAs are 
expressed at higher levels than normal and therapeutic manipulation of IFNα regulation of 
miRNA expression for better antiviral responses appears to have no chances of success. For 
the special case in HCV, the effect of IFNα on DICER may support blocking of miR-122 
maturation, which is important for the HCV life cycle. Finally, therapeutic antagonizing of 
miR-122 by miravirsen (Santaris Pharma SPC3649, LNA-antimiR-122) to improve or replace 
current therapy against HCV is promising and clinical phase 2a was completed recently 
(ClinicalTrials.gov # NCT01200420).
THERAPEUTIC IMPLICATIONS
Deregulation of SOCS1 and SOCS3 can be found in patients with HCV and is associated with 
HCC and melanoma. On the one hand, antiviral, anti-tumor and antiproliferative effects of IFNα 
in the treatment of these diseases are markedly reduced when SOCS proteins are 
overexpressed. On the other hand, signaling through growth factors and inflammatory cytokines 
is enhanced when SOCS expression is silenced and this may induce the risk for cancer 
formation and its growth potential. Abundant SOCS expression interferes with antiviral and 
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antitumor properties of therapeutic IFNα and inactivation of SOCS transcriptional regulation 
translate to carcinogenic conditions. Thus, the use of SOCS inhibitors and activators as 
therapeutics bears a huge potential.
Viral infection leads to excessive cytokine stimulation and expression of SOCS proteins, what 
may indicate insufficiency in inflammatory signaling and resistance to IFNα. HCV core protein 
seems to be directly involved in the induction of SOCS1 and SOCS3 mRNA (Zhang et al. 
2011b; Bode et al. 2003; El-Zayadi et al. 2012). The expression of SOCS proteins then leads to 
a desensitization of the cells towards IFNα. The refractoriness in response to IFNα correlates 
with expression of SOCS proteins and other factors such as insulin or leptin resistance (Dai et 
al. 2009). Moreover, HCV induced SOCS expression is dependent on the HCV core protein 
sequence, reduces levels of insulin receptor substrate and may account for both insulin 
resistance and lack of IFNα therapy response (Pascarella et al. 2011; El-Zayadi and Anis 2012). 
This argues that the negative influence of SOCS levels on anti-viral treatment can be monitored 
using symptoms such as body mass index (Kamal et al. 2002; Gylvin et al. 2009). In practice, it 
seems that the reduction of insulin resistance by diet restriction and physical exercise may 
increase the number of patients that benefit from IFNα therapy (Machado et al. 2009). 
Additionally, alcohol induces the expression of SOCS, thereby inhibits IFNα-based innate 
immunity in hepatocytes and contributes to the chronicity of hepatitis infection and poor therapy 
efficacy (Norkina et al. 2008; Ye et al. 2010). Elimination of SOCS proteins can prolong IFN 
signaling and STAT activation and thereby increases efficient viral clearance and supports 
survival of otherwise lethal infection (Fenner et al. 2006; Yasukawa et al. 2003). Therefore, 
SOCS inhibitors may prolong therapeutic effects of IFNs, decrease injection frequency and 
finally increase comfort for patients and reduce health care costs. However, the clinical 
applicability of SOCS inhibitors for re-sensitization of IFNα non-responders in HCV therapy 
remains to be demonstrated. Moreover, results from IFNα stimulated blood cells of different type 
of responders neither showed a correlation with SOCS1 inducibility nor SOCS1 non-stimulated 
levels (personal communication M. Mitsuhashi, Hitachi Chemical Research Center). In contrast, 
lack of SOCS1 suppression at baseline levels or 7 days after treatment in blood could predict 
failure to achieve SVR in CHC patients (Younossi et al. 2012). Therefore, selection of patients 
that may benefit of therapeutic SOCS inhibitors is not trivial. Moreover, development of an 
effective therapeutic SOCS inhibitor is challenging for three reasons. First, SOCS1 levels are 
not elevated longer than 3 hours after initial IFNα administration in mice and this short period 
could probably not be long enough to generate a significant benefit (Sarasin-Filipowicz et al. 
2009b). Second, even if SOCS3 levels stay significantly upregulated longer than this in mice 
with continuously high serum concentrations of IFNα, SOCS3 or STAT3 deficient mice also 
show prolonged IFNα refractoriness (Sarasin-Filipowicz et al. 2009b). For these two reasons, 
adjuvant therapy with SOCS inhibitors could probably be only of limited benefit for the patient. 
Finally, unspecific delivery of SOCS inhibitors may alter development of immune cells or impede 
stem cell maintenance, enhance risk of cancer formation or interfere with other antiviral 
pathways for example mediated by mTOR activation (Shao et al. 2010). This contradicts an 
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important impact of SOCS proteins in IFNα desensitization during treatment of CHC patients. 
Other factors than SOCS1, such as the ubiquitin specific peptidase USP18, have been 
associated with loss of treatment effect during prolonged administration (Randall et al. 2006; 
Sarasin-Filipowicz et al. 2009b). Furthermore, new formulations of IFNα are available or in 
development, for example pegylated interferon, albuferon, oral interferons or type III IFN (IFNλ) 
that shows fewer side effects. These improvements in IFN therapy can reduce injection rates 
and healthcare costs and improve acceptance of drug intake in HCV patients. Another 
promising approach is direct targeting of viral proteins using small chemicals to avoid host factor 
differences such as high SOCS levels. However, effective immune response in patients is 
probably still needed for long-term clearance of the virus.
In contrast to enhanced levels in non-responders to antiviral IFNα therapy, the inactivation of 
SOCS gene expression can be an important factor in carcinogenesis to limit growth control. 
Deregulation of SOCS1 can be observed in the pre-malignant tumor stage in HCV infected 
patients (Yoshida et al. 2004). In the later stage of hepatocellular carcinomas following HCV 
infection the SOCS1 promoter is frequently hypermethylated and silencing of the suppressor 
supports cancer growth (Yoshikawa et al. 2001; Yoshimura 2006; Yang et al. 2003). The impact 
of SOCS proteins in the development of tumors is confirmed by hepatocyte specific deletion of 
SOCS3 promoting hepatitis C related hepatocellular carcinoma (Ogata et al. 2006). Moreover, 
SOCS1 suppression can lead to spontaneous cancer formation in mice (Hanada et al. 2006). In 
addition, selective SOCS3 deletion in intestinal epithelial cells leads to STAT3 hyperactivation 
and enhanced colon tumorigenesis following injury and inflammation (Rigby et al. 2007). STAT3 
is also activated in SOCS3 deficient liver cells when liver regenerative conditions are simulated 
(Riehle et al. 2008).
The knockdown of endogenous SOCS levels or the silencing of the cytokine response through 
SOCS promoter methylation could therefore result in a growth advantage to cancer cells. DNA 
methylation in the promoter of SOCS genes is frequently observed in various cancers 
(Yoshikawa et al. 2001; Galm et al. 2003; Nagai et al. 2003; Komazaki et al. 2004; Evans et al. 
2007; Capello et al. 2008; Chu et al. 2010). In addition, SOCS1 promoter hypermethylation can 
be detected even in the pre-malignant stage of HCV infected patients (Yoshida et al. 2004). 
Therefore, SOCS1 can be classified as an anti-oncogene in hepatitis-induced carcinogenesis. 
The mechanism how proliferation rates in HCC cells are increased by SOCS promoter 
methylation is probably linked to enhanced activation of STAT proteins involved in growth 
signaling. Because SOCS proteins limit cancer growth, SOCS proteins can be assigned as 
tumor suppressors (Elliott et al. 2008). Therefore, SOCS proteins or mimics may be useful to 
control cancer growth when SOCS promoters are inactivated or in inflammatory diseases where 
cytokine signaling is out of control. It has been shown that adenoviral mediated SOCS3 transfer 
inhibits growth and increases radio-sensitivity of non-small cell lung cancer cells of the cells (Lin 
et al. 2010). In addition, overexpression of SOCS3 promotes preclinical antitumor activity 
against malignant pleural mesothelioma (Iwahori et al. 2011). A reduction of side effects may be 
achieved by using only parts of the SOCS proteins. A small molecule mimicking SOCS proteins 
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is TKIP (tyrosine-kinase inhibitor peptide). TKIP is able to inhibit JAK2-mediated 
phosphorylation of STAT1 (Flowers et al. 2004; Waiboci et al. 2007). TKIP suppresses also the 
proliferation of prostate cancer cell lines, in which STAT3 is constitutively activated (Mujtaba et 
al. 2005; Flowers et al. 2005). Thus, an efficient drug-delivery system with TKIP has a great 
potential to treat cancer and inflammatory diseases (Yoshimura et al. 2007). However, we can 
only speculate on the consequences of using SOCS mimics or antagonists in the clinics and on 
the role of SOCS proteins in human disease at the moment but it may be beneficial to treat viral 
infections and cancer by modulation of SOCS expression and its activity.
In contrast to SOCS agonists, the use of SOCS inhibitors may enhance the therapeutic outcome 
in IFN-based cancer treatment because knockdown of SOCS transcripts results in an increase 
in IFN mediated STAT phosphorylation (Lesinski et al. 2010). In renal cell carcinoma for 
example, suppression of SOCS3 increases susceptibility to IFNα (Tomita et al. 2011). However, 
discussion is ongoing whether IFNα-based therapy is mainly acting on the cancer cells or on 
immune cells. The administration of IFNα increase the survival of wild-type mice but not STAT1-
deficient mice challenged with STAT1-proficient tumor cells, suggesting that IFNs mediate their 
antitumor effects mainly through acting on the immune cells (Lesinski et al. 2003). Moreover, the 
immunomodulatory effect of IFNα is important for antitumor action in mice and is regulated by 
SOCS proteins (Zimmerer et al. 2007). Systemic therapy could therefore enhance both the anti-
proliferative action of IFNα in cancer cells as well as antitumor effects of hematopoietic cells at 
the same time. Gene expression changes by IFNα stimulation are similar in PBMC of melanoma 
patients in vitro and in vivo (Zimmerer et al. 2008). Therefore, the antitumor immunomodulatory 
potential of SOCS inhibitors together with IFNα may be screened in the lab from blood samples 
of cancer patients. A similar approach is the down-modulation of SOCS gene expression by 
siRNA therapy or by a dominant negative form of the protein. Suppression of SOCS1 using 
siRNA technology enhances the antiproliferative effects induced by IFNγ (Takahashi et al. 
2008). Therefore, therapeutic siRNAs targeting SOCS1 may also improve the growth inhibitory 
effects of IFNα in cancer treatment or inhibitors that target SOCS1 and SOCS3 activity may be 
used to reactivate IFNα mediated antitumor effects in metastatic melanoma cells. The ability of 
dendritic cells to induce strong antitumor immunity by enhanced antigen presentation can be 
significantly enhanced by targeting SOCS1 with siRNA (Shen et al. 2004). In addition, 
administration of these siRNAs by a nanotube carrier reduces tumor growth in mice (Yang et al. 
2006). As an auxiliary effect, siRNAs against SOCS1 and SOCS3 can improve insulin sensitivity 
and ameliorate hepatic steatosis (Ueki et al. 2005). In summary, on the one hand SOCS 
inhibitors may be used to enhance antitumor and antiviral properties of immune cells and to 
reduce cancer growth and viral proliferation in cells. On the other hand SOCS agonist could be 
used to regain control of proliferation in cancer cells.
Conclusion
Our results indicate that SOCS levels are important in the treatment of diseases like HCV or 
cancer with cytokines. SOCS targeting therapies are in development motivated by the possibility 
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that changes in SOCS levels during IFNα therapy may reflect refractoriness to cytokine 
stimulation by silencing antiviral and antiproliferative effect of the protein based drug. Here we 
have shown that over-expression of SOCS1 is very potent in suppression of gene induction by 
high doses of IFNα in vitro. Interferon stimulated protein expression was less reduced by 
overexpression of SOCS3 and no effect on gene expression patterns could be observed in 
melanoma-derived SOCS3 overexpressing cells. This shows that IFNα sensitive tumor-derived 
cells that is proficient in upregulating SOCS3 in response to cytokine stimulation can be both 
responsive or not to high SOCS3 expression levels. This may also be true in the clinics where 
patients benefit differently from IFNα treatment. We suggest therefore to measure SOCS1 and 
SOCS3 levels whenever feasible before and during the treatment for a better understanding of 
the factors that are involved in resistance to IFNα therapy. Finally, the capacity of rapid feedback 
regulation could be assessed by monitoring of SOCS induction some minutes after the first 
injection and adjustment of IFNα concentration or the use of SOCS inhibitors may be taken into 
account to improve therapy outcome.
Acknowledgments
The authors thank Dr. L. Burleigh, Roche, West Sussex, UK and Dr. R. Walser, University of 
Basel, Switzerland for critical review of the manuscript. Thanks are also due to Dr. T. Singer, 
Roche, Basel, Switzerland for continuous advice and support.
Disclosures
The author reports no conflicts of interest in this work.
References
References
Androulidaki A, Iliopoulos D, Arranz A, Doxaki C, Schworer S, Zacharioudaki V, Margioris AN, 
Tsichlis PN, Tsatsanis C. 2009 Aug. The kinase Akt1 controls macrophage response to 
lipopolysaccharide by regulating microRNAs. Immunity 31(2): 220-231.
Babon JJ, Kershaw NJ, Murphy JM, Varghese LN, Laktyushin A, Young SN, Lucet IS, Norton 
RS, Nicola NA. 2012 Feb. Suppression of cytokine signaling by SOCS3: characterization of the 
mode of inhibition and the basis of its specificity. Immunity 36(2): 239-250.
Babon JJ, McManus EJ, Yao S, DeSouza DP, Mielke LA, Sprigg NS, Willson TA, Hilton DJ, 
Nicola NA, Baca M, Nicholson SE, Norton RS. 2006 Apr. The structure of SOCS3 reveals the 
basis of the extended SH2 domain function and identifies an unstructured insertion that 
regulates stability. Mol. Cell 22(2): 205-216.
Baetz A, Koelsche C, Strebovsky J, Heeg K, Dalpke AH. 2008 Dec. Identification of a nuclear 
localization signal in suppressor of cytokine signaling 1. FASEB J. 22(12): 4296-4305.
2C20
Bakre A, Mitchell P, Coleman JK, Jones LP, Saavedra G, Teng M, Tompkins SM, Tripp RA. 2012 
Nov. Respiratory syncytial virus modifies microRNAs regulating host genes that affect virus 
replication. J. Gen. Virol. 93(Pt 11): 2346-2356.
Ben-Yair L, Slaaby R, Herman A, Cohen Y, Biener E, Moran N, Yoshimura A, Whittaker J, De 
Meyts P, Herman B, Gertler A. 2002 Aug. Preparation and expression of biologically active 
prolactin and growth hormone receptors and suppressor of cytokine signaling proteins 1, 2, 3, 
and 6 tagged with cyan and yellow fluorescent proteins. Protein Expr. Purif. 25(3): 456-464.
Bode JG, Ludwig S, Ehrhardt C, Albrecht U, Erhardt A, Schaper F, Heinrich PC, Häussinger D. 
2003 Mar. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor 
of cytokine signaling-3. FASEB J. 17(3): 488-490.
Boyle K, Zhang J, Nicholson SE, Trounson E, Babon JJ, McManus EJ, Nicola NA, Robb L. 2009 
Mar. Deletion of the SOCS box of suppressor of cytokine signaling 3 (SOCS3) in embryonic 
stem cells reveals SOCS box-dependent regulation of JAK but not STAT phosphorylation. Cell. 
Signal. 21(3): 394-404.
Brem R, Oraszlan-Szovik K, Foser S, Bohrmann B, Certa U. 2003 Jun. Inhibition of proliferation 
by 1-8U in interferon-alpha-responsive and non-responsive cell lines. Cell. Mol. Life Sci. 60(6): 
1235-1248.
Brender C, Lovato P, Sommer VH, Woetmann A, Mathiesen A, Geisler C, Wasik M, Ødum N. 
2005 Feb. Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition 
by IFNalpha. Leukemia 19(2): 209-213.
Calabrese V, Mallette FA, Deschênes-Simard X, Ramanathan S, Gagnon J, Moores A, 
Ilangumaran S, Ferbeyre G. 2009 Dec. SOCS1 links cytokine signaling to p53 and 
senescence. Mol. Cell 36(5): 754-767.
Capello D, Deambrogi C, Rossi D, Lischetti T, Piranda D, Cerri M, Spina V, Rasi S, Gaidano G, 
Lunghi M. 2008 May. Epigenetic inactivation of suppressors of cytokine signalling in 
Philadelphia-negative chronic myeloproliferative disorders. Br. J. Haematol. 141(4): 504-511.
Cardoso AL, Guedes JR, Pereira de Almeida L, Pedroso de Lima MC. 2012 Jan. miR-155 
modulates microglia-mediated immune response by down-regulating SOCS-1 and promoting 
cytokine and nitric oxide production. Immunology 135(1): 73-88.
Chang C, Zhang Q, Liu Z, Clynes RA, Suciu-Foca N, Vlad G. 2012 Apr. Downregulation of 
inflammatory microRNAs by Ig-like transcript 3 is essential for the differentiation of human 
CD8(+) T suppressor cells. J. Immunol. 188(7): 3042-3052.
Chen XP, Losman JA, Cowan S, Donahue E, Fay S, Vuong BQ, Nawijn MC, Capece D, Cohan 
VL, Rothman P. 2002 Feb. Pim serine/threonine kinases regulate the stability of Socs-1 
protein. Proc. Natl. Acad. Sci. U.S.A. 99(4): 2175-2180.
Chu P, Yeh C, Hsu NC, Chang Y, Chang J, Yeh K. 2010. Epigenetic alteration of the SOCS1 
gene in hepatocellular carcinoma. Swiss Med Wkly 140: w13065.
Croker BA, Kiu H, Nicholson SE. 2008 Aug. SOCS regulation of the JAK/STAT signalling 
pathway. Semin. Cell Dev. Biol. 19(4): 414-422.
Croker BA, Krebs DL, Zhang J, Wormald S, Willson TA, Stanley EG, Robb L, Greenhalgh CJ, 
Förster I, Clausen BE, Nicola NA, Metcalf D, Hilton DJ, Roberts AW, Alexander WS. 2003 Jun. 
SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 4(6): 540-545.
Dai C, Huang J, Hsieh M, Hou N, Lin Z, Chen S, Hsieh M, Wang L, Chang W, Chuang W, Yu M. 
2009 Apr. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination 
therapy in chronic hepatitis C patients. J. Hepatol. 50(4): 712-718.
Darnell JEJ, Kerr IM, Stark GR. 1994 Jun. Jak-STAT pathways and transcriptional activation in 
response to IFNs and other extracellular signaling proteins. Science 264(5164): 1415-1421.
Du P, Kibbe WA, Lin SM. 2008 Jul. lumi: a pipeline for processing Illumina microarray. 
Bioinformatics 24(13): 1547-1548.
El-Zayadi A, Anis M. 2012 Jan. Hepatitis C virus induced insulin resistance impairs response to 
anti viral therapy. World J. Gastroenterol. 18(3): 212-224.
Elliott J, Hookham MB, Johnston JA. 2008 Jun. The suppressors of cytokine signalling E3 
ligases behave as tumour suppressors. Biochem. Soc. Trans. 36(Pt 3): 464-468.
Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura 
S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N, Taniguchi T, Fujita T, Kanakura Y, Komiya S, 
Yoshimura A. 1997 Jun. A new protein containing an SH2 domain that inhibits JAK kinases. 
Nature 387(6636): 921-924.
Evans MK, Yu C, Lohani A, Mahdi RM, Liu X, Trzeciak AR, Egwuagu CE. 2007 Mar. Expression 
of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to 
proinflammatory cytokine and growth factor signals. Oncogene 26(13): 1941-1948.
2C21
Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, Schweigler LM, Theodore D, Zacks 
SL, Liang TJ, Fried MW. 2007 Nov. Hepatic gene expression during treatment with 
peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 
46(5): 1548-1563.
Feng Z, Chandrashekaran IR, Low A, Speed TP, Nicholson SE, Norton RS. 2012 Mar. The N-
terminal domains of SOCS proteins: a conserved region in the disordered N-termini of SOCS4 
and 5. Proteins 80(3): 946-957.
Fenner JE, Starr R, Cornish AL, Zhang J, Metcalf D, Schreiber RD, Sheehan K, Hilton DJ, 
Alexander WS, Hertzog PJ. 2006 Jan. Suppressor of cytokine signaling 1 regulates the 
immune response to infection by a unique inhibition of type I interferon activity. Nat. Immunol. 
7(1): 33-39.
Flowers LO, Johnson HM, Mujtaba MG, Ellis MR, Haider SMI, Subramaniam PS. 2004 Jun. 
Characterization of a peptide inhibitor of Janus kinase 2 that mimics suppressor of cytokine 
signaling 1 function. J. Immunol. 172(12): 7510-7518.
Flowers LO, Subramaniam PS, Johnson HM. 2005 Mar. A SOCS-1 peptide mimetic inhibits both 
constitutive and IL-6 induced activation of STAT3 in prostate cancer cells. Oncogene 24(12): 
2114-2120.
Fojtova M, Boudny V, Kovarik A, Lauerova L, Adamkova L, Souckova K, Jarkovsky J, Kovarik J. 
2007 Jul. Development of IFN-gamma resistance is associated with attenuation of SOCS 
genes induction and constitutive expression of SOCS 3 in melanoma cells. Br. J. Cancer 97(2): 
231-237.
Friedman RC, Farh KK, Burge CB, Bartel DP. 2009 Jan. Most mammalian mRNAs are 
conserved targets of microRNAs. Genome Res. 19(1): 92-105.
Fujimoto M, Naka T. 2003 Dec. Regulation of cytokine signaling by SOCS family molecules. 
Trends Immunol. 24(12): 659-666.
Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG. 2003 Apr. SOCS-1, a negative 
regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. 
Blood 101(7): 2784-2788.
Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, Grob J, Malvehy J, Newton-
Bishop J, Stratigos A, Pehamberger H, Eggermont A. 2010 Jan. Diagnosis and treatment of 
melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 46(2): 270-
283.
Gong B, Xie Q, Xiang X, Wang L, Zhao G, An F, Wang H, Lin L, Yu H, Bao S. 2010 Jun. Effect 
of ribavirin and interferon beta on miRNA profile in the hepatitis C virus subgenomic replicon-
bearing Huh7 cells. Int. J. Mol. Med. 25(6): 853-859.
Greenhalgh CJ, Hilton DJ. 2001 Sep. Negative regulation of cytokine signaling. J. Leukoc. Biol. 
70(3): 348-356.
Guenterberg KD, Grignol VP, Raig ET, Zimmerer JM, Chan AN, Blaskovits FM, Young GS, 
Nuovo GJ, Mundy BL, Lesinski GB, Carson WE3. 2010 Feb. Interleukin-29 binds to melanoma 
cells inducing Jak-STAT signal transduction and apoptosis. Mol. Cancer Ther. 9(2): 510-520.
Gylvin T, Ek J, Nolsøe R, Albrechtsen A, Andersen G, Bergholdt R, Brorsson C, Bang-
Berthelsen CH, Hansen T, Karlsen AE, Billestrup N, Borch-Johnsen K, Jørgensen T, Pedersen 
O, Mandrup-Poulsen T, Nerup J, Pociot F. 2009 Mar. Functional SOCS1 polymorphisms are 
associated with variation in obesity in whites. Diabetes Obes Metab 11(3): 196-203.
Haan S, Wüller S, Kaczor J, Rolvering C, Nöcker T, Behrmann I, Haan C. 2009 Aug. SOCS-
mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-
independent signaling. Oncogene 28(34): 3069-3080.
Hallen LC, Burki Y, Ebeling M, Broger C, Siegrist F, Oroszlan-Szovik K, Bohrmann B, Certa U, 
Foser S. 2007 Aug. Antiproliferative activity of the human IFN-alpha-inducible protein IFI44. J. 
Interferon Cytokine Res. 27(8): 675-680.
Hanada T, Kobayashi T, Chinen T, Saeki K, Takaki H, Koga K, Minoda Y, Sanada T, Yoshioka T, 
Mimata H, Kato S, Yoshimura A. 2006 Jun. IFNgamma-dependent, spontaneous development 
of colorectal carcinomas in SOCS1-deficient mice. J. Exp. Med. 203(6): 1391-1397.
Hu G, Zhou R, Liu J, Gong A, Chen X. 2010 Jul. MicroRNA-98 and let-7 regulate expression of 
suppressor of cytokine signaling 4 in biliary epithelial cells in response to Cryptosporidium 
parvum infection. J. Infect. Dis. 202(1): 125-135.
Hu G, Zhou R, Liu J, Gong A, Eischeid AN, Dittman JW, Chen X. 2009 Aug. MicroRNA-98 and 
let-7 confer cholangiocyte expression of cytokine-inducible Src homology 2-containing protein 
in response to microbial challenge. J. Immunol. 183(3): 1617-1624.
Huang Y, Feld JJ, Sapp RK, Nanda S, Lin J, Blatt LM, Fried MW, Murthy K, Liang TJ. 2007 Feb. 
2C22
Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in 
chronic hepatitis C. Gastroenterology 132(2): 733-744.
Iwahori K, Serada S, Fujimoto M, Nomura S, Osaki T, Lee CM, Mizuguchi H, Takahashi T, 
Ripley B, Okumura M, Kawase I, Kishimoto T, Naka T. 2011 Aug. Overexpression of SOCS3 
exhibits preclinical antitumor activity against malignant pleural mesothelioma. Int. J. Cancer 
129(4): 1005-1017.
Jangra RK, Yi M, Lemon SM. 2010 Jul. Regulation of hepatitis C virus translation and infectious 
virus production by the microRNA miR-122. J. Virol. 84(13): 6615-6625.
Jiang S, Zhang H, Lu M, He X, Li Y, Gu H, Liu M, Wang E. 2010 Apr. MicroRNA-155 functions 
as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. 
Cancer Res. 70(8): 3119-3127.
Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. 2005 Sep. Modulation of hepatitis C 
virus RNA abundance by a liver-specific MicroRNA. Science 309(5740): 1577-1581.
Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW. 2002 Oct. Peginterferon alone or with 
ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. 
Gastroenterology 123(4): 1070-1083.
Keppler A, Pick H, Arrivoli C, Vogel H, Johnsson K. 2004 Jul. Labeling of fusion proteins with 
synthetic fluorophores in live cells. Proc. Natl. Acad. Sci. U.S.A. 101(27): 9955-9959.
Kim K, Lin W, Tai AW, Shao R, Weinberg E, De Sa Borges CB, Bhan AK, Zheng H, Kamegaya 
Y, Chung RT. 2009 Apr. Hepatic SOCS3 expression is strongly associated with non-response 
to therapy and race in HCV and HCV/HIV infection. J. Hepatol. 50(4): 705-711.
Koelsche C, Strebovsky J, Baetz A, Dalpke AH. 2009 Aug. Structural and functional analysis of 
a nuclear localization signal in SOCS1. Mol. Immunol. 46(13): 2474-2480.
Komazaki T, Nagai H, Emi M, Terada Y, Yabe A, Jin E, Kawanami O, Konishi N, Moriyama Y, 
Naka T, Kishimoto T. 2004 Apr. Hypermethylation-associated inactivation of the SOCS-1 gene, 
a JAK/STAT inhibitor, in human pancreatic cancers. Jpn. J. Clin. Oncol. 34(4): 191-194.
Kovarik A, Fojtova M, Boudny V, Adamkova L, Lauerova L, Kovarik J. 2005 Dec. Interferon-
gamma, but not interferon-alpha, induces SOCS 3 expression in human melanoma cell lines. 
Melanoma Res. 15(6): 481-488.
Lanford RE, Guerra B, Lee H, Chavez D, Brasky KM, Bigger CB. 2006 May. Genomic response 
to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C 
kinetics. Hepatology 43(5): 961-972.
Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, 
Ørum H. 2010 Jan. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C 
virus infection. Science 327(5962): 198-201.
Lena AM, Shalom-Feuerstein R, Rivetti di Val Cervo P, Aberdam D, Knight RA, Melino G, Candi 
E. 2008 Jul. miR-203 represses 'stemness' by repressing DeltaNp63. Cell Death Differ. 15(7): 
1187-1195.
Lesinski GB, Anghelina M, Zimmerer J, Bakalakos T, Badgwell B, Parihar R, Hu Y, Becknell B, 
Abood G, Chaudhury AR, Magro C, Durbin J, Carson WE3. 2003 Jul. The antitumor effects of 
IFN-alpha are abrogated in a STAT1-deficient mouse. J. Clin. Invest. 112(2): 170-180.
Lesinski GB, Zimmerer JM, Kreiner M, Trefry J, Bill MA, Young GS, Becknell B, Carson WE3. 
2010. Modulation of SOCS protein expression influences the interferon responsiveness of 
human melanoma cells. BMC Cancer 10: 142.
Li Z, Metze D, Nashan D, Müller-Tidow C, Serve HL, Poremba C, Luger TA, Böhm M. 2004 Oct. 
Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J. Invest. 
Dermatol. 123(4): 737-745.
Lin SM, Du P, Huber W, Kibbe WA. 2008 Feb. Model-based variance-stabilizing transformation 
for Illumina microarray data. Nucleic Acids Res. 36(2): e11.
Lin Y, Lin C, Tsai Y, Weng H, Li Y, You L, Chen J, Jablons DM, Yang C. 2010 Dec. Adenovirus-
mediated SOCS3 gene transfer inhibits the growth and enhances the radiosensitivity of human 
non-small cell lung cancer cells. Oncol. Rep. 24(6): 1605-1612.
Lu L, Thai T, Calado DP, Chaudhry A, Kubo M, Tanaka K, Loeb GB, Lee H, Yoshimura A, 
Rajewsky K, Rudensky AY. 2009 Jan. Foxp3-dependent microRNA155 confers competitive 
fitness to regulatory T cells by targeting SOCS1 protein. Immunity 30(1): 80-91.
Ma N, Li F, Li D, Hui Y, Wang X, Qiao Y, Zhang Y, Xiang Y, Zhou J, Zhou L, Zheng X, Gao X. 
2012 Feb. Igf2-derived intronic miR-483 promotes mouse hepatocellular carcinoma cell 
proliferation. Mol. Cell. Biochem. 361(1-2): 337-343.
Machado MV, Cortez-Pinto H. 2009. Insulin resistance and steatosis in chronic hepatitis C. Ann 
Hepatol 8 Suppl 1: S67-75.
2C23
Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, Donnelly RP, Gamero AM. 
2008 Jul. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of 
JAK/STAT signaling activity. Cancer Biol. Ther. 7(7): 1109-1115.
Maine GN, Mao X, Komarck CM, Burstein E. 2007 Jan. COMMD1 promotes the ubiquitination of 
NF-kappaB subunits through a cullin-containing ubiquitin ligase. EMBO J. 26(2): 436-447.
Mallette FA, Moiseeva O, Calabrese V, Mao B, Gaumont-Leclerc M, Ferbeyre G. 2010 Jun. 
Transcriptome analysis and tumor suppressor requirements of STAT5-induced senescence. 
Ann. N. Y. Acad. Sci. 1197: 142-151.
Meng F, Henson R, Wehbe-Janek H, Smith H, Ueno Y, Patel T. 2007 Mar. The MicroRNA let-7a 
modulates interleukin-6-dependent STAT-3 survival signaling in malignant human 
cholangiocytes. J. Biol. Chem. 282(11): 8256-8264.
Miyaaki H, Ichikawa T, Nakao K, Matsuzaki T, Muraoka T, Honda T, Takeshita S, Shibata H, 
Ozawa E, Akiyama M, Miuma S, Eguchi K. 2009 Sep. Predictive value of suppressor of 
cytokine signal 3 (SOCS3) in the outcome of interferon therapy in chronic hepatitis C. Hepatol. 
Res. 39(9): 850-855.
Moffatt CE, Lamont RJ. 2011 Jul. Porphyromonas gingivalis induction of microRNA-203 
expression controls suppressor of cytokine signaling 3 in gingival epithelial cells. Infect. 
Immun. 79(7): 2632-2637.
Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault M, Sobesky R, Martinot-
Peignoux M, Maylin S, Nicolas-Chanoine M, Paradis V, Vidaud M, Valla D, Bedossa P, 
Marcellin P. 2008 Feb. Insulin resistance in chronic hepatitis C: association with genotypes 1 
and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 134(2): 416-423.
Mujtaba MG, Flowers LO, Patel CB, Patel RA, Haider MI, Johnson HM. 2005 Oct. Treatment of 
mice with the suppressor of cytokine signaling-1 mimetic peptide, tyrosine kinase inhibitor 
peptide, prevents development of the acute form of experimental allergic encephalomyelitis 
and induces stable remission in the chronic relapsing/remitting form. J. Immunol. 175(8): 5077-
5086.
Nagai H, Naka T, Terada Y, Komazaki T, Yabe A, Jin E, Kawanami O, Kishimoto T, Konishi N, 
Nakamura M, Kobayashi Y, Emi M. 2003. Hypermethylation associated with inactivation of the 
SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas. J. Hum. Genet. 48(2): 65-69.
Nguyen V, Zhang H, Kadakia S, Krolewski JJ [unpublished]. Attenuation of interferon-alpha 
signaling by SOCS-1 and SOCS-3 [Internet]. [cited 2006 Dec 29]. Available from: 
http://www.pathology.uci.edu/faculty/jkrolewski/51NguyenSubmitted.pdf
Nicholson SE, Willson TA, Farley A, Starr R, Zhang JG, Baca M, Alexander WS, Metcalf D, 
Hilton DJ, Nicola NA. 1999 Jan. Mutational analyses of the SOCS proteins suggest a dual 
domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. 
EMBO J. 18(2): 375-385.
Norkina O, Dolganiuc A, Catalano D, Kodys K, Mandrekar P, Syed A, Efros M, Szabo G. 2008 
Sep. Acute alcohol intake induces SOCS1 and SOCS3 and inhibits cytokine-induced STAT1 
and STAT3 signaling in human monocytes. Alcohol. Clin. Exp. Res. 32(9): 1565-1573.
Ogata H, Kobayashi T, Chinen T, Takaki H, Sanada T, Minoda Y, Koga K, Takaesu G, Maehara 
Y, Iida M, Yoshimura A. 2006 Jul. Deletion of the SOCS3 gene in liver parenchymal cells 
promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology 131(1): 179-193.
Pascarella S, Clément S, Guilloux K, Conzelmann S, Penin F, Negro F. 2011 Jun. Effects of 
hepatitis C virus on suppressor of cytokine signaling mRNA levels: comparison between 
different genotypes and core protein sequence analysis. J. Med. Virol. 83(6): 1005-1015.
Pazienza V, Clément S, Pugnale P, Conzelman S, Foti M, Mangia A, Negro F. 2007 May. The 
hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 
1 through genotype-specific mechanisms. Hepatology 45(5): 1164-1171.
Pazienza V, Clément S, Pugnale P, Conzelmann S, Pascarella S, Mangia A, Negro F. 2009 May. 
Gene expression profile of Huh-7 cells expressing hepatitis C virus genotype 1b or 3a core 
proteins. Liver Int. 29(5): 661-669.
Pazienza V, Vinciguerra M, Andriulli A, Mangia A. 2010 Jul. Hepatitis C virus core protein 
genotype 3a increases SOCS-7 expression through PPAR-{gamma} in Huh-7 cells. J. Gen. 
Virol. 91(Pt 7): 1678-1686.
Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, David M. 2007 Oct. 
Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449(7164): 
919-922.
Peltola KJ, Paukku K, Aho TLT, Ruuska M, Silvennoinen O, Koskinen PJ. 2004 May. Pim-1 
kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. 
2C24
Blood 103(10): 3744-3750.
Persico M, Capasso M, Persico E, Svelto M, Russo R, Spano D, Crocè L, La Mura V, Moschella 
F, Masutti F, Torella R, Tiribelli C, Iolascon A. 2007 Oct. Suppressor of cytokine signaling 3 
(SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and 
response to antiviral therapy. Hepatology 46(4): 1009-1015.
Persico M, Iolascon A. 2010 Mar. Steatosis as a co-factor in chronic liver diseases. World J. 
Gastroenterol. 16(10): 1171-1176.
Persico M, Russo R, Persico E, Svelto M, Spano D, Andolfo I, La Mura V, Capasso M, Tiribelli 
C, Torella R, Iolascon A. 2009. SOCS3 and IRS-1 gene expression differs between genotype 1 
and genotype 2 hepatitis C virus-infected HepG2 cells. Clin. Chem. Lab. Med. 47(10): 1217-
1225.
Petta S, Cammà C, Di Marco V, Alessi N, Cabibi D, Caldarella R, Licata A, Massenti F, Tarantino 
G, Marchesini G, Craxì A. 2008 May. Insulin resistance and diabetes increase fibrosis in the 
liver of patients with genotype 1 HCV infection. Am. J. Gastroenterol. 103(5): 1136-1144.
Pichiorri F, Suh S, Ladetto M, Kuehl M, Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, 
Hagan JP, Munker R, Volinia S, Boccadoro M, Garzon R, Palumbo A, Aqeilan RI, Croce CM. 
2008 Sep. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. 
Proc. Natl. Acad. Sci. U.S.A. 105(35): 12885-12890.
Piessevaux J, Lavens D, Peelman F, Tavernier J. 2008 Oct-Dec. The many faces of the SOCS 
box. Cytokine Growth Factor Rev. 19(5-6): 371-381.
Piganis RAR, De Weerd NA, Gould JA, Schindler CW, Mansell A, Nicholson SE, Hertzog PJ. 
2011 Sep. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling 
via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2. J. Biol. Chem. 
286(39): 33811-33818.
Qin H, Niyongere SA, Lee SJ, Baker BJ, Benveniste EN. 2008 Sep. Expression and functional 
significance of SOCS-1 and SOCS-3 in astrocytes. J. Immunol. 181(5): 3167-3176.
Qing Y, Costa-Pereira AP, Watling D, Stark GR. 2005 Jan. Role of tyrosine 441 of interferon-
gamma receptor subunit 1 in SOCS-1-mediated attenuation of STAT1 activation. J. Biol. 
Chem. 280(3): 1849-1853.
Randall G, Chen L, Panis M, Fischer AK, Lindenbach BD, Sun J, Heathcote J, Rice CM, 
Edwards AM, McGilvray ID. 2006 Nov. Silencing of USP18 potentiates the antiviral activity of 
interferon against hepatitis C virus infection. Gastroenterology 131(5): 1584-1591.
Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodolets KE, Pfeffer S, Landthaler M, 
Landgraf P, Kan S, Lindenbach BD, Chien M, Weir DB, Russo JJ, Ju J, Brownstein MJ, 
Sheridan R, Sander C, Zavolan M, Tuschl T, Rice CM. 2007 Jul. Cellular cofactors affecting 
hepatitis C virus infection and replication. Proc. Natl. Acad. Sci. U.S.A. 104(31): 12884-12889.
Rani MRS, Croze E, Wei T, Shrock J, Josyula A, Kalvakolanu DV, Ransohoff RM. 2010 Mar. 
STAT-phosphorylation-independent induction of interferon regulatory factor-9 by interferon-
beta. J. Interferon Cytokine Res. 30(3): 163-170.
Riehle KJ, Campbell JS, McMahan RS, Johnson MM, Beyer RP, Bammler TK, Fausto N. 2008 
Jan. Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine 
signaling 3. J. Exp. Med. 205(1): 91-103.
Rigby RJ, Simmons JG, Greenhalgh CJ, Alexander WS, Lund PK. 2007 Jul. Suppressor of 
cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and 
inflammation-associated tumorigenesis in the colon. Oncogene 26(33): 4833-4841.
Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Cervantes F, Barrios M, Colomer D, 
Heiniger A, Torres A. 2004 Jan. The suppressor of cytokine signaling-1 is constitutively 
expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to 
interferon-alpha. Haematologica 89(1): 42-48.
Rossa CJ, Sommer G, Spolidorio LC, Rosenzweig SA, Watson DK, Kirkwood KL. 2012. Loss of 
expression and function of SOCS3 is an early event in HNSCC: altered subcellular localization 
as a possible mechanism involved in proliferation, migration and invasion. PLoS ONE 7(9): 
e45197.
Ru P, Steele R, Hsueh EC, Ray RB. 2011 Jul. Anti-miR-203 Upregulates SOCS3 Expression in 
Breast Cancer Cells and Enhances Cisplatin Chemosensitivity. Genes Cancer 2(7): 720-727.
Sakai I, Takeuchi K, Yamauchi H, Narumi H, Fujita S. 2002 Oct. Constitutive expression of 
SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood 100(8): 
2926-2931.
Sakamoto H, Yasukawa H, Masuhara M, Tanimura S, Sasaki A, Yuge K, Ohtsubo M, Ohtsuka A, 
Fujita T, Ohta T, Furukawa Y, Iwase S, Yamada H, Yoshimura A. 1998 Sep. A Janus kinase 
2C25
inhibitor, JAB, is an interferon-gamma-inducible gene and confers resistance to interferons. 
Blood 92(5): 1668-1676.
Sarasin-Filipowicz M. 2010 Jan. Interferon therapy of hepatitis C: molecular insights into 
success and failure. Swiss Med Wkly 140(1-2): 3-11.
Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. 2009a Jan. Decreased 
levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon 
therapy. Nat. Med. 15(1): 31-33.
Sarasin-Filipowicz M, Oakeley EJ, Duong FHT, Christen V, Terracciano L, Filipowicz W, Heim 
MH. 2008 May. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl. 
Acad. Sci. U.S.A. 105(19): 7034-7039.
Sarasin-Filipowicz M, Wang X, Yan M, Duong FHT, Poli V, Hilton DJ, Zhang D, Heim MH. 2009b 
Sep. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse 
liver through induction of USP18/UBP43. Mol. Cell. Biol. 29(17): 4841-4851.
Sasaki A, Inagaki-Ohara K, Yoshida T, Yamanaka A, Sasaki M, Yasukawa H, Koromilas AE, 
Yoshimura A. 2003 Jan. The N-terminal truncated isoform of SOCS3 translated from an 
alternative initiation AUG codon under stress conditions is stable due to the lack of a major 
ubiquitination site, Lys-6. J. Biol. Chem. 278(4): 2432-2436.
Schlüter G, Boinska D, Nieman-Seyde SC. 2000 Feb. Evidence for translational repression of 
the SOCS-1 major open reading frame by an upstream open reading frame. Biochem. 
Biophys. Res. Commun. 268(2): 255-261.
Shao R, Zhang L, Peng LF, Sun E, Chung WJ, Jang JY, Tsai W, Hyppolite G, Chung RT. 2010 
Jun. Suppressor of cytokine signaling 3 suppresses hepatitis C virus replication in an mTOR-
dependent manner. J. Virol. 84(12): 6060-6069.
Shen L, Evel-Kabler K, Strube R, Chen S. 2004 Dec. Silencing of SOCS1 enhances antigen 
presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat. Biotechnol. 
22(12): 1546-1553.
Shuai K. 2006 Feb. Regulation of cytokine signaling pathways by PIAS proteins. Cell Res. 
16(2): 196-202.
Siegrist F, Certa U. 2008. Micro RNA Induction by Interferon Alpha and a Potential Role to 
Interfere with SOCS. 7th Joint Conference – Montréal, Québec, Canada, October 12-16, 2008. 
Editor: John Hiscott. Medimont International Proceedings: 93-97.
Siegrist F, Singer T, Certa U. 2009 Dec. MicroRNA Expression Profiling by Bead Array 
Technology in Human Tumor Cell Lines Treated with Interferon-Alpha-2a. Biol Proced Online 
11: 113-129.
Smyth GK. 2004. Linear models and empirical bayes methods for assessing differential 
expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
Song MM, Shuai K. 1998 Dec. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but 
not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J. Biol. 
Chem. 273(52): 35056-35062.
Sonkoly E, Wei T, Janson PCJ, Sääf A, Lundeberg L, Tengvall-Linder M, Norstedt G, Alenius H, 
Homey B, Scheynius A, Ståhle M, Pivarcsi A. 2007. MicroRNAs: novel regulators involved in 
the pathogenesis of psoriasis ? PLoS ONE 2(7): e610.
Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. 1998. How cells respond to 
interferons. Annu. Rev. Biochem. 67: 227-264.
Starr R, Fuchsberger M, Lau LS, Uldrich AP, Goradia A, Willson TA, Verhagen AM, Alexander 
WS, Smyth MJ. 2009 Oct. SOCS-1 binding to tyrosine 441 of IFN-gamma receptor subunit 1 
contributes to the attenuation of IFN-gamma signaling in vivo. J. Immunol. 183(7): 4537-4544.
Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, 
Metcalf D, Nicola NA, Hilton DJ. 1997 Jun. A family of cytokine-inducible inhibitors of signalling. 
Nature 387(6636): 917-921.
Sun BK, Tsao H. 2008 Nov. Small RNAs in development and disease. J. Am. Acad. Dermatol. 
59(5): 725-737.
Takahashi Y, Kaneda H, Takasuka N, Hattori K, Nishikawa M, Watanabe Y, Takakura Y. 2008 
Aug. Enhancement of antiproliferative activity of interferons by RNA interference-mediated 
silencing of SOCS gene expression in tumor cells. Cancer Sci. 99(8): 1650-1655.
Takeuchi K, Sakai I, Narumi H, Yasukawa M, Kojima K, Minamoto Y, Fujisaki T, Tanimoto K, 
Hara M, Numata A, Gondo H, Takahashi M, Fujii N, Masuda K, Fujita S. 2005 Feb. Expression 
of SOCS3 mRNA in bone marrow cells from CML patients associated with cytogenetic 
response to IFN-alpha. Leuk. Res. 29(2): 173-178.
Tarassishin L, Loudig O, Bauman A, Shafit-Zagardo B, Suh H, Lee SC. 2011 Dec. Interferon 
2C26
regulatory factor 3 inhibits astrocyte inflammatory gene expression through suppression of the 
proinflammatory miR-155 and miR-155*. Glia 59(12): 1911-1922.
Tili E, Michaille J, Cimino A, Costinean S, Dumitru CD, Adair B, Fabbri M, Alder H, Liu CG, Calin 
GA, Croce CM. 2007 Oct. Modulation of miR-155 and miR-125b levels following 
lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to 
endotoxin shock. J. Immunol. 179(8): 5082-5089.
Tomita S, Ishibashi K, Hashimoto K, Sugino T, Yanagida T, Kushida N, Shishido K, Aikawa K, 
Sato Y, Suzutani T, Yamaguchi O. 2011 Jan. Suppression of SOCS3 increases susceptibility of 
renal cell carcinoma to interferon-α. Cancer Sci. 102(1): 57-63.
Ueki K, Kadowaki T, Kahn CR. 2005 Oct. Role of suppressors of cytokine signaling SOCS-1 and 
SOCS-3 in hepatic steatosis and the metabolic syndrome. Hepatol. Res. 33(2): 185-192.
Vanni E, Abate ML, Gentilcore E, Hickman I, Gambino R, Cassader M, Smedile A, Ferrannini E, 
Rizzetto M, Marchesini G, Gastaldelli A, Bugianesi E. 2009 Sep. Sites and mechanisms of 
insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology 50(3): 
697-706.
Vlotides G, Sörensen AS, Kopp F, Zitzmann K, Cengic N, Brand S, Zachoval R, Auernhammer 
CJ. 2004 Jul. SOCS-1 and SOCS-3 inhibit IFN-alpha-induced expression of the antiviral 
proteins 2,5-OAS and MxA. Biochem. Biophys. Res. Commun. 320(3): 1007-1014.
Waiboci LW, Ahmed CM, Mujtaba MG, Flowers LO, Martin JP, Haider MI, Johnson HM. 2007 
Apr. Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-
1 mimetic bind to JAK2 autophosphorylation site: implications for the development of a SOCS-
1 antagonist. J. Immunol. 178(8): 5058-5068.
Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, Powell EE. 2006 
Apr. Non-response to antiviral therapy is associated with obesity and increased hepatic 
expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, 
viral genotype 1. Gut 55(4): 529-535.
Wang P, Hou J, Lin L, Wang C, Liu X, Li D, Ma F, Wang Z, Cao X. 2010 Nov. Inducible 
microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting 
suppressor of cytokine signaling 1. J. Immunol. 185(10): 6226-6233.
Wang X, Zhao Q, Matta R, Meng X, Liu X, Liu C, Nelin LD, Liu Y. 2009 Oct. Inducible nitric-
oxide synthase expression is regulated by mitogen-activated protein kinase phosphatase-1. J. 
Biol. Chem. 284(40): 27123-27134.
Wei T, Orfanidis K, Xu N, Janson P, Ståhle M, Pivarcsi A, Sonkoly E. 2010 Sep. The expression 
of microRNA-203 during human skin morphogenesis. Exp. Dermatol. 19(9): 854-856.
Wiesen JL, Tomasi TB. 2009 Mar. Dicer is regulated by cellular stresses and interferons. Mol. 
Immunol. 46(6): 1222-1228.
Xiao C, Rajewsky K. 2009 Jan. MicroRNA control in the immune system: basic principles. Cell 
136(1): 26-36.
Yang B, Guo M, Herman JG, Clark DP. 2003 Sep. Aberrant promoter methylation profiles of 
tumor suppressor genes in hepatocellular carcinoma. Am. J. Pathol. 163(3): 1101-1107.
Yang R, Yang X, Zhang Z, Zhang Y, Wang S, Cai Z, Jia Y, Ma Y, Zheng C, Lu Y, Roden R, Chen 
Y. 2006 Dec. Single-walled carbon nanotubes-mediated in vivo and in vitro delivery of siRNA 
into antigen-presenting cells. Gene Ther. 13(24): 1714-1723.
Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T, Ohtsuka S, Imaizumi 
T, Matsuda T, Ihle JN, Yoshimura A. 1999 Mar. The JAK-binding protein JAB inhibits Janus 
tyrosine kinase activity through binding in the activation loop. EMBO J. 18(5): 1309-1320.
Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, Aki D, Hanada T, Takeda K, Akira S, 
Hoshijima M, Hirano T, Chien KR, Yoshimura A. 2003 Jun. IL-6 induces an anti-inflammatory 
response in the absence of SOCS3 in macrophages. Nat. Immunol. 4(6): 551-556.
Ye L, Wang S, Wang X, Zhou Y, Li J, Persidsky Y, Ho W. 2010 Nov. Alcohol impairs interferon 
signaling and enhances full cycle hepatitis C virus JFH-1 infection of human hepatocytes. Drug 
Alcohol Depend 112(1-2): 107-116.
Yoshida T, Ogata H, Kamio M, Joo A, Shiraishi H, Tokunaga Y, Sata M, Nagai H, Yoshimura A. 
2004 Jun. SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. J. 
Exp. Med. 199(12): 1701-1707.
Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC, 
Herman JG. 2001 May. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by 
methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. 
Genet. 28(1): 29-35.
Yoshikawa T, Takata A, Otsuka M, Kishikawa T, Kojima K, Yoshida H, Koike K. 2012. Silencing 
2C27
of microRNA-122 enhances interferon-α signaling in the liver through regulating SOCS3 
promoter methylation. Sci Rep 2: 637.
Yoshimura A. 2006 Jun. Signal transduction of inflammatory cytokines and tumor development. 
Cancer Sci. 97(6): 439-447.
Yoshimura A, Naka T, Kubo M. 2007 Jun. SOCS proteins, cytokine signalling and immune 
regulation. Nat. Rev. Immunol. 7(6): 454-465.
Yoshimura A, Nishinakamura H, Matsumura Y, Hanada T. 2005. Negative regulation of cytokine 
signaling and immune responses by SOCS proteins. Arthritis Res. Ther. 7(3): 100-110.
Younossi ZM, Birerdinc A, Estep M, Stepanova M, Afendy A, Baranova A. 2012. The impact of 
IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with 
pegylated interferon alpha and ribavirin. J Transl Med 10: 25.
Zhang J, Zhao H, Chen J, Xia B, Jin Y, Wei W, Shen J, Huang Y. 2012 Sep. Interferon-β-
induced miR-155 inhibits osteoclast differentiation by targeting SOCS1 and MITF. FEBS Lett. 
586(19): 3255-3262.
Zhang M, Liu F, Jia H, Zhang Q, Yin L, Liu W, Li H, Yu B, Wu J. 2011a Aug. Inhibition of 
microRNA let-7i depresses maturation and functional state of dendritic cells in response to 
lipopolysaccharide stimulation via targeting suppressor of cytokine signaling 1. J. Immunol. 
187(4): 1674-1683.
Zhang Y, Ma CJ, Ni L, Zhang CL, Wu XY, Kumaraguru U, Li CF, Moorman JP, Yao ZQ. 2011b 
Mar. Cross-Talk between Programmed Death-1 and Suppressor of Cytokine Signaling-1 in 
Inhibition of IL-12 Production by Monocytes/Macrophages in Hepatitis C Virus Infection. J. 
Immunol. 186(5): 3093-3103.
Zimmerer JM, Lesinski GB, Kondadasula SV, Karpa VI, Lehman A, Raychaudhury A, Becknell 
B, Carson WE3. 2007 Apr. IFN-alpha-induced signal transduction, gene expression, and 
antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine 
signaling proteins. J. Immunol. 178(8): 4832-4845.
Zimmerer JM, Lesinski GB, Ruppert AS, Radmacher MD, Noble C, Kendra K, Walker MJ, 
Carson WE3. 2008 Sep. Gene expression profiling reveals similarities between the in vitro and 
in vivo responses of immune effector cells to IFN-alpha. Clin. Cancer Res. 14(18): 5900-5906.
2C28
Figures
Figure 1 SOCS and PIAS mRNA induction by IFNα.
a – ME-15 cells were supplemented 2 hours before lysis with 1 % culture 
medium without or with IFNα (1000 U/ml). Fold changes from RT-PCR are 
relative to the average of GAPDH and RPL32 endogenous controls and to 
untreated controls. Fold change for separate calculation of biological duplicates 
are shown as black dots.
b – Time course analysis of SOCS1 and SOCS3 induction by IFNα in a 
melanoma and hepatoma cell line. ME-15 and HuH7 cells were cultivated for 1, 
2, 4, 8 or 24 hours after addition of 1 % IFNα (1000 U/ml) or control medium. 
Time-point 6* indicates treatment for 4 hours and replacement of medium from 
reference cell cultures for 2 hours. RT-PCR fold changes are relative to RPL32 
endogenous control and to pre-treatment levels. Fold changes for triplicates 
calculated separately are shown as black and white dots for INFα treated and 
non-treated samples, respectively. Endogenous SOCS1 levels were higher in 
HuH7 control cultures according to ct values, which partially explain the lower 
fold induction.
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Figure 2 Subcellular localization of SOCS1, SOCS3 and SOCS4 in ME-15 
melanoma cells.
ME-15 cells were transfected with expression plasmid pSEMS1-26m for N- and 
C-terminal SNAP-tagged SOCSs and cultured for 16 hours in chamber-slides 
before the proteins were covalently linked to the TMR-Star fluorescent 
substrate. Images were recorded with a 40x objective on a confocal microscope 
and original size is indicated with scale-bars of 50 μm.
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Figure 3 Effect on SOCS overexpression on IFITM3 protein induction by 
IFNα.
Western blots analysis of IFNα induced IFITM3 protein expression in melanoma 
and hepatoma cells. ME-15 and HuH7 cells were cultured in medium containing 
100-1000 U/ml IFNα for 4 or 24 hours. Cell lysates were analysed by 
immunoblotting with an anti-IFITM antibody. Results for cell lines used in the 
microarray experiment are shown in the upper part and their signal intensities 
are represented as red dots in the graphs below. IFITM3 protein induction was 
quantified three times in untransfected cells, in three cells lines each derived 
from SOCS1-  and SOCS3-pcDNA3.1 transfection and two with SOCS4 control. 
Protein content was calculated based on the area under the curve (AUC) above 
background from chemiluminescent signals of the peak in the IFITM3 band 
region from immunoblots.
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Figure 4 IFNα-stimulated whole genome expression profiles.
Parent and SOCS expressing ME-15 and HuH7 cell lines were cultured for 4 or 
24 hours in normal or IFNα -containing (1000 U/ml) medium. Log2 factor 
changes were calculated from Illumina gene-expression arrays. Heat map 
shows a hierarchical clustering of the 250 most significant probes (p-value < 1.4 
x 10-7). Blue color indicates downregulation, white represents unchanged mRNA 
levels and red color upregulation. Density distribution for maximal or minimal 
changes is shown in green in the color legend.
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Figure 5 MiRNA profiling of SOCS-expressing cell lines.
Melanoma and hepatoma cells stably overexpressing SOCS proteins were 
treated with 1000U/ml IFNα for 4 and 24 hours. MiRNA probe intensities were 
assessed by Illumina microarrays and significant probes identified by an ANOVA 
model of the 4 hours time-point values correcting for cell type (p-value < 0.05). 
Log2 factor change values were clustered for probes and maximal (2^1.6=3 fold 
change) or minimal (2^-1.6=-0.33) changes indicated as a density distribution in 
the color legend.
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Gene RefSeq ID Start End Orientation Sequence
SOCS1 NM_003745.1 155 175 forward taggatccgccgccATGGTAGCACACAACCAGGTG
SOCS1 NM_003745.1 790 767 reverse tgccggaattcTCAAATCTGGAAGGGGAAGGAGCT
SOCS1 NM_003745.1 787 782 non-stop tgccggaattcAATCTG
SOCS3 NM_003955.3 413 436 forward cgtggatccgcCGCCATGGTCACCCACAGCAAGTT
SOCS3 NM_003955.3 1095 1070 reverse ccccgaattGTTAAAGCGGGGCATCGTACTGGTCC
SOCS3 NM_003955.3 1091 1087 non-stop cttcccgaattcAAGCG
SOCS4 NM_080867.2 436 460 forward caaggatccgccgcCATGGCAGAAAATAATGAAAATATT
SOCS4 NM_080867.2 1759 1736 reverse tgttagaattcCTAGCATGGCTGTTCTGGTGCATC
SOCS4 NM_080867.2 1756 1745 non-stop agaattcGCATTGCTGTTC
Supplementary Table 1 Primer sequences for molecular cloning of SOCS genes
The sequence match with the RefSeq mRNA sequence are given in capital letters and in small letters the 
auxiliary nucleotide for introduction of restriction enzyme target sites and Kozak sequence are indicated. For 
primers matching to the reverse copy strand of the mRNA indicated have higher start than end positions.
Gene RefSeq ID orientation Prod.size Start End Tm GC% Sequence 5' - 3'
CISH NM_145071.2 forward 121 476 496 54.11 47.62 ATGCCAGAAGGCACGTTCTTA
NM_013324.5 reverse 596 577 54.79 60.00 GGAAGCTGGAGTCGGCATAC
SOCS1 NM_003745.1 forward 140 377 396 55.21 60.00 GACGCCTGCGGATTCTACTG
reverse 516 496 55.02 57.14 GAGGCCATCTTCACGCTAAGG
SOCS2 NM_003877.3 forward EB 107 726 749 55.35 50.00 ACAGGATGGTACTGGGGAAGTATG
reverse 832 806 56.51 44.44 AGGTAGTCTGAATGCGAGCTATCTCTA
SOCS3 NM_003955.3 forward 148 489 510 56.17 54.54 TTCAGCTCCAAGAGCGAGTACC
reverse 636 617 54.74 55.00 AGCTGTCGCGGATCAGAAAG
SOCS4 NM_080867.2 forward 129 1203 1225 54.37 43.48 TGCAGTTGGAAACACCTCCTAAA
NM_199421.1 reverse 1331 1310 54.67 50.00 GTGCTTCGGCTGCGTATTTATC
SOCS5 NM_014011.4 forward 104 1173 1193 55.68 52.38 AGGCAGAAGCAGCGTCAGATA
NM_144949.2 reverse 1276 1254 55.79 52.17 GGCACGAGGCAGTGTATGTAATC
SOCS6 NM_004232.3 forward 122 1368 1389 54.27 50.00 CTCCTGGGGTTGCAAGAGTTTA
reverse 1489 1469 55.13 52.38 ACGTGTGATTGGTCCCCAGTA
SOCS7 NM_014598.2 forward EB 137 1605 1624 55.35 55.00 TTCCAGGACTGCCACCAACT
reverse 1741 1721 53.97 57.14 CAGTGGGAGATCTGGGATGTG
PIAS1 NM_016166.1 forward 104 1679 1699 53.73 52.38 GGCATCCTTTCCACATGACAC
reverse 1782 1762 54.94 52.38 GGCAAGCAAGGAGGTGTTGTA
PIAS2 NM_173206.2 forward 140 416 437 55.07 50.00 TGGTGGCTCATCACCTGTAGAA
NM_004671.2 reverse EB 555 531 54.15 44.00 GCATCTCAAATGTGGGCTTAGTATC
PIAS3 NM_006099.3 forward 129 1658 1678 54.19 52.38 GGAGCCGACATCCAAGGTTTA
reverse 1786 1766 54.95 57.14 GGTCCCTCGGTACTGGAAGAA
PIAS4 NM_015897.2 forward EB 133 453 473 53.56 52.38 CCACCGAATTAGTCCCACAGA
reverse EB 585 566 55.52 55.00 ACGACCTGCACGGCTTTAAC
RPL32 NM_000994.3 forward 111 353 373 54.79 47.62 GTGCTGCTGATGTGCAACAAA
reverse 463 443 55.12 57.14 GGTGACTCTGATGGCCAGTTG
GAPDH NM_0024046.3 forward 300 639 668 66.07 56.67 TGCCATCACTGCCACCCAGAAGACTGTGGA
reverse 938 909 66.20 60.00 TGCTCAGTGTAGCCCAGGATGCCCTTGAGG
Supplementary Table 2 qPCR primer sequences for RT-PCR SOCS and PIAS mRNA 
quantification
qPCR primers were selected to generate a product size of 100 to 150 bp (100 as optimal). Primers covering 
an exon boundary were given preference. Primers for CISH, SOCS4, SOCS5 and PIAS2 are designed to 
amplify both transcript variants alpha and beta, the position are given for the first mRNA sequence and have 
a perfect match in the second on other positions (in italic). Primer that span over an exon boundary are 
marked with EB.
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Supplementary Figure 1 SOCS1 mRNA induction by IFNα in ten carcinoma cell lines
Cells were grown in RPMI 1640 medium with IFNα (100 U/ml) for 4 hours or without IFNα (mock). The 
experimental details have been previously reported (Hallen et al. 2007) and data submitted to NCBI GEO 
database with accession number GSE21158. Expression levels are indicated as log relative luciferase levels 
(RLU). 8 out of 10 cell lines have significantly higher SOCS1 levels after addition of IFNα based on a one-
tailed t-test (* indicates p-values below 0.05).
Supplementary Figure 2 Venn diagrams of IFNα induced probes
Number of probes significantly changed (fdr adjusted p-value < 0.05) by IFNα treatment in HuH7 and ME-15 
cell lines derived by SOCS1, SOCS3 and SOCS4 construct transfection.
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Supplementary Figure 3 Scatter-plot of SOCS ME-15 cell lines
Log factor change of control cells (ME-15) on the x-axis is plotted against log factor change of SOCS1-, 
SOCS3- or SOCS4-expressing cells on the y-axis. SOCS4 overexpression is only marginal and thus no 
effect is expected. Some probes are annotated manually for better orientation across all samples and to 
stress discordant values.
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Supplementary Figure 4 Scatter-plot of SOCS HuH7 cell lines
Log factor change of control cells (HuH7) on the x-axis is plotted against log factor change of SOCS1-, 
SOCS3- or SOCS4-expressing cells on the y-axis. SOCS4 overexpression is only marginal and thus no 
effect is expected. Some probes are annotated manually for better orientation across all samples and to 
stress discordant values.
2C37
Supplementary Figure 5 Volcano-plot of IFNα-induced miRNAs
Cell lines were treated for four hours with IFNα. Microarray intensities from individual miRNA probes of HuH7 
and ME-15 cell lines and SOCS-expressing derivatives were recorded using bead arrays. Probability for 
change by IFNα treatment (fdr adjusted p-value) is plotted against the intensity of the change (log2 fold 
changes). Annotations are given as numbers for miRNAs from Sanger miRBase 
(http://microrna.sanger.ac.uk/; Release 10.0: August 2007) or with prefix HS or tHS for 272 miRNAs 
according to annotation given by Illumina 'taken from the literature'.
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Abstract
INTRODUCTION: Epigenetic silencing of tumor suppressor genes contributes significantly 
to malignant transformation in colorectal cancer (CRC). Silencing occurs by aberrant DNA 
methylation in gene promoters. METHODS: To identify genomic sequences undergoing 
aberrant methylation at early stages of colorectal carcinogenesis, we integrated results 
from three different genomic analyses: i) Gene expression profiling of 32 matched pairs of 
colorectal adenoma and normal mucosa tissues to identify gens downregulated early in 
carcinogenesis; ii) gene expression analysis of a CRC cell line showing wide-spread DNA 
hypermethylation (SW48) before and after 5-Aza-Cytidine/Trichostatin A induced 
demethylation to identify targets of methylation dependent gene silencing; and iii) DNA 
methylation profiling of matched primary tumor (CRC), cancer-associated mucosa (CAM) 
and blood from two colorectal cancer patients to identify cancer-specific methylation 
targets. Aberrant methylation at newly discovered targets were validated and cancer-
specific methylation cut-offs determined by quantitative methylation-specific PCR in 
matched CRC, CAM and blood samples from 106 CRC patients. To assess “normal 
methylation” at these targets, we analyzed colorectal mucosa tissues (NM) from 31 healthy 
subjects. RESULTS: By integrating the results of these genome-wide analyses, we 
identified a number of potent targets that are specifically hypermethylated in an 
appreciable number of CRCs; e.g. FOXF1 was hypermethylated in 67% of cancers, CA4 in 
21%, NPY1R in 19%, IFITM1 in 15% and GREM1 in 13%. FOXF1 hypermethylation 
turned out to be a strong marker for right sided neoplasia with a sensitivity of 91% (29/32). 
A panel consisting of all five markers and the two tumor suppressor genes MGMT and 
hMLH1 specifically identified 82% of all (87/106) and 94% of right sided colorectal cancers 
(30/32). CONCLUSION: The combination of genome-wide analyses of gene expression 
and DNA methylation in strategically matched samples is a powerful approach to identify 
hypermethylation targets fulfilling specific criteria. In our case, this strategy led to the 
discovery of a panel of novel and potent markers of colorectal carcinogenesis.
Introduction
Epigenetic silencing of tumor suppressor genes contributes significantly to malignant 
transformation in colorectal cancer (CRC). Silencing occurs by aberrant DNA methylation 
in gene promoters. Proposed mechanisms by which gene silencing occurs include DNA 
methylation and histone protein modification. Together, these epigenetic modifications 
determine the chromatin state and the accessibility of gene promoters. Gene silencing by 
aberrant promoter methylation appears to occur early in colorectal carcinogenesis since 
adenomas already display a different DNA methylation profile compared to normal 
colorectal tissue. This observation makes DNA methylation a promising diagnostic tool for 
cancer.
3A2
Aim of this project
To identify novel diagnostic DNA 
methylation targets in colorectal 
cancer which
• are detectable early in 
colorectal carcinogenesis
• show methylation-dependent 
gene expression (functional 
relevance)
• are cancer-specifically 
hypermethylated
To this end, we integrated the 
results of three different genome-
wide analyses and validated the 
resulting candidate methylation 
markers with a newly established 
sensitive and quantitative 
methylation-specific PCR (qMSP) 
assay in 106 colorectal cancer 
patients and 31 healthy individuals.
Methods
Genome-wide analyses: 
Affymetrix Human Genome U133 
Plus 2.0: Raw gene expression 
data generated by GeneChip 
Operating Software (Affymetrix) 
were imported into ROCHE 
Affymetrix Chip Experiment Analysis 
(RACE-A) Software and normalized 
per chip (i.e., to the median of all 
values on a given array) and per 
gene (i.e., to the median expression 
level of the given gene across all 
samples). Probes were selected, 
which had expression values of > 
110 % in normal tissue in at least 30 
of 32 of the adenoma samples. 
Boxplot-Jitter plots of 2092 probes 
in 32 patients representing 1249 
unique genes, were computed using 
R software and Bioconductor.
60% of genes contain dense clusters of CpG-dinucleotids 
in their promoters (CpG island=CGI), which regulate  
transcription. In a normal cell, the CGIs of tumor  
suppressor genes are unmethylated allowing the 
transcription of the gene. In ageing cells the CGI becomes 
progressively methylated by unknown mechanisms. 
Exceeding a critical level of methylation the transcription of  
the tumor suppressor gene is irreversibly blocked.
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Illumina HumanWG-6 v3 Expression BeadChip: Illumina probe intensity data was 
processed by variance stabilization transformation (VST) using R/Bioconductor software 
(affy library), followed by quantile normalization. Significance of effects for probes was 
tested by in R/Bioconductor (limma library) using moderated t-test and the false discovery 
rate (fdr) method by the Benjamini and Hochberg for multiple testing correction. Probes 
were selected for significant change after 5'-Azacytidine/TSA treatment (p-value < 0.05) 
and a log factor change of > 0.3 to generate a list of 2758 probes with probability of false 
positives of less than 5% representing 2245 unique genes. Illumina 
HumanMethylation27 BeadChip: Sodium Bisulfite converted DNA was applied to a MIDI 
plate and analyzed by Infinium HumanMethylation27 bead chips (Illumina) allowing to 
survey genome-wide methylation including 27’578 CpG sites at single site resolution. Chip 
analysis was performed using background subtraction by Bead studio software (Illumina). 
Methylation status of every CpG site analyzed is expressed as relative level of methylation 
(β), and is calculated as the ratio of methylated-probe signal to total locus signal intensity 
in Beadstudio (Beta value). 1701 probes fulfilled the criteria of unmethylated in blood 
(beta-value < 0.25) and 
~10% higher methylation in 
cancer tissue compared to 
normal mucosa in both 
patients representing 1203 
unique genes.
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Drug treatment: The human microsatellite-instable CRC cell line SW48 was used for 
demethylating drug treatment with 5'-Aza-cytidine (DNA methyltransferase inhibitor) and/or 
Trichostatin A (Histone deacetylase inhibitor). After 24 h of culture the DMEM was replaced 
with medium containing 1 µM 5´-Aza-C or 0.5 µM TSA and incubated for five and two 
days, respectively. The medium was renewed every 24 h. For the double treatment, cells 
were initially treated with 5-Aza-cytidine followed by Trichostatin A treatment. The cells 
were harvested and the genomic DNA and total RNA were extracted with TRI REAGENT 
(Sigma).
Biological samples: Specimens from colorectal cancer patients and healthy subject were 
obtained from the Department of Surgery of the Kantonsspital Aarau, Switzerland. All 
patients gave their informed consent for the use of their tissue specimens for research 
purposes. Samples from 106 colorectal cancer patients were randomly collected on the 
occasion of the surgical therapy. From each patient two biopsies were taken, one from the 
primary tumor (CRC) and the other 7 cm proximal to the primary tumor from the adjacent 
macroscopically normal mucosa (= cancer-associated mucosa = CAM). Specimens from 
31 healthy individuals were randomly collected in the context of a colonoscopy screening 
program in the cantonal hospital of Uri, Switzerland. 
DNA extraction and bisulfite conversion: Genomic DNA from colorectal tissue as well 
as from human colorectal cancer cell lines was extracted with the QIAamp DNA mini kit 
(Qiagen). An RNAse A treatment was included in the protocol according to the 
manufacturer’s protocol. Genomic DNA from blood samples was extracted with the 
NucleoSpin Blood L Kit (Macherey-Nagel). For methy-lation analysis 2 µg of the extracted 
DNA was sodium bisulfite converted using the EZ DNA Methylation Kit (Zymo).
Locus-normalized quantitative me-thylation specific PCR (ln-qMSP):  A standardizer 
primer set in proximity to the studied CpG site was introduced in order to normalize for 
DNA input after bisulfite conversion and for the investigated locus, thereby excluding ploidy 
aberration bias. For methylation quantification standard curves were generated by real 
time amplification of serial 1:10 dilutions (from 100 to 0.1% = Dynamic range) of M.sssI 
methylase and sodium bisulfite treated blood DNA with methylation-specific-(M) and the 
standardizer (S)-primers. The tester DNA was amplified by two separate real-time PCR 
runs with the M- and the S-primer set. The percentage of methylated alleles (PMA) was 
calculated by the ratio between the values of the amplification with the M- and the S-primer 
set (see picture below).
Results
1. Experiment
Downregulated early in carcinogenesis
Affymetrix Human Genome U133 Plus 2.0: Transcriptome of 32 matched 
colorectal adenoma and normal mucosa tissues *
Criteria for targets:
Expression level < 91% of corresponding normal tissue in 
≥ 30 adenomas (corresponding to change factor < -0.1)
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2. Experiment
DNA methylation dependent gene expression
Scatterplot of the probes meeting the above criterium. 5'-Aza-C: 5'-Azacytidine; TSA: Trichostatin  
A; Fdr: false discovery rate.
Scatterplot of the probes of all 32 tissue pairs meeting the above criteria. * Sabates-Bellver, J. et  
al. (2007) Transcriptome profile of human colorectal adenomas. Mol Cancer Res, 5, 1263-1275.
Illumina HumanWG-6 v3 Expression BeadChip : Transcriptome of the SW48 
colorectal cancer cell line displaying wide-spread DNA methylation before and 
after demethylating 5'-Azacytidine and/or Trichostatin A treatment
Criteria for targets:
Higher expression after treatment (p value <0.05, Fdr adjusted, moderate t-test, and ‑
log factor change > 0.3)
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3. Experiment
Hypermethylated in the primary cancer
Integration of the three transcriptome and methylome experiments
Illumina HumanMethylation27 BeadChip: 
Methylome of the matched colorectal cancer tissue (CRC), cancer-associated 
mucosa (CAM) and blood (B) from two patients
Criteria for targets:
Beta-value * < 0.25 in blood and
Beta-value > 0.1 higher in CRC than in CAM and
 criteria must be fulfilled in both patients
VENN Diagram of the resulting candidate genes. Numbers indicate “unique” genes after  
converting probes to genes. 
Scatterplot of the probes meeting the above criteria. * Beta-value = Relative level of methylation 
(β), is calculated as the ratio of methylated-probe signal to total locus signal intensity (see 
methods).
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Seven marker panel is sensitive in early colorectal neoplasia
Resulting targets display low level methylation in normal colorectal tissue
Resulting targets are specifically hypermethylated in cancer
Cancer sensitivity (frequency) of panel and targets in tumors of different stages of the disease 
(AJCC/UICC). Early stage I tumors are hypermethylated at the following frequencies: Panel 82%,  
FOXF1 73%.  I: n=22; II: n = 24; III: n = 32; IV: n = 28. * p-value < 0.05 (Chi square-test).
Scatterplot of the 
ln-qMSP analyses 
of normal colorectal  
tissues from 31 
healthy subjects  
taken from the 
right- and the left  
colonic side.  
Average target-
specific tissue 
methylation ranges 
from 0.7 (FOXF1) 
to 2.8% (CA4).
Cancer sensitivity (coverage) of panel  
and targets. 106 colorectal cancer 
tissues were hypermethylated at the 
following frequencies: Panel 82%, 
FOXF1 67%, MGMT 36%. n=106 
cancer tissues.
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Seven marker panel covers 82% of colorectal cancers
Seven marker panel and FOXF1 are highly sensitive in right sided cancers
Conclusions
The combination of genome-wide analyses of gene expression and DNA methylation in 
strategically matched samples is a powerful approach to identify DNA hypermethylation 
targets. In our case, this strategy led to the discovery of a panel of novel and potent 
markers of colorectal carcinogenesis. A diagnostic panel consisting of the five markers 
FOXF1, CA4, NPY1R, GREM1, IFITM1 and the well-known methylation targets MGMT 
and hMLH1 specifically detected 82% of all and 94% of right-sided colorectal cancers. All 
of the five targets identified by this comprehensive genome-wide approach displayed a 
low-level methylation (0.7-2.8% of alleles) in normal colorectal tissue from healthy 
subjects. Thus, cancer-specific DNA methylation is determined by levels rather than 
presence or absence.
Cancer sensitivity (frequency) of panel and targets in right- (n=32) and left-sided (n=74) colorectal  
cancer tissues. Right-sided tumors were hypermethylated at the following frequencies: Panel 94%, 
FOXF1 91%. *p-value < 0.05 (Fisher's exact test).
ln-qMSP analyses of the colorectal cancer (CRC), cancer-associated mucosa tissue (CAM) and 
blood from 106 patients (n). The following cancer- and target-specific methylation cut-offs were  
defined at the 99% specificity level: FOXF1 4%, MGMT 5%, CA4 5%, NPY1R 5%, IFITM1 7%,  
GREM1 6.5%, hMLH1 6% (gray bar). Samples displaying methylation above these cut-offs were  
defined hypermethylated for the respective target.
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Abstract
The IFNα response gene IFITM3 has antiproliferative properties in a number of 
biological systems. In the human melanoma cell line D10 IFITM3 is constitutively 
expressed and we show that the core promoter is significantly hypomethylated compared 
to ME15 cells where IFITM3 is tightly controlled. We demonstrate that treatment of ME15 
cells with the demethylating agent 5’-aza-2’deoxycytidine (DAC) enhances IFITM3 
expression following IFNα treatment. In a time course experiment, we show that IFNα 
induces demethylation of specific CpG sites of the IFITM3 core promoter 6 hours after 
stimulation and promoter methylation is precisely re-set to the naïve state 24 hours after 
stimulation. This cyclable modification of methylation requires co-stimulation with TGFβ or 
expression of the calcium binding protein S100A2 which are known co-factors for 
enhancement of antiproliferative activity in ME15 cells. Thus, the transcriptional response 
to IFNα can be enhanced by promoter demethylation of a subset of inducible genes such 
as IFITM3. This epigenetic modulation might be crucial to augment the immune response 
under critical conditions in vivo.
Key words. Interferon signaling, cytokine inducible DNA demethylation, cell proliferation
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1. Introduction
Interferon was discovered 50 years ago as a host derived interference activity 
induced by heat inactivated viral particles (Isaacs and Lindenmann 1957). The advent of a 
novel technique termed “high performance liquid chromatography” enabled purification of 
interferon from virus infected leukocytes 20 years after its discovery (Rubinstein and 
others 1978). Cloning and recombinant expression of IFNα paved the way for the first 
protein based medicine (Maeda and others 1980). Since then, several additional 
interferons were discovered that are involved either in antiviral responses (type I) or play a 
role in immune defense (type II) (Stark and others 1998).
A hallmark of interferon type I activity is the induction of antiproliferative activity 
coupled to transcriptional activation of target genes. IFNα inducible genes are divided into 
primary and secondary response genes (PRG’s and SRG’s) according to their activation 
mode. PRG’s are induced early after cytokine stimulation and contain single or tandem 
interferon stimulated regulatory elements (ISRE’s) in the core promoter region whilst 
SRG’s lack such motifs and show delayed induction by an unknown mechanism. 
Microarray experiments have revealed, that IFNα resistance is associated with reduced  
but not defective transcriptional activity in human melanoma cell lines (Certa and others 
2003). The exact mechanism of resistance in clinical settings like hepatitis C virus 
infections is still unclear and dependent on host and pathogen factors (Gale and Foy 2005; 
Mbow and Sarisky 2004).
We have shown, that co-stimulation of human melanoma cell lines with IFNα and 
TGFβ results in significant enhancement of anti-proliferative activity. In the resistant cell 
line D10, restoration of antiproliferative activity is associated with cooperative up-regulation 
of 28 genes (Foser and others 2006). In particular the small calcium binding protein 
S100A2 and the insulin-like growth factor binding protein 3 (IGFBP3) are important for cell 
cycle control as shown in stably transfected cell lines and the molecular mechanism is 
unknown. In IFNα sensitive cells like ME15, expression of IFITM3, a gene with 
antiproliferative activity is tightly controlled, and further up-regulation by TGFβ or S100A2 
would provide a plausible explanation for increased antiproliferative activity. In D10 
melanoma cells IFITM3 is constitutively expressed and further upregulated by IFNα 
treatment. The IFITM3 core promoter sequence in D10 and ME15 cells is identical and it 
was proposed that epigenetic DNA hypomethylation might be related to loss of control 
(Brem and others 2003).
Several studies link DNA methylation and IFNα signaling, e.g. senescence can be 
induced in the immortalized Li-Fraumeni syndrome cells by treatment with the DNA 
demethylating and DNA methyltransferase (DNMT) inhibitory agent 5’-aza-2’deoxycytidine 
(DAC) and interestingly IFNα treatment induces a similar effect in these cells (Fridman and 
others 2007). In mice, suppression of endogenous IFNs enhances development of 
metastases (Reid and others 1981) and microarray studies with DAC treated immortalized 
human cells revealed deregulation of a significant number of  IFN pathway genes (Kulaeva 
and others 2003).
To study a possible role of DNA methylation as part of the promoter control system in 
IFNα signaling, we used ME15 and D10 cells and IFITM3 as model. We show that the 
methylation inhibiting agent 5- aza-2’-deoxycytidine (DAC) modifies IFITM3 expression 
levels in ME15 cells following IFNα stimulation whilst such a response is undetectable in 
D10 cells. In contrast to ME15 cells, the IFITM3 promoter is hypomethylated in D10 cells 
under naïve conditions. In a time course experiment we show that IFNα induces 
hypomethylation of the IFITM3 promoter in ME15 cells 6 hours after stimulation in the 
presence of the co-factors TGFβ or S100A2 and remarkably the system is re-set  to the 
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naïve state 24 hours after stimulation. Microarray based mRNA profiling shows that only a 
small number of IFNα response genes are up-regulated like IFITM3 by co-stimulation in 
ME15 cells and gene expression in D10 cells is apparently not affected.
2. Material and Methods
2.1. Cell lines
The primary human melanoma cell lines D10 and ME15 were kindly supplied by 
Prof. Giulio Spagnioli (University of Basel) and have been described elsewhere (Luscher 
and others 1994; Pansky and others 2000). The S100A2 transgenic cell lines D10-5 and 
ME15-3 have been described by Foser et. al. (Brem and others 2003; Foser and others 
2006; Luscher and others 1994; Pansky and others 2000). 
2.2. Antibodies, cytokines and reagents
Antibody against IFITM3 (1-8U) has been described previously (Brem and others 2003). 
IFNα (IFNα2a, Roferon®-A) and its monopegylated isomer K134 (IFNαK134 (Foser and 
others 2006)) were provided by F. Hoffmann-La Roche Ltd. (Basel, Switzerland). TGFβ 
was purchased from Calobiochem (Germany) and 5- aza-2’-deoxycytidine (DAC) from 
Sigma (Basel, Switzerland).
2.3. Cell culture
All cell lines were cultured at 37°C in a 5% CO2 atmosphere in RPMI 1640 medium 
(GIBCO Life Sciences, Paisley, U.K.) supplemented with 10% fetal bovine serum (FBS), L-
glutamine (2 mM), sodium pyruvate (1 mM), nonessential amino acids, antibiotics, and 10 
mM HEPES buffer (Certa and others 2003).
2.4. Cell treatments
For genome wide demethylation the cell lines were treated with 5- aza-2’-
deoxycytidine (DAC) (2 µg/ml) or a control along with IFNα (1000 U/ml), TGFβ (1 ng/ml) or 
a combination of both cytokines with incubation times depicted in the figures 1 and 2. For 
the IFITM3 promoter methylation analysis D10, ME15, D10-5 and ME15-3 cells were 
stimulated with IFNα (1000 U/ml), TGFβ (2 ng/ml) or a combination of both cytokines with 
incubation times depicted in the figures 1 and 2. For oligonucleotide array analysis D10, 
ME15, D10-5 and ME15-3 melanoma cell lines were grown in triplicate cultures for 2 days 
stimulated with either IFNαK134 (1000 U/ml), TGFβ (2 ng/ml) or a combination of both 
cytokines (Fig. 3). 
2.5. Oligonucleotide array analysis
Total RNA was isolated, processed and hybridized to Affymetrix U95Av2 human 
microarrays according to the manufacturer’s instructions (for details see (Foser and others 
2006)). After intensities were recorded by laser scanning normalized data was analyzed for 
differential expression using RACE-A software as described (Certa and others 2003). 
Genes with a standard deviation smaller than the absolute change in signal intensity as 
well as a signal intensity of a minimum of 50 RFUs were considered only with the absolute 
change factor (CHF) threshold set to 2 (Certa and others 2003). Expression data from 
untreated cells (D10, ME15, D10-5 and ME15-3) were used as baseline to calculate the 
change factor values. The raw data are available on request.
2.6. Immunoblotting
Total calibrated protein extracts, were separated by SDS PAGE and electroblotted 
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onto nitrocellulose membranes, which were blocked in commercial blocking buffer. 
Proteins were detected using 1st antibodies against IFITM3 at a dilution of 1:2000 and a 
horse-radish-peroxidase (HRP)-conjugated 2nd  antibody diluted 1:5000 for detection with a 
chemiluminescent substrate (BCA Assay; SuperBlock® Blocking Buffer; SuperSignal West 
Pico Chemiluminescent; Pierce Chemical Co., Thermo Fisher Scientific Inc., Rockford, IL, 
USA; XCell SureLock™ System; Invitrogen, Basel, Switzerland).
2.7. DNA wide demethylation by 5- aza-2’-deoxycytidine (DAC) treatment
Approximately 10’000 ME15 cells and 20’000 D10, D10-5 and ME15-3 cells were 
seeded in 6-well plates. Cells were grown for three days following stimulation with TGFβ (1 
ng/ml), IFNα (1000 U/ml) or a combination of both cytokines, in the presence or absence 
of DAC (2 µg/ml). After 6,12, 24 and 51 hours cells were washed twice with PBS, 
resuspended in standard lysis buffer and the whole protein extract was thereafter used for 
immunoblot analysis (Fig. 1A and 2A). 
2.8. Promoter methylation analysis
D10, ME15 and ME15-3 melanoma cell lines were treated with IFNα (1000 U/ml) for 
1, 6 and 24 hours. Cells were also pretreated with TGFβ (2 ng/ml) for 2 days. Isolated 
genomic DNA was bisulfite treated using the Zymo EZ DNA Methylation™ Kit (Orange, 
CA, USA) according to the manufactures protocol with 2µg of DNA input. The bottom 
strand of the IFITM3 promoter was amplified to yield an 820 bp fragment using bisulfite 
adjusted primers designed to cover 19 CpG sites adjacent to the translation initiation site 
(ATG). Note that ME15 cells have a SNP at site 422, therefore the analysis for the ME15 
and ME15-3 cell lines covers 18 CpG sites. (forward primer (Chromosome 11: 311612) 5’-
ATA ATC CAA CTA CCT AAA CAC CATA and backward primer (Chromosome 11: 310821) 
5’- AT TTG TGG TAG TTA GTG TGA TAG GTT TGG) with the PCR program consisting of 
following parameters: initial incubation time of 10 minutes at 95°C, 40 cycles with 1 minute 
at 94°C, 1 minute at 58°C and 1 minute at 72°C and an additional 10 minutes at 72°C for 
final elongation. Amplified fragments were cloned into the pCR®2.1-TOPO® vector 
(Invitrogen, Basel, Switzerland) and transformed into XL1-blue (Stratagene, La Jolla, CA, 
USA) or TOP10 (Invitrogen, Basel, Switzerland) competent cells and plated on IPTG/ X-gal 
containing agar plates. Plasmids from white colonies were isolated and sequenced using 
an ABI 3730xl DNA analyzer instrument and generic vector based primers using standard 
procedures. Following computer assisted alignment with the clustalw GCG-program the 
methylation state of CpG sites was determined.
3. Results
3.1. Methylation state of the IFITM3 core promoter in D10 and ME15 cells
The interferon inducible transmembrane protein IFITM3 has antiproliferative activity 
in several biological system (Siegrist and others 2010). We have previously shown that the 
IFNα-resistant human melanoma cell line D10 expresses IFITM3 in the absence of IFNα 
stimulation whilst expression is tightly controlled in the responder line ME15. The IFITM3 
core promoter sequences are identical in D10 and ME15 cells which led to the proposal 
that hypomethylation of the IFITM3 core promoter in D10 cells accounts for loss of 
interferon control (Brem and others 2003). Microarray studies with DAC treated cells show 
enhanced expression of several IFNα target genes suggesting that promoter methylation 
occurs in IFNα response genes (Kulaeva and others 2003). Resistance to interferon in 
renal carcinoma as well as melanoma cells can be overcome either by DAC therapy or by 
knock-down of the DNA methylase DNMT1 using antisense transfection (Reu and others 
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2006).
To analyze the methylation status of the IFITM3 promoter, we compared the 
induction of the IFITM3 protein in D10 and ME15 cells by IFNα or TGFβ or the 
combination of both in the presence or absence of the cytosine analog DAC as a generic 
DNA methylation inhibitor. Following treatment, cell lysates were analyzed by 
immunoblotting using polyclonal rabbit serum against IFITM3 as probe (Brem and others 
2003). In D10 cells, neither DAC treatment nor incubation with TGFβ had a significant 
effect on IFITM3 expression but IFNα treatment upregulated the expression level as 
expected (Fig. 1A). In ME15 cells, DAC treatment extended the IFITM3 expression period 
to at least 51 hours and even unstimulated cells express low levels of IFITM3 at this time 
point (Fig. 1A; indicated by the asterix). Co-stimulation with TGFβ results in earlier onset of 
IFITM3 expression independent of DAC co-treatment (Fig. 1A). The insensitivity of the 
IFITM3 promoter to DAC treatment in D10 cells supports the proposal, that constitutive 
expression of IFITM3 in this cell line is indeed due to hypomethylation of the core 
promoter. Along the same lines, the increase of IFITM3 expression in the presence of DAC 
in ME15 cells suggests core promoter methylation in ME15 under naïve conditions. This 
model is strongly supported by bisulfite sequencing analysis of the IFITM3 core promoter 
in untreated ME15 and D10 cells (Frommer and others 1992). Genomic DNA was 
extracted from bisulfite treated cells and the core promoter was amplified by PCR followed 
by subcloning and sequencing of individual clones. Consistent with our model, the IFITM3 
core promoter is clearly hypomethylated in D10 cells compared to ME15 cells in the native 
state in particular at residues close to the ATG codon (Fig. 1B). The fully hypomethylated 
CpG residue 107 next to the ISRE site is part of a consensus binding motif for the generic 
transcription factor Sp1 which allows IFNα independent transcription. To conclude, the 
data above strongly support the view that native hypomethylation of the IFITM3 promoter 
in D10 cells causes leakiness and constitutive expression. In ME15 cells, DAC treatment 
results in an increase of IFITM3 protein expression consistent with the demethylation of 
key residues.
3.2. Cyclable methylation of the IFITM3 core promoter in ME15 and ME15-3 cells
We next address the question, whether modulation of the IFITM3 core promoter 
methylation occurs in vivo in response to IFNα. It is expected that IFITM3 levels above the 
IFNα inducible threshold would further enhance the antiproliferative activity in ME15 cells 
which has been shown following co-stimulation with TGFβ (Foser and others 2006). 
Presuming a methylation based mechanism of IFITM3 up-regulation, we would expect that 
modification of the IFITM3 core promoter requires TGFβ stimulation as co-factor. ME15 
cells were stimulated for 1, 6 and 24 hours with IFNα either with or without TGFβ co-
stimulation. Following DNA extraction and bisulfite treatment the PCR amplicons were 
subcloned and the methylation status of individual clones was assessed by DNA 
sequencing with untreated cells as reference for the naive state (Fig. 2; top panel). The 
methylation pattern of the core promoter in the absence of TGFβ remains virtually stable. 
We noted minor demethylation of the IFITM3 core promoter at four CpG sites (392, 418, 
425 and 427; Fig. 2). When TGFβ is present, significant hypomethylation across all CpG 
sites occurs specifically at the 6 hour time point which coincides with protein expression 
upon co-stimulation with both cytokines (Fig. 1A). After 24 hours the promoter is precisely 
set-back to the native state. 
Interestingly enough, Foser and others (Foser and others 2006) have shown that 
stable expression of the TGFβ inducible calcium binding protein S100A2 is sufficient to 
enhance the antiproliferative activity of IFNα in ME15 cells. We stimulated the S100A2 
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stably transfected cell line ME15-3 with IFNα in the presence or absence of TGFβ in a time 
course experiment as above and determined the methylation state of the IFITM3 core-
promoter. S100A2 as co-factor was indeed sufficient to induce cyclable changes in DNA 
methylation in response to IFNα in the absence of TGFβ with a very similar kinetic. 
Interestingly, the activity of TGFβ on promoter methylation at the 6 hour time point was 
suppressed presumably by S100A2 expression in ME15-3 cells. Treatment of D10 cells 
with DAC had no impact on the protein levels of IFITM3 (Fig. 1A) and we anticipated that 
IFNα stimulation would not affect the methylation pattern. We incubated D10 cells under 
the same conditions as above and examined the methylation pattern at each time point by 
sequencing (Fig. 2). In contrast to ME15 cells, we did not find any significant alterations in 
the methylation pattern of the IFITM3 promoter in D10 cells upon cytokine stimulation and 
the core promoter is not re-methylated after 24 hours in culture either. We conclude that 
IFNα can induce cyclable methylation of a target gene promoter.
3.3. Transcriptional responses to IFNα in the presence of S100A2
Having shown reversible demethylation of the IFITM3 promoter, we asked whether 
additional IFNα response genes are upregulated in ME15 cells expressing the co-factor 
S100A2 (ME15-3; (Foser and others 2006)). ME15 and ME15-3 cells were treated with 
pegylated IFNα (K134), TGFβ and the combination of both cytokines for 2 days followed 
by transcript profiling using Affymetrix U95Av2 microarrays. Untreated sample data were 
used to calculate treatment induced changes in gene expression (Fig. 3). This analysis 
revealed two clusters of IFNα response genes. Cluster 1 (CL1) contains genes with 
unaltered expression in ME15 and ME15-3 cells while genes in cluster 2 (CL2) are further 
upregulated beyond maximal IFNα inducible levels in ME15-3 cells including IFITM3 as 
expected. For clarity, the names and the calculated change factors for these genes are 
summarized in table 1 and the majority of these genes are bona fide IFNα response 
genes. As control, we also profiled D10 cells and a S100A2 overexpressing clone of this 
line (D10-5; (Foser and others 2006)) under the same experimental conditions. In contrast 
to ME15-3 we were not able to identify genes showing significant up-regulation in D10-5 
(data not shown). We conclude that overexpression of the methylation co-factor S100A2 
affects only a subset of interferon inducible genes suggesting functional significance.
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4. Discussion
We have shown that expression of the IFNα inducible gene IFITM3 is controlled by 
DNA methylation of key residues in the core promoter. Constitutive expression of IFITM3 in 
D10 cells is most likely associated with extensive hypo-methylation of CpG sites close to 
the transcriptional start site (Fig. 1B). Interestingly this region contains a consensus 
binding motif for the transcription factor Sp1 which binds to promoter regions given their 
binding sites are demethylated (Zhu and others 2003). The insulin-like growth factor 
binding protein 3 (IGFBP3) for example inhibits the growth of non-small-cell lung cancer 
(NSCLC) cells by inducing apoptosis and expression is frequently abolished in cancers. It 
was shown, that IGFBP3 expression is controlled by CpG site methylation which inhibits 
binding of the transcription factor Sp1 (Chang and others 2004). Additional binding of the 
methyl CpG binding protein 2 (MeCP2) to the core promoter further suppresses Sp1 
mediated transcription (Kudo 1998). Liu et al. showed that the Sp1 site in the IFITM3 core 
promoter region (Fig. 1B and 2, 5’ CpG position # 107) is functional because removal by 
mutagenesis diminishes IFITM3 expression to about 50% (Liu and others 2002). Thus, the 
hypomethylation of CpG residue 107 in D10 cells apparently enables binding of Sp1 to the 
target sequence which provides a plausible explanation for constitutive IFITM3 expression 
in this cell line. We show in figure 1A that treatment of ME15 cells with the demethylating 
agent DAC augments IFITM3 expression following IFNα stimulation. We show by bisulfite 
sequencing that IFNα induces hypomethylation of the IFITM3 core promoter in the 
presence of TGFβ stimulation or expression of S100A2 as co-factor. This includes the Sp1 
CpG site which is now accessible for Sp1 binding resulting in upregulation of IFITM3 
transcription. 24 hours after stimulation the promoter is silenced and the methylation 
pattern is precisely reset to the naive state. 
Mechanisms of dynamic, inducible CpG methylation have been shown previously. 
The trefoil factor 1 (TFF1) is a protein that is known to be under estrogen control and its 
promoter undergoes cyclical demethylation upon estrogen stimulation by recruitment of the 
de novo DNA methyltransferase 3a and 3b (DNMT3a and DNMT3b), thymine DNA 
glycosylase (TDG) and base excision repair (BER) proteins in a cell cycle independent 
manner (Kangaspeska and others 2008; Metivier and others 2008). The promoter of the 
inflammatory cytokine IL2 undergoes demethylation upon  stimulation with PMA (phorbol 
12-myristate 13-acetate) (Murayama and others 2006). The mechanism in this case 
involves intracellular calcium release, which results in translocation of the T-cell 
transcription factor NFAT from the cytoplasm to the nucleus and binding to the IL2 core 
promoter where a single CpG site of the promoter is hypomethylated. This  leads to 
transition of the “naive state” to the “active state” and facilitates transcription by OCT1 1 
hour after PMA stimulation. In contrast to IL2, the IFITM3 is inducible even in the presence 
of DNA methylation suggesting an open, accessible configuration of the ISRE for ISGF3 
binding. It is interesting to note that evidence is arising that DNA repair enzymes as well as 
glycosylases might function as active demethylating agents in mammals as suggested for 
the GADD45 protein which is induced in our experimental system following IFNα and 
TGFβ stimulation (Foser and others 2006; Ma and others 2009a; Schmitz and others 
2009).
We have shown previously, that IFNα induces significant and fast intracellular 
calcium release (Foser and others 2006). In neuronal cells it has been shown, that 
GADD45β promoted calcium sensitive demethylation of specific genes like BDNF or FGF 
(Ma and others 2009b). Interestingly, GADD45β is induced in hepatocellular carcinoma 
cells through promoter hypomethylation following growth arrest which resembles the state 
of our experimental system (Qiu and others 2004). Thus, it is possible that calcium 
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activated GADFD45β is involved in the demethylation of the IFITM3 core promoter. After 
24 hours, the IFNα signaling has ceased and normal growth conditions may lead to faithful 
DNA methylation of the target CpG sites in the IFITM3 core promoter. This model can now 
be validated experimentally by siRNA knock-down of GADFD45β in IFNα induced ME15-3 
cells. Further, resistance to IFNα in renal carcinoma as well as melanoma cells can be 
overcome either by DAC treatment or DNA methyltransferase (DNMT1) depletion by 
transfection of antisense oligonucleotides (Reu and others 2006). IFNα resistant HCV 
replicon harboring cells become sensitive to IFNα upon treatment with DAC (Naka and 
others 2006). Thus, modification of IFNα target gene expression through promoter 
methylation might be a natural mechanism to adapt the responses to pathogen challenge. 
The analysis of additional cell lines, target genes and model organisms is now granted for 
validation of cyclable IFNα mediated promoter methylation as an additional layer of gene 
expression control. 
We have shown by microarray profiling of cytokine treated ME15 and ME15-3 cells, 
that only a small subset of bona fide IFNα inducible genes are further induced in ME15-3 
cells (Fig. 3, cluster 2; table 1). Genes of the IFITM-family for instance control cell 
proliferation (for review see (Siegrist and others 2010)) and oligoadenylate synthase 1 and 
2 are associated with antiviral responses (Table 1). Thus, further upregulation of such 
genes under critical conditions would augment the potency of IFNα defense responses. At 
this point we can only speculate whether upregulation of genes is related to promoter 
hypomethylation as shown for IFITM3. Expression of genes in cluster 1 is  unaffected by 
TGFβ or S100A2 as co-factors and they show no obvious functional relation to host 
defense. 
The functional significance of TGFβ signaling and S100A2 as co-factors for cyclable 
DNA methylation is unknown. We have previously shown that S100A2 and TGFβ signaling 
have marked impact on the proliferation of ME15 cells and the microarray analysis showed 
indeed overexpression of genes with antiproliferative properties such as IFITM3. The 
catalytic function of S100A2 and of the majority of calcium binding protein family members 
is unknown (Eckert and others 2004). In addition, S100A2 is located in the cytoplasm of 
ME15 cells, which eliminates to a large extent a direct role in transcription (R. Scott; 
unpublished data).  
In conclusion, dynamic promoter methylation adds an additional layer of complexity 
to the IFNα signaling pathways and tight control of IFNα key response genes like IFITM3 
might be required for comprehensive control of the IFNα response.
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Figure legends
FIG. 1. IFNα-induced dynamic and reversible methylation of the IFITM3 core promoter.
Impact of DAC (5’-aza-2’-deoxycytidine) treatment on the expression of IFITM3 in D10 and 
ME15 cell lines (A) treated with cytokines for 6, 12, 24 or 51 hours as indicated in the 
presence (DAC +) or absence (DAC -) of DAC. Detection of IFITM3 protein in DAC treated 
D10 and ME15 cells by immunoblotting. Cell lysates were electroblotted for each condition 
and probed with anti-IFITM3. D10 cells are not affected by DAC treatment. DAC treatment 
affects the IFITM3 levels in ME15 cells and low-level expression occurs 51 hours after 
DAC treatment without IFNα stimulation in ME15 (highlighted by a white asterisk in the left 
data panel). 
IFITM3 core promoter methylation analysis (B). Total genomic DNA from D10 and ME15 
cells was isolated, bisulfite treated and the IFITM3 core promoter was amplified using a 
bisulfite converted DNA adapted PCR protocol (for details see materials and methods). 
The amplicons were subcloned and sequenced from both ends using vector born primers. 
The number of clones sequenced per time point and treatment conditions is indicated on 
the right to the methylation status of individual CpG sites displayed as boxes. White filling 
indicates bisulfite conversion of individual CpG sites in at least nine out of ten clones (0-
10% methylation). Grey indicates conversion of single CpG sites in two to eight per ten 
sequence reads(11-89% methylation) and black indicates conversion in one out of ten 
sequence reads (90-100% methylation). The nucleotide positions of the CpG sites 
upstream of the ATG start codon are indicated and the position of the ISRE consensus 
binding site as well as the Sp1 binding site is depicted. The CpG site 422 is a known SNP 
which is altered in our cell line ME15 (C T), therefore eliminating one methylation site 
from our investigation resulting in 18 CpG sites.
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FIG. 2. IFNα-induced dynamic and reversible methylation of the IFITM3 core promoter. 
D10, ME15 and ME15-3 cells were cultured in the absence or presence of TGFβ. All cell 
lines were analyzed 0, 1, 6 and 24 hours after IFNα stimulus. Total genomic DNA from 
each culture was isolated, bisulfite treated and the IFITM3 core promoter was amplified 
using a bisulfite converted DNA adapted PCR protocol (for details see materials and 
methods). The amplicons were subcloned and sequenced from both ends using vector 
born primers. The number of clones sequenced per time point and treatment conditions is 
indicated on the right to the methylation status of individual CpG sites displayed as boxes. 
White filling indicates bisulfite conversion of individual CpG sites in at least nine out of ten 
clones (0-10% methylation). Grey indicates conversion of single CpG sites in two to eight 
per ten sequence reads(11-89% methylation) and black indicates conversion in one out of 
ten sequence reads (90-100% methylation). The nucleotide positions of the CpG sites 
upstream of the ATG start codon are indicated and the position of the ISRE consensus 
binding site as well as the Sp1 binding site is depicted.
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FIG. 3. S100A2 modulates expression efficiency of IFNα-inducible genes in ME15 cells. 
S100A2 modulates the transcription of selected IFNα target genes in ME15 cells (A). 
ME15 wt and ME15 recombinant S100A2 (ME15-3) cell cultures were treated with 
IFNαK134, TGFβ or both cytokines for two days followed by RNA extraction and processing 
of the samples for microarray analysis and data processing. Downregulated genes are 
shown in blue and induced genes in red and maximum color intensity corresponds to a 2- 
fold change (CHF). IFNα-inducible genes with a common S100A2-dependent expression 
mode after IFNα induction in ME15 cells are boxed (cluster 2, CL2) and IFNα-inducible 
genes with no apparent S100A2 dependency appear in cluster 1 (CL1).
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Table 1. Change factors of genes in clusters 1 and 2 (Fig. 3)
DESCRIPTION SYMBOL
CHGF ME15
wt
CHGF ME15-3 
S100A2
cluster 1
beta-2-microglobulin B2M 3.3 2.94
interferon-induced protein 35 IFI35 1.83 1.98
beta-2-microglobulin B2M 2.93 2.51
beta-2-microglobulin B2M 2.38 2.1
signal transducer and activator of transcription 1, 91kda STAT1 3.72 3.07
signal transducer and activator of transcription 1, 91kda STAT1 4.28 3.1
interferon-induced protein with tetratricopeptide repeats 1 IFIT1 11.78 6.35
signal transducer and activator of transcription 1, 91kda STAT1 16.79 11.77
interferon-induced protein with tetratricopeptide repeats 1 IFIT1 8.59 5.27
ubiquitin-conjugating enzyme e2l 6 UBE2L6 7.78 4.42
lectin, galactoside-binding, soluble, 3 binding protein LGALS3 1.4 1.71
major histocompatibility complex, class i, f HLA-F 1.55 1.4
major histocompatibility complex, class i, f HLA-F 2.96 2.57
major histocompatibility complex, class i, b HLA-B 3.35 4.37
isg15 ubiquitin-like modifier ISG15 14.84 14.17
interferon, alpha-inducible protein 6 IFI6 9.09 13.12
isg15 ubiquitin-like modifier ISG15 18.43 22.7
cluster 2
small proline-rich protein 2d SPRR2D 0.5 1.37
dehydrogenase/reductase (sdr family) member 2 DHRS2 0.64 6.22
interferon-induced protein 44-like IFI44L 5.89 8.86
interferon induced transmembrane protein 3 (1-8u) IFITM3 1.6 6.52
interferon induced transmembrane protein 1 (9-27) IFITM1 9.73 27.19
proteasome (prosome, macropain) subunit, beta type, 9 PSMB9 1.97 2.46
interferon induced transmembrane protein 1 (9-27) IFITM1 3.62 19.79
interferon-induced protein 35 IFI35 1.43 2.69
interferon-stimulated transcription factor 3, gamma 48kda IRF9 1.71 4.07
2`,5`-oligoadenylate synthetase 1, 40/46kda OAS1 5.75 13.62
2`-5`-oligoadenylate synthetase 2, 69/71kda OAS2 1.42 2.19
bone marrow stromal cell antigen 2 BST2 41.07 62.6
interferon, alpha-inducible protein 27 IFI27 65.94 111.36
Table 1. The calculated change factors for the interferon-induced genes in clusters 1 and 2 
of figure 3 are shown together with the annotation and the official gene symbol. Change 
factors (CHF) were calculated as described in material and methodIntegrating 
transcriptome and epigenome analyses to identify DNA methylation changes associated 
with colorectal carcinogenesiss (section 2.5). ME15 wt refers to native cells and ME15-3 
are cells stably transfected with S100A2 cDNA.
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Maintaining Epigenetic Stability
Daniel Cortázar1*, Christophe Kunz1*, Jim Selfridge2, Teresa Lettieri3#**, Yusuke Saito1**, 
Eilidh MacDougall2, Annika Wirz1, David Schuermann1, Angelika Jacobs1, Fredy Siegrist4, 
Roland Steinacher1##, Josef Jiricny3, Adrian Bird2 & Primo Schär1§
1 Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel,  
Basel, Switzerland; 2 The Wellcome Trust Centre for Cell Biology, University of Edinburgh,  
Edinburgh, United Kingdom; 3 Institute of Molecular Cancer Research, University of  
Zürich, Zürich, Switzerland; 4 Pharmaceutical Research, Global Preclinical Safety, F.  
Hoffmann-La Roche Ltd., Basel, Switzerland
*,** These authors contributed equally to this work
§ Corresponding author: Primo Schär, Institute of Biochemistry and Genetics, Department of Biomedicine, 
University of Basel, Mattenstrasse 28, CH-4058 Basel, Switzerland. Phone: +41 61 267 0767; Fax: +41 61 
267 3666; Mail: primo.schaer@unibas.ch
# Present address: European Commission, Joint Research Centre, Institute for Environment and 
Sustainability, Ispra, Italy
## Present address: Department of Biochemistry, University of Oxford, United Kingdom
TDG is a member of the uracil DNA glycosylase superfamily of DNA repair enzymes. 
Owing to its ability to excise thymine when mispaired with guanine, it was proposed to act 
against the mutability of 5-methylcytosine (5-mC) deamination in mammalian DNA 1. 
However, TDG was also found to interact with transcription factors 2,3, histone 
actetyltransferases 4, and de novo DNA methyltransferases 5,6, and it has been associated 
with DNA demethylation in gene promoters following activation of transcription 7–9, 
altogether implicating an engagement in gene regulation rather than DNA repair. We 
pursued a mouse genetic approach to determine the biological function of this multifaceted 
DNA repair enzyme. We found that, unlike other DNA glycosylases, TDG is essential for 
embryonic development, and that this phenotype is associated with epigenetic aberrations 
affecting the expression of developmental genes. Fibroblasts derived from Tgd null 
embryos (MEFs) show impaired gene regulation, coincident with imbalanced histone 
modification and CpG methylation at promoters of affected genes. TDG associates with 
the promoters of such genes both in fibroblasts and in embryonic stem cells, but 
epigenetic aberrations only appear upon cell lineage commitment. We show that TDG 
contributes to the maintenance of active and bivalent chromatin throughout cell 
differentiation, facilitating a proper assembly of chromatin-modifying complexes and 
initiating base excision repair to counter aberrant de novo methylation. We thus conclude 
that TDG-dependent DNA repair has evolved to provide epigenetic stability in lineage 
committed cells.
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TDG is one of four enzymes with uracil DNA glycosylase (UDG) activity in 
mammalian cells, but its biological function has remained enigmatic 10. We thus set out to 
generate and phenotypically investigate a Tdg knockout mouse (Supplementary Fig. 1a-c). 
ESC clones carrying the targeted allele gave rise to healthy heterozygous Tdg knockout 
mice but attempts to generate homozygous null mutants failed, indicating that TDG-
deficiency may cause embryonic lethality. This was unexpected, given the generally mild 
phenotype of other DNA glycosylase knockouts 11. In timed matings, Tdg null embryos 
isolated up to day E10.5 appeared alive and normal, whereas those isolated at E12.5 were 
dead, and none were detectable at E16.5 (Fig. 1a, Supplementary Fig. 1d). Tdg null 
embryos at E10.5 produced viable fibroblasts (MEFs) but only a third of E11.5 embryos did 
so, suggesting that by this stage the majority of them was dead. We thus concluded that 
lethality in Tdg null embryos occurs around E11.5. With regard to the actual cause of 
lethality, closer examination of the Tdg null embryos at E10.5 indicated internal 
haemorrhage, and evidence for haemorrhagic necrosis (data not shown), but did not 
reveal an informative pathology otherwise.
We then explored the essential function of TDG in MEFs and ESCs, first addressing 
a potential DNA repair defect by classical genotoxicity and mutator analyses. The TDG 
status did not affect cell survival following ionizing radiation or H2O2 exposure, both of 
which induce DNA base lesions processed by TDG in vitro 10, nor did it affect mutation 
frequencies in a Big Blue® transgenic mutation assay (Supplementary Fig. 2). We 
therefore concluded that the role of TDG in the repair of canonical base damage is minor 
and therefore unlikely to account for its essential function in mouse embryogenesis.
We next investigated a possible involvement of TDG in gene regulation by 
expression profiling of TDG proficient and deficient MEFs. To limit potential clonal biases, 
we compared the transcriptomes of early passages of litter-matched populations of SV40 
immortalized MEFs. This identified 461 differentially transcribed genes (p≤0.05, FC≥1.5, 
Fig. 1b), comprising many transcription factors and, thus, likely reflecting both direct and 
indirect consequences of TDG loss. Global pathway analyses revealed gene networks 
associated with embryogenesis and development as being most significantly misregulated 
in the absence of TDG (Supplementary Fig. 3a). Four out of six target genes analyzed 
showed TDG-dependent differential expression also in independently isolated primary 
MEF (Supplementary Fig. 3b).
Considering its putative involvement in DNA demethylation 7–9, we next investigated a 
possible occurrence of aberrant promoter methylation in TDG deficient cells. We examined 
the CpG islands (CGIs) in the promoters of Hoxa10, Hoxd13, Sfrp2, Twist2, and Rarb, all 
of which were downregulated in TDG deficient MEFs (Fig. 1b, Supplementary Fig. 3a). 
These genes are developmentally regulated by the polycomb repressive system 12 and 
their promoter CGIs are unmethylated in most normal tissues but subject to aberrant de 
novo methylated in human cancers 13,14. Na-bisulfite sequencing of the respective CGIs 
revealed an increased occurrence of de novo methylation in the TDG deficient MEFs (Fig. 
1c, Supplementary Fig. 4, 5a). The patterns and frequency of these methylation events 
indicated that the loss of TDG generates hotspots of de novo methylation in certain gene 
promoters. We then used chromatin-immunoprecipitation (ChIP) to examine a possible 
association of TDG with the promoters of these and additional differentially expressed 
genes. Compared to a randomly chosen intergenic sequence or the silent promoters of 
Oct4 and Tuba3, DNA fragments surrounding the promoters of all genes examined were 
significantly enriched in the TDG-precipitates (Fig. 1d). This indicated that TDG is targeted 
to specific gene promoters, possibly to protect them from acquiring aberrant CpG 
methylation and eventual epigenetic silencing. Consistently, further examination of the 
chromatin status revealed a general loss of activating (H3K4me2) and a concomitant 
increase of repressive histone marks (H3K27me3, H3K9me3) in TDG deficient cells with 
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promoter-specific scenarios (Fig. 1e): A complete loss of H3K4 dimethylation was 
accompanied by a strong increase of H3K27 and/or H3K9 trimethylation at the Hoxd13 
and Hoxa10 promoters; a partial reduction of H3K4me2 coincided with an enrichment of 
H3K27me3 but not H3K9me3 at the Sfrp2 and Twist2 promoters; and reduction of 
H3K4me2 was coupled with an increase in H3K9me3 but not H3K27me3 at the Rarb 
promoter. Thus, promoter de novo methylation in TDG deficient cells is associated with a 
loss of H3K4 dimethylation and a concomitant increase in trimethylation of H3K27 more 
than H3K9.
Stable expression of a Tdg encoding cDNA in Tdg-/- MEFs (Supplementary Fig. 1f) 
restored activity to the Sfrp2 and Twist2 genes (Fig. 2a). This correlated with a loss of 
H3K27 trimethylation in their promoters and an increase in H3K4 dimethylation in the case 
of Twist2 (Fig. 3b). Expression of Hoxd13 and Hoxa10, however, was not restored 
although a partial reduction of H3K27 trimethylation also occurred. This indicated that, 
once H3K4 methylation is lost (Hoxd13, Hoxa10), the repressive chromatin maintained by 
H3K9 and H3K27 methylation and aberrant CpG methylation cannot be reversed to an 
active state by re-expression of Tdg. If residual H3K4 methylation is present, however, 
promoter reactivation is possible, and this requires the catalytic function of TDG 15 as 
shown for Sfrp2 and Twist2 (Fig. 2a).
To address the origin of the epigenetic aberrations in Tdg null MEFs, we investigated 
gene expression and chromatin states in TDG proficient and deficient ESCs before and 
after retinoic acid (RA) induced in vitro differentiation to neuronal progenitor cells (NPs) 16 
(Supplementary Fig. 6a). Strikingly, gene expression differences were minor in ESCs (16 
genes, p ≤ 0.05, FC ≥ 1.5) but increased significantly upon differentiation to NPs (297 
genes, p ≤ 0.05, FC ≥ 1.5) (Fig. 3a). This was not due to an inability of TDG deficient 
ESCs to transcriptionally respond to RA (Supplementary Fig. 6b), although they showed 
somewhat faster kinetics of silencing pluripotency genes (Oct4, Nanog) and activating 
developmental genes (e.g. Gata6, Pax6) (Supplementary Fig. 6c). Similar to the situation 
in MEFs, the genes most significantly misregulated in TDG deficient NPs control 
developmental functions, most of them having CGIs in their promoters and being targets of 
the polycomb repressive system (Supplementary Fig. 7a). Using ChIP, we confirmed an 
enrichment of TDG at the promoters of differentially expressed genes both in ESCs and in 
NPs (Fig. 3b). This also revealed that TDG associates with the promoters of Oct4 and 
Nanog in ESCs but not in NPs and MEFs (Fig. 3b, Supplementary Fig. 6d), suggesting 
that its interaction is lost upon heterochromatinization of these promoters. Notably, the 
inability to associate with heterochromatized promoters may explain why re-expression of 
TDG in Tdg null MEFs failed to restore Hoxd13 and Hoxa10 transcription (Fig. 2).
Next, we examined the status of CpG methylation in gene promoters down-regulated 
in TDG deficient NPs, making use of Na-bisulfite (pyro)sequencing and methylated DNA-
immunoprecipitation (MeDIP). While MeDIP only detected trends for methylation 
differences at specific promoters (Supplementary Fig.7b, unpublished data), 
pyrosequencing revealed significantly increased DNA methylation in Tdg null NPs at three 
out of five gene promoters tested (Hoxa10, Pax6, Tgfb2). Notably, these methylation 
differences were not present in ESCs nor in freshly dissociated embryonic bodies, they 
arose within 48 hours of cultivation of the NPs in progenitor medium (Fig 3c, 
Supplementary Fig. 7c), and the phenotype was complemented by ectopic expression of 
Tdg during NP differentiation. Similarly, histone methylation marks were not different 
between TDG proficient and deficient ESCs but arose in NPs with an enrichment of 
H3K27me3 at the promoters of Hoxd13, Hoxa10 (Supplementary Fig. 8) and Pdgfra 
(unpublished data). Thus, differences in DNA methylation and histone modifications 
became apparent at the NP stage but were not as pronounced as in MEFs, indicating an 
epigenetic phenotype that may progress upon further differentiation and/or cultivation. 
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Consistently, attempts to differentiate TDG deficient NPs to terminal neurons failed 
because of a rapid loss of cell viability in neuronal rich medium.
We then wondered whether this epigenetic function of TDG involves active DNA 
repair as implicated by the inability of a catalytic-dead TDG (N151A) to complement the 
loss of Sfrp2 and Twist2 expression in Tdg null MEFs (Fig. 2). To monitor a possible 
engagement of downstream base excision repair (BER), we first performed ChIP for 
XRCC1 17. This revealed a specific, TDG-dependent enrichment of this critical BER protein 
at the Hoxd13, Hoxa10, Sfrp2 and Twist2 promoters in MEFs but not in ESCs (Fig. 4a, 
Supplementary Fig. 5b). Hence, in MEFs, where TDG helps maintain these promoters in 
an active state, its presence correlates with an enrichment of XRCC1. In ESCs, however, 
where TDG also associates with these promoters but does not affect their chromatin 
status, XRCC1 enrichment is not observed. Besides XRCC1, we also found APE1, 
another component of BER, to associate with these promoters in a TDG dependent 
manner in MEFs (Fig. 4a). Moreover, RA treatment of ESCs for 8 hours increased the 
number of chromatin-associated XRCC1 foci in the presence but not in the absence of 
TDG (Supplementary Fig. 9), and TDG proficient cells were significantly more sensitive to 
PARP inhibition than TDG deficient cells upon RA-induced differentiation (Supplementary 
Fig. 10). These observations strongly suggest that cell differentiation-induced TDG activity 
feeds into PARP and XRCC1-dependent DNA single-strand break repair 18.
Addressing the phenotype on histone modifications, we then found by ChIP that the 
absence of TDG also compromises the association of the H3K4-specific methyl-
transferase MLL1 with the promoters of Hoxd13, Hoxa10, Sfrp2, and Twist2 (Fig. 4b). This 
was apparent in TDG deficient MEFs but not in ESCs, with the former indeed showing a 
loss of H3K4 methylation and an occurrence of aberrant CpG methylation at gene 
promoters reminiscent of the phenotype of MLL defects 19–21. Similar to MLL, the binding of 
CBP/p300 to these promoters was significantly reduced in the Tdg null MEFs (Fig. 4b). 
CBP/p300 is a transcription activating histone acetyl transferase known to interact with 
TDG 4 and, notably, its association with gene promoters has been reported to protect from 
polycomb mediated H3K27 trimethylation 22.
Taken together, our data suggest structural and catalytic functions of TDG in 
epigenetic maintenance (Fig. 4c). As a structural component, TDG complexes with 
activating histone modifiers (e.g. MLL, CBP/p300) to maintain states of active (H3K4me2) 
and bivalent (H3K4me2, H3K27me3) chromatin during cell differentiation. In the absence 
of TDG, the assembly and function of such complexes is distorted and, consequently, 
chromatin modifications imbalanced towards repressive states. TDG also provides DNA 
repair capacity to locally erase CpG methylation. Aberrant methylation arises at GC-rich 
promoters in TDG deficient cells following lineage commitment, and the frequencies and 
patterns of these events indicate an underlying stochastic process of de novo methylation. 
Hence, TDG keeps de novo DNMT activities in check to avoid erroneous methylation, and 
the engagement of XRCC1 and APE1 suggests that it operates through BER. A number of 
previous studies have implicated TDG in active DNA demethylation 8,9,23. Mechanistically, it 
may do so on its own acting as a 5-mC DNA glycosylase 23, or it may cooperate with a 5-
mC deaminase (e.g. AID/Apobec 24,25 or DNMTs 8), or a 5-mC hydroxylase (e.g. TET1 26,27) 
that would convert 5-mC into a favourable substrate for TDG. Numerous efforts to 
reproduce 5-mC glycosylase activity for mouse and human TDG have failed 
(Supplementary Fig. 11, unpublished data). We therefore consider a deamination or 
hydroxylation-mediated, TDG-dependent repair process a preferable scenario for active 
cytosine demethylation. The mouse Tdg knockout phenotype shows that such an 
epigenetic control system has evolved to protect critical DNA sequences from de novo 
methylation and heterochromatinization during development.
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Methods Summary
Tdg knockout mouse and cell lines. The Tdg-targeting construct (Supplementary Fig. 1) 
was generated by replacement of a NarI – PacI fragment enclosing Exons 6 and 7 by a 
neomycin resistance cassette in a cloned fragment spanning Exons 5 to 10 of the Tdg 
locus. This construct was used to target the Tdg allele in 129 mouse ESCs, which were 
then used to generate chimera and, ultimately, Tdg+/- heterozygotes by backcrossing to 
C57BL/6. The generation and establishment of MEF’s and Tdg-/- ESCs was previously 
described 28.
In vitro differentiation. In vitro differentiation of ESCs was performed essentially 
according to the protocol published in ref. 16. RNA isolation for transcriptome analysis of 
MEF’s or ESCs and NPs was performed using the RNeasy Mini Kit (Qiagen) or the Trizol 
reagent (Invitrogen), respectively. Antibodies and sequences of oligonucleotides used for 
RT-PCR, bisulfite sequencing and ChIP analysis are listed in Supplementary Tables 1-4. 
Full methods and associated references are available in the online version of the paper at 
www.nature.com/nature
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Legends to Figures
Figure 1 | Embryonic essential function of Tdg in epigenetic gene regulation. a, 
Whole-mount images of typical examples of Tdg+/+ and Tdg-/- littermate embryos taken at 
E10.5 and E12.5. b, Scatter plot comparing gene expression levels of matched Tdg+/- and 
Tdg-/- MEFs. Differentially expressed genes at p<0.05 and p<0.01 are indicated by green 
and red dots, respectively, and examples of developmental genes affected are denoted. c, 
Na-bisulfite sequencing of the Hoxd13 and Sfrp2 promoters in Tdg+/+, Tdg+/- and Tdg-/- 
MEFs. White and black circles indicate unmethylated and methylated CpGs, respectively. 
p-values indicate statistical difference of methylation frequencies as determined by 
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contingency tables and Chi-square test. d, ChIP-qPCR analysis of TDG association with 
the promoters of the genes indicated in chromatin from Tdg+/+ and Tdg-/- MEFs. Shown are 
relative enrichments of TDG at these promoters normalized to a randomly chosen 
intergenic control region (means±s.e.m.; n≥3; *, p<0.05; **, p<0.01, unpaired Students t-
test). e, ChIP-qPCR analyses in Tdg+/+ and Tdg-/- MEFs to assess the presence of 
activating (H3K4me2) and repressive (H3K9me3, H3K27me3) histone modifications at the 
promoter regions indicated. Shown are relative enrichments relative to appropriate 
negative controls; intracisternal A-particle (Iap) transposon for active chromatin marks and 
the Hprt promoter for silencing marks (means±s.e.m.; n≥3; *, p<0.05; **, p<0.01; unpaired 
Student’s t-test). T, target region; C, control region.
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Figure 2 | Complementation of the loss of gene expression depends on the 
chromatin state of the promoter. a, Hoxd13, Hoxa10, Sfrp2, and Twist2 expression in 
Tdg+/+ and Tdg-/- MEFs complemented with vectors expressing either a wildtype (pTdg) or 
a catalytically deficient Tdg (pTdgcat-, N151A), or a vector control (pV). Target-specific 
mRNA levels were assessed by qRT-PCR and normalized to Gapdh mRNA; values 
represent arbitrary units (means±s.d.; n≥3; *, p<0.05, unpaired Student’s t-test). b, ChIP-
qPCR analyses to detect H3K27me3 and H3K4me2 marks at the gene promoters 
indicated in chromatin of Tdg+/+, Tdg-/- and Tdg-/- MEFs complemented with a wildtype Tdg 
cDNA. IAP and the Hprt promoter were used as normalizers for active and repressive 
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chromatin marks, respectively (means±s.e.m.; n=3; *, p<0.05; **, p<0.01; unpaired 
Student’s t-test). T, target region; C, control region.
Figure 3 | TDG-dependent differences in gene expression and chromatin status 
arise during cell differentiation. a, Scatter plots comparing gene expression profiles of 
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Tdg+/- and Tdg-/- embryonic stem cells (ESCs) or in vitro differentiated neuronal progenitors 
(NPs). Green and red dots indicate differentially expressed genes at p<0.05 and p<0.01, 
respectively. b, ChIP-qPCR analysis of TDG association with the gene promoters 
indicated in chromatin from Tdg+/- and Tdg-/- ESCs and NPs. Shown is the relative 
enrichment of TDG at these promoters normalized to a randomly chosen intergenic control 
region (means±s.e.m.; ESCs, n=3; NPs, n=3; *, p<0.05, **, p<0.01; unpaired Student’s t-
test). T, target region; C, control region. c, DNA methylation states at the Hoxa10 and Pax6 
promoters in TDG deficient ESCs and NPs analyzed by bisulfite-Pyrosequencing. 
Promoter regions are depicted schematically at the top. Vertical tick marks indicate CpG 
sites, bent arrows transcription start sites, and horizontal brackets the CpGs for which 
methylation data is presented in the graphs. Methylation levels are given as percentage of 
methylated cytosines at each CpG analyzed. Shown are means with the 95% confidence 
intervals (bars) as obtained from three differentiation experiments. *, p<0.05; **, p<0.01; 
unpaired Student’s t-test.
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Figure 4 | Structural and catalytic functions of TDG in epigenetic maintenance. a, 
ChIP-qPCR analysis of XRCC1 and APE1 association with the gene promoters indicated 
in chromatin of TDG proficient and deficient MEFs and ESCs. Shown are relative 
enrichments of XRCC1 and APE1 at these promoters normalized to a randomly chosen 
intergenic control region (means±s.e.m.; n≥3; *, p<0.05; **, p<0.01, unpaired Student’s t-
test). b, ChIP-qPCR analysis of MLL1 and CBP/p300 association with the gene promoters 
indicated in chromatin of TDG proficient and deficient MEFs and ESCs. Shown are relative 
enrichments of MLL1 and CBP/p200 at these promoters normalized to a randomly chosen 
3C13
intergenic control region (means±s.e.m.; n≥3; *, p<0.05; **, p<0.01, unpaired Student’s t-
test). T, target region; C, control region. c, Model summarizing epigenetic aberrations and 
implicated functions observed in the absence of TDG. In ESCs TDG associates with gene 
promoters in an active “open” (H3K4me2, e.g. Sfrp2, Twist2, left side) or transiently silent 
“bivalent” chromatin conformation (H3K4me2 and H3K27me3, e.g. Hoxd13 and Hoxa10, 
right side). In active chromatin, the lack of TDG results in a partial loss of H3K4 
dimethylation and a gain of H3K27 trimethylation as well as in sporadic DNA 
hypermethylation (red balls) upon cell differentiation. Differentiation associated activation 
of promoters in “bivalent” chromatin involves the demethylation of H3K27me3 and 
transcription factor binding. The absence of TDG results in an aberrant loss of H3K4 
dimethylation accompanied by a gain in repressive H3K9 and H3K27 trimethylation and in 
DNA methylation, eventually directing irreversible transcriptional silencing. In both cases, 
the loss of active and the gain in repressive histone marks can be accounted for by a 
failure of TDG deficient cells to target MLL and CBP to these promoters. We propose that 
TDG, as part of transcription regulatory complexes, assures the establishment and the 
maintenance of proper epigenetic states at developmentally regulated gene promoters. As 
a DNA glycosylase, it protects these regions from aberrant CpG methylation in a process 
that engages XRCC1 and APE1, factors essential for downstream BER.
Methods
Cell culture and ES cell differentiation. SV40 immortalized MEF cell lines were 
previously described 29 and cultivated in growth medium (DMEM, 10% FCS, 2 mM L-
glutamine) at 37°C in a humidified atmosphere containing 5% CO2. For growth of cell lines 
complemented with Tdg expressing vectors the growth medium was additionally 
supplemented with 1 μg/ml puromycin.
For isolation of primary MEFs, 10.5 dpc embryos were dissected, homogenized and 
cells dissociated in 0.05% Trypsin-EDTA for 5 min before plating in modified ES cell 
medium without LIF (DMEM, 10% FCS seraplus, 1x nonessential amino acids, 1 mM 
sodium pyruvate, 2 mM L-glutamine and 50 µM β-mercaptoethanol, 1x 
penicillin/streptomycin) and cultivation for 10 days.
ES cells (ESC) were grown in the presence of feeder cells at 37°C in ES cell medium 
(ECM: DMEM, 15% heat inactivated FCS, LIF (1,000 U/ml), 1x nonessential amino acids, 
1 mM Na-pyruvate, 2 mM L-glutamine and 90 µM β-mercaptoethanol) in a humidified 
atmosphere containing 5% CO2. 
Before differentiation experiments for neuronal differentiation, time-course, PARP 
inhibitor and immunofluorescence experiments, ESC were grown in the absence of feeder 
cells for two passages. For embryoid body formation during neuronal differentiation 4 x 106 
Tdg+/- or Tdg-/- ESC were plated into nonadherent bacterial dishes (Greiner Bio-one, 
Germany) in differentiation medium (ECM without LIF and with 10% FCS) and grown at 
37°C with a medium exchange after two days. After four days, 5 µM all-trans retinoic acid 
(RA) was added and cells were further incubated for four days with a medium exchange 
after two days. Embryoid bodies were washed twice with 1x PBS and dissociated with 
freshly prepared trypsin solution (0.05% TPCK-treated trypsin in 0.05% EDTA/1x PBS) at 
37°C for 3 min. Dissociated embryoid bodies were resuspended in 10 ml differentiation 
medium and collected by centrifugation at 700g for 5 min at room temperature (RT). The 
pellet was resuspended in N2 medium (DMEM-F12 nutrient mixture 1:1, 1x N2 
supplement) and the cell suspension filtered through a 40 µm nylon cell strainer (BD, 
USA). Filtered cells were immediately plated onto poly-L-lysine (PLL) and laminin-coated 
dishes at a density of 5 x 106 cells/60 mm dish or 1.5 x 107 cells/100 mm dish. The N2 
medium was exchanged after 2 and 24 hours after plating and cells were harvested after 4 
and 48 hours for further analysis. 
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RA induced differentiation of ESC for time-course, PARP inhibitor and 
immunofluorescence experiments was induced in ECM without LIF in the presence of 1 or 
5 µM RA. The RA containing medium was exchanged every 24 hours and cells were 
harvested at the indicated time points. For immunofluorescence experiments, 105 ESC 
were seeded onto gelatin-coated cover slips one day prior to differentiation. For the 
analysis of PARP inhibition on cell survival during differentiation, 105 ESC were seeded 
into gelatin-coated 12-well dishes, one day before the addition of 5 µM RA or further 
cultivation in ECM. After 24 hours, increasing concentrations of the PARP inhibitor AG-
014699 (a generous gift of SelleckChem) were added and cell numbers determined 24 
hours later with the CASYcell counter. The 50% lethal dose (LD50) of the inhibitor and 
statistical differences between Tdg proficient and deficient cells were calculated on 
triplicate experiments by linear regression with 95% confidence interval using the 
GraphPad PRISM software.
Microarray gene expression analysis. For the analysis of differential gene expression 
among Tdg+/- and Tdg-/- MEF’s, total RNA was isolated form three independent cultures of 
each cell line using the RNeasy Mini Kit (Qiagen, Germany), cDNA synthesized from 13 µg 
RNA with the SuperScript double-Stranded cDNA Synthesis kit (Invitrogen) followed by in  
vitro transcription reactions using the MEGA Script T7 Kit (Ambion, USA) supplemented 
with 1.5 mM Bio-11-CTP and Bio-16-UTP (Enzo Life Sciences, USA). cDNAs and cRNAs 
were purified using the GeneChip® Sample Cleanup Module (Qiagen, Germany). 15 µg of 
cRNA were fragmented and hybridized to GeneChip Mouse Expression Arrays 430A 
(Affymetrix, USA). Hybridized arrays were stained and washed according to the 
manufacturers’ protocol and scanned with the Affymetrix Scanner 3000 7G. Scanned 
images were processed with the Microarray Suite software and obtained ‘cel’-files used for 
further data analysis. 
For gene expression analysis of ESC and in vitro differentiated NP cells, total RNA 
was extracted from independent triplicates using the Trizol reagent (Invitrogen, USA). RNA 
was quantified using the Quant-iT™ RiboGreen® RNA Assay (Invitrogen, USA) and 500 
ng of total RNA subjected to cDNA synthesis and subsequent in vitro transcription to 
biotiylated cRNA using the Illumina® TotalPrep RNA Amplification Kit (Ambion, USA). 1.5 
μg of cRNA was hybridized to MouseWG-6v2 slides (Illumina, USA) according to the 
manufacturer’s protocol. Bead arrays were washed and stained using FluoroLink Cy3 
Streptavidin (GE Healthcare, USA). Fluorescent signals were imaged using the iScan 
system (Illumina, USA). Scanner images files were processed to probe intensity files by 
the manufacturers’ software and further processed with the genome studio software 
(Illumina, USA.) without normalization and background correction.
Affymetrix data and Illumina probe intensity data were either processed by robust 
multi-array average (RMA) or variance stabilization transformation (VST), respectively 
using the R/Bioconductor software and “affy” or “lumi” libraries, followed by quantile 
normalization. Significance of effects for probes (Illumina) or probe-sets (Affymetrix) was 
tested in R/Bioconductor (“limma” library) using a moderated t-test and the false discovery 
rate (FDR = 5%) method by Benjamini and Hochberg for multiple testing correction. No 
unspecific filter was applied and multiple probe-sets per gene or probe-sets with 
ambiguous genomic target were retained.
Methylation analyses. Genomic DNA from MEF, ESC, and NP cells was isolated 
with the QIAamp DNA Mini Kit (Qiagen, Germany). 2 µg of DNA were subjected to bisulfite 
conversion using the EZ DNA Methylation Kit (ZYMO RESEARCH, USA). Respective 
target regions were amplified from bisulfite treated DNA with TrueStart Taq polymerase 
(New England Biolabs, USA). For conventional bisulfite sequencing, Hoxd13 or Sfrp2 
promoter regions were amplified from converted DNA and cloned into the XhoI and BamHI 
restrictions sites of pBluescript SK- before sequencing of individual clones. For 
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Pyrosequencing, potential regions of hypermethylation were first identified by COBRA. 
Pyrosequencing primers (Supplementary Table 1) were designed using the PyroMark 
Assays Design Software (v. 2.0.1.15, Qiagen, Germany). Primer pairs included either one 
biotinylated primer or one primer containing a universal region. In the latter case products 
were subjected to a second amplification using a biotinylated universal primer and Phusion 
Hot Start High-Fidelity DNA Polymerase (Finnzymes, Finland). PCR products were purified 
using the QIAquick PCR Purification Kit (Qiagen, Germany), quantified and 300 to 500 ng 
were used for pyrosequencing in a PyroMark Q24 (Qiagen, Germany). Reactions were 
analysed using the PyroMark Q24 Software (v. 2.0.6, Qiagen, Germany). Significance of 
methylation differences between different Tdg proficient and deficient cell lines at 
individual CpG sites was evaluated by unpaired, two-tailed t-tests. 
Chromatin immunoprecipitations (ChIP). To crosslink protein bound DNA, MEFs, ESC 
and NPs were incubated in freshly prepared crosslinking solution (PBS pH 7.4, 1% 
formaldehyde) at RT. The reaction was quenched after 10 min by addition of glycine to a 
final concentration of 125 mM. After washing twice with cold PBS cells were collected 
using a cell scraper and subsequent centrifugation at 600g and 4°C. Nuclei were isolated 
by incubation in 200 µl of cold ChIP Buffer I (10 mM HEPES [pH 6.5], 10 mM EDTA, 0.5 
mM EGTA, 0.25% Triton X-100) for 5 min on ice followed by two incubations of 5 min on 
ice in 200 µl cold ChIP buffer II (10 mM HEPES pH 6.5, 1 mM EDTA, 0.5 mM EGTA, 200 
mM NaCl). Pelleted nuclei were lysed in 400 µl ChIP buffer III (50 mM Tris-HCl pH 8.0, 1 
mM EDTA, 0.5% Triton X-100, 1% SDS, 1 mM PMSF) for 10 min on ice followed by 
sonication for 15 min (15 seconds ON, 30 seconds OFF, power HIGH) using a 
BIORUPTOR sonicator (Diagenode, UK) to produce random chromatin fragments ranging 
from 300 to 1'000 bp. The solution was cleared by centrifugation at 14'000g and 4°C for 10 
min and the concentration of chromatin was estimated by OD260 absorption. For ChIP of 
TDG, MLL and APE1 100-150 µg of chromatin were diluted 10 times in ChIP dilution buffer 
I (50 mM Tris-HCl pH 8.0, 1 mM EDTA, 150 mM NaCl, 0.1% Triton X-100, 1 mM PMSF). 
For Histone ChIPs, 25-75 µg of chromatin were diluted in ChIP dilution Buffer II (16.7 mM 
Tris-HCl pH 8.0, 1.2 mM EDTA, 167 mM NaCl, 1.1% Triton X-100, 0.01% SDS, 1 mM 
PMSF). Diluted chromatin was precleared at 4°C for 1 hour with 40 µl of a 50% slurry of 
magnetic Protein G beads (Invitrogen, USA) preblocked with 1 mg/ml BSA and 1 mg/ml 
tRNA (TDG, XRCC1, APE1, and MLL-ChIPs) or salmon sperm ssDNA (histone ChIPs). 
Precleared chromatin was incubated with 2-5 µg of the respective antibody 
(Supplementary table 2) overnight at 4°C under slow rotation. Immuno-complexes were 
precipitated with 40 µl of a 50% slurry of blocked Protein G beads and further incubation at 
4°C for 2 hours. Beads were then serially washed with 500 µl ChIP wash buffer I (20 mM 
Tris-HCl pH 8.0, 2 mM EDTA, 150 mM NaCl, 0.1% SDS, 1% Triton X-100), 500 µl ChIP 
wash buffer II (20 mM Tris-HCl pH 8.0, 2 mM EDTA, 500 mM NaCl, 0.1% SDS, 1% Triton 
X-100) and 500 µl ChIP wash buffer III (10 mM Tris-HCl pH 8.0, 1 mM EDTA, 250 mM 
LiCl, 1% sodium deoxycholate, 1% NP-40). In case of TDG, APE1 and MLL ChIPs, beads 
were washed once with 500 µl ChIP wash buffer I and twice with 500 µl ChIP wash buffer 
II. After two additional washes with 500 µl TE (10 mM Tris-HCl pH 8.0, 1 mM EDTA), 
bound complexes were eluted by two sequential incubations with 150 µl elution buffer (1% 
SDS, 0.1 M NaHCO3) at 65°C for 10 min. Crosslink reversal of eluates and respective 
input samples (1% of chromatin used for ChIP) was done in the presence of 200 mM NaCl 
at 65°C for 4 hours followed by Proteinase K digestion (50 µg/ml) in the presence of 10 
mM EDTA at 45°C for one hour. DNA was purified by phenol/chloroform extraction and 
Na-acetate/ethanol precipitation and resuspended in 10 mM Tris-HCl pH 8.0. qPCR 
analysis with target specific primers (Supplementary Table 3) was performed using 
Quantitect SYBR Green (Qiagen, Germany) with a Rotor-Gene 3000 thermocycler 
(Qiagen, Germany). The significance of different ChIP efficiencies among Tdg proficient 
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and deficient cell lines was evaluated from triplicate experiments by non-paired, two-tailed 
t-tests.
Methylated DNA Immunoprecipitation (MeDIP). MeDIP assays were performed as 
described in ref. 30. Shortly, genomic DNA was prepared from 5 x 106 cells by incubation 
in lysis buffer (20 mM Tris-HCl pH 8.0, 4 mM EDTA, 20 mM NaCl, 1% SDS and 1 mg/ml 
Proteinase K) at 55°C for 5 hours and subsequent phenol/chloroform extraction and Na-
acetate/ethanol precipitation. DNA pellets were resuspended in TE containing 20 µg/ml 
RNase. DNA was sonicated as described for ChIP followed by NaCl(400 mM)/EtOH 
precipitation in the presence of glycogen-carrier. 4 µg of fragmented DNA in 450 µl TE 
were denatured at 95°C for 10 min and immediately chilled on ice. After addition of 10x IP 
buffer (100 mM sodium phosphate pH 7.0, 1.4 M NaCl, 0.5% Triton X-100) the DNA was 
incubated with 10 µg of a monoclonal anti 5-methylcytidine antibody (clone 33D2, 
Eurogentec, Belgium) at 4°C for 2 hours. Immuno-complexes were precipitated by the 
addition of 40 µl M-280 sheep anti mouse IgG antibody coupled Dynabeads (Invitrogen, 
USA) and incubation at 4°C for 2 hours followed by three washes in 700 µl IP buffer. 
Bound material was treated with 250 µl Proteinase K digestion buffer (50 mM Tris-HCl pH 
8.0, 10 mM EDTA, 0.5% SDS and 0.25 mg/ml Proteinase K) at 50°C for 3 hours. 
Immunoprecipitated methylated DNA was purified by phenol/chloroform extraction followed 
by Na-acetate/ethanol precipitation and resuspended in TE. qPCR analysis of sonicated 
genomic input DNA and MeDIP DNA with target specific primers (Supplementary table 3) 
was performed as described for ChIP and significance of MeDIP efficiencies tested by 
non-paired, two-tailed t-tests. 
Quantitative RT-PCR analyses. 2-4 µg of total RNA extracted by RNeasy Mini Kit or by 
Trizol methods were reverse transcribed with the RevertAid™ H Minus M-MuLV Kit 
(Fermetas, Germany) according to the manufacturers’ protocol. qPCR with target specific 
primers (Supplementary table 4) was performed using Power SYBR Green Master Mix 
(Applied Biosystems, USA) with a Rotor-Gene 3000 thermocycler. Conditions for each 
target were validated by standard and melting curve analyses. Target specific 
amplifications were normalized to a GAPDH control and data of at least three independent 
experiments were analyzed by unpaired, two-tailed t-tests. Tdg genotype-specific target 
gene expression in primary MEFs were analyzed by the non-parametric Kruskal-Wallis test 
and post-hoc Dunn’s multiple comparison.
Western blot analyses. Whole cell extracts were prepared by cell lysis in lysis buffer (50 
mM Na-phosphate pH 8.0, 125 mM NaCl, 1% NP-40, 0.5 mM EDTA, 1 mM PMSF, 1 mM 
DTT, 1x Complete protease inhibitor, 2x phosphatase inhibitor cocktail 1 and 2) on ice for 
30 min and clarification by centrifugation (15 min, 20,000g, 4°C). Chromatin extracts were 
isolated as described for ChIP assays. 50 μg of soluble proteins were separated on 7% or 
10% SDS-polyacrylamide gels and transferred to a nitrocellulose membrane (Millipore, 
USA). Membranes were washed once with TBS-T (100 mM Tris-HCl pH 8.0, 150 mM 
NaCl, 0.1% Tween-20), blocked with blocking buffer (TBS-T, 5% dry milk) at RT for 1 hour 
and incubated with the primary antibody at 33°C (anti-mTDG) or RT (anti-DNMT1, anti-
DNMT3a, anti-XRCC1, anti-APE1, anti-MLL, anti–β-actin) for 1 hour in blocking buffer. 
Dilutions were: 1:10’000 for the rabbit anti-mTDG, the mouse anti-β-actin and the anti-
DNMT1 antibodies; 1:1’000 for the anti-DNMT3a and anti-XRCC1 antibodies; 1:500 for the 
anti-APE1 and anti-MLL antibodies. Washing steps after hybridization were: once at 33°C 
and twice at RT for 15 min for anti-mTDG or three times at RT for 10 min for all other 
antibodies. Membranes were incubated with secondary HRP–conjugated antibodies 
diluted 1:5’000 in blocking buffer and at RT for 1 hour. After three washing steps of 10 min 
at RT, detection of the signals was carried out using the Immobilon Western 
Chemiluminescent HRP Substrate (Millipore, USA).
Cytotoxicity assays. For measurement of γ-ray sensitivity, MEF single cell suspensions 
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at a cell density of 2 x 105 cells/ml in PBS were irradiated with the indicated doses in a 
Gammacell 40 irradiator using 137Cs as a radioactive source. Irradiated cells were plated in 
96-well microtiter plates at a density of 1000 cells/well in growth medium and survival was 
measured after 3 days using the cell counting kit 8 (Dojindo, Japan). Alternatively, survival 
was determined by clonogenic growth by plating 500 to 2000 cells in triplicate in 10 cm 
dishes containing growth medium and counting of Giemsa stained colonies after 10 days. 
For measurement of sensitivity to H2O2 cells were plated at 2500 cells/well in 96-well 
plates. After 24 hours cells were treated for 15 min with the indicated concentrations of 
H2O2, washed with PBS and incubated in fresh growth medium for further 24 hours before 
measurement of survival with the cell counting kit 8. Survival was determined as percent of 
mock treated cells.
Base release assay. For base release assays, 25 to 50 μg of ESC whole cell extracts 
were incubated with 0.5 pmol of a fluorescein-labelled GC/TG, GCm/CG or GCm/mCG 
DNA substrate in reaction buffer (50 mM Tris-HCl [pH 8.0], 1 mM EDTA, 1 mM DTT, 1 
mg/ml BSA) at 37°C for 1 hour (GC/TG) or overnight (methylated substrates). Resulting 
AP-sites were cleaved by the addition of NaOH to a final concentration of 100 mM and 
heating to 95°C for 10 min. Subsequently, DNA was ethanol precipitated overnight at −20 
°C in the presence of 0.3 M Na-acetate pH 5.2 and 0.4 mg/ml carrier t-RNA. DNA was 
collected by centrifugation (20 min, 20’000g, 4°C) and washed with 80% ethanol. Air-dried 
pellets were resuspended in loading buffer (1x TBE, 90% formamide), heated at 95°C for 5 
min and immediately chilled on ice. Reaction products were separated on denaturing 8 M 
urea/15% polyacrylamide gels in 1x TBE. The fluorescein-labelled DNA was visualized 
with a Typhoon 9400 and quantified using the ImageQuant TL software (GE Healthcare, 
USA).
Immunofluorescence. For detection of XRCC1 foci during RA stimulation, cells were 
fixed in ice-cold methanol for 5 min, then permeated in 0.2% Triton X-100/PBS pH 7.4 and 
0.2% Triton X-100/0.2% NaBH4/PBS pH 7.4 on ice for 5 min each. The induceability of 
XRCC1 foci formation in ESC was tested by incubation with H2O2 (50µM in PBS) or PBS 
for 15 min at 37°C and additional 5 min in ECM with LIF before further processing. 
Coverslips were blocked in blocking buffer (BF:1% BSA/0.05% Tween20/PBS pH 7.4), 
stained with rabbit anti-XRCC1 antibody (1:100 in BF) at RT for 1 hour, washed 3 times for 
10 min with BF before labelling with goat anti-rabbit Alexa594 (1:200 in BF) for 30-60 min. 
After two washes of 10 min with BF, cells were again fixed in -20°C cold methanol, 
incubated in BF for 1 hour and stained with a mouse monoclonal anti-PCNA antibody 
(1:100 dilution) in BF overnight at 4°C. Slides were counterstained for DNA with 50ng/ml 
DAPI and mounted in VectaShield mounting medium (Vector Lab, USA). Slides were 
randomized and blinded before z-stacks were acquired on a Leica SP5 with the 405 nm 
diode, Argon 488 nm and He-Ne 594 nm laser lines. XRCC1 foci-number for individual 
cells were determined by visual inspection of the 3D stacks. 150 (RA stimulation) or 50 
(H2O2) cells per sample were analyzed. For co-staining of PAR and XRCC1 during RA 
differentiation, cells were fixed with 2% formaldehyde/PBS at RT for 30 min, permeabilized 
with PBS/0.2% Triton-X100 for 30 min. Antigene detection was done with a 1:250 diluted 
monoclonal α-PAR antibody 10H (Enzo Life Sciences) and a polyclonal α-XRCC1 as 
described above but using 1:250 diluted anti-rabbit AlexaFluor-594 and anti-mouse 
AlexaFluor-488 secondary antibodies (Invitrogen). Pictures were acquired with a Nikon 
Diaphot 300 epifluorescence microscope using identical settings for all slides.
29. Kunz, C. et al. Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-
fluorouracil. PLoS Biol 7, e91 (2009).
30. Weber, M. et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA 
methylation in normal and transformed human cells. Nat Genet 37, 853-862 (2005).
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